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ABSTRACT 
 
Activated protein C (APC) is a natural anticoagulant. In addition to this well-
described function, APC also mediates endothelial cell (EC) cytoprotection, 
including anti-apoptotic, anti-inflammatory and endothelial barrier integrity 
stabilising effects. APC confers these effects through proteolytic activation of 
protease activated receptor 1 (PAR1), but only when it is bound to its receptor, 
endothelial protein C receptor (EPCR). Interestingly, thrombin exerts opposing 
cellular responses (including induction of endothelial hyperpermeability) through 
activation of PAR1. How activation of the same receptor can mediate such different 
signals remains unclear. I hypothesised that, downstream of PAR1 cleavage, 
activation of different protein kinase C (PKC) isoforms may account for the 
divergent signal transduction. The aim of my thesis was to explore the contribution 
of specific PKC isozyme(s) that are involved in APC and thrombin mediated 
signalling. To do this, I expressed, purified and characterised a panel of APC 
variants lacking either anticoagulant activity, EPCR binding, PAR1 binding or 
proteolytic activity. I demonstrated that both APC and thrombin activate Erk1/2 
pathway in the endothelial cells in a dose and time-dependent manner. APC also 
dose-dependently stabilised endothelial monolayer integrity, whereas thrombin 
disrupted this. APC’s cytoprotective properties, based on this established cell assay 
model, were found to be PAR1 and EPCR dependent. Using peptides that inhibit 
specific PKC isozymes, I found that the atypical PKCζ isozyme, was involved in 
Erk1/2 phosphorylation triggered by thrombin and both classical PKC isozymes 
(PKCβ1) and PKCζ were involved in the hyperpermeability induced by thrombin. In 
contrast, no PKC isozyme was found to play roles in the APC-mediated Erk1/2 
activation as well as EC permeability reduction. These findings might indicate that 
the difference in PKC involvement may contribute to the diverse intracellular 
signalling pathways of APC and thrombin, and hence their opposite cellular 
responses.  
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Chapter 1 Introduction 
 
1.1 Haemostasis 
 
Haemostasis is a normal physiological response that helps to both maintain blood 
fluidity and yet also prevents extensive blood loss upon injury in the body. This 
process is tightly regulated and abnormalities in this system can result in either 
haemorrhage or thrombosis. Generally, haemostasis is considered to consist of 
three mechanistic stages, primary haemostasis (platelet adhesion/aggregation), 
secondary haemostasis (coagulation) and fibrinolysis (clot dissolution) [1]. 
 
1.1.1 Primary haemostasis 
 
Primary haemostasis is initiated when a blood vessel is injured, and involves the 
formation of a platelet plug at the site of damage. Upon damage, an immediate 
reflex occurs. This induces vasoconstriction which is the first step to diminish the 
bleeding. Exposed extravascular collagen at the injury site recruits circulating 
platelets, which is mediated by von Willebrand factor (VWF). VWF is a large 
multimeric glycoprotein and is stretched by the shear stress of the blood flow [2]. It 
acts as an intermediary between a specific glycoprotein receptor complex 
(GPIb/V/IX) on the platelet surface and the exposed collagen fibrils so that platelets 
are tethered to the subendothelium [2,3]. The platelets become activated upon their 
adhesion to the exposed collagens and as a consequence of subsequent 
intracellular signalling. Thrombin also induces platelet activation through platelet 
receptors such as GPIb and protease activated receptors (PARs) [4]. Activated 
platelets undergo degranulation, during which the platelet aggregating agonists 
such as adenosine diphosphate (ADP) and thromboxane A 2 are released. ADP 
along with thromboxane A 2 further promote platelet activation [5]. Another 
important event of platelet activation is the activation of certain integrins on the 
platelet surface. Integrins are heterodimeric cell surface receptors that mediate cell-
cell or cell-matrix interactions [6] The platelet integrin is able to bind collagen and 
fibrinogen/fibrin, such that  platelet aggregation is induced through the binding to 
fibrinogen, which leads to the formation of an unstable primary platelet plug [5]. 
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Platelet activation also causes the presentation of phosphatidylserine on the 
platelet membrane, providing the negatively charged phospholipid surface which 
serves to assembly components of coagulation cascade [7]. 
 
1.1.2 Secondary haemostasis 
 
Secondary haemostasis, also referred to as the coagulation cascade, involves 
proteolytic activation of a number of coagulation factors and cofactors that work in a 
highly coordinated manner to generate thrombin and finally lead to fibrin formation. 
Fibrin then strengthens the primary platelet plug and forms a more stable fibrin clot.  
 
The coagulation cascade comprises a series of ordered enzymatic conversions, 
which was first proposed to depend on the activation of two coagulation pathways, 
termed intrinsic and extrinsic (Figure 1.1) [8]. In the currently accepted model of in 
vivo coagulation, tissue factor (TF) represents the main initiator of clotting. TF is a 
transmembrane protein, the expression of which is not normally in direct contract 
with blood [9]. Under normal physiological conditions, coagulation factors usually 
circulate in their inactive zymogen form, with a small proportion (1%) of factor VII 
(FVII) circulating in its active form [10]. Upon vascular injury, activated factor VII 
(FVIIa) gains access to the exposed TF thereby initiating the ‘extrinsic pathway’ 
(Figure 1.1) [9]. The TF/FVIIa complex catalyses the activation of FIX and FX, from 
which the latter can produce trace amounts of thrombin by activating prothrombin 
(Figure 1.1) [11]. The small amount of thrombin generated in this initiation phase 
promotes the feedback activation of cofactors FV and FVIII, and the protease 
zymogen FXI [11]. The amplification of the clotting process involves the formation of 
the ‘tenase complex’ by FIXa with its cofactor FVIIIa on the negatively charged 
phospholipid surface (provided by activated platelets) [11]. This complex promotes 
a more efficient FXa activation (50-100 fold) than that of TF/FVIIa and, as a result, 
bypasses the reliance on TF/FVIIa as a major source of FXa formation [1,12]. 
Additionally, thrombin generated FVa also serves as a cofactor for FXa to form 
prothrombinase, which catalyses prothrombin activation 1×105 more efficient than 
FXa alone (Figure 1.1) [13]. As a result, thrombin is rapidly generated locally at the 
site of vascular injury. 
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It is suggested that the extrinsic pathway is critical in the initiation of the coagulation 
cascade, whilst the intrinsic pathway is important for the maintenance and growth of 
clot formation [5]. In the intrinsic pathway, FXIa is generated through “contact 
activation”, involving the interaction of the molecules such as prekallikrein (PK), 
high-molecular weight kininogen (HK) and FXIIa (Figure 1.1) [14]. FXIa also 
activates FIXa, allowing a greater formation of FIXa, thereby accelerating thrombin 
generation. 
 
A major role of thrombin is to convert fibrinogen into fibrin by proteolytic removal of 
two pairs of fibrinopeptides, leading to the formation of a fibrin monomer [1]. Fibrin 
monomers spontaneously polymerise and are covalently cross-linked by FXIIIa, 
which is also activated by thrombin to form a stable fibrin clot [1]. The pivotal role of 
thrombin in haemostasis is further emphasised, as it also initiates an 
anticoagulation pathway by activating the potent anticoagulant protein C. The 
activation of protein C occurs when excessive thrombin is generated at the injury 
site. Thrombin binds to thrombomodulin (TM) on the adjacent endothelium and is 
then positioned to activate protein C. Activated protein C (APC), with its cofactor 
protein S, inactivates FVa and FVIIIa, downregulating the coagulation. 
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Figure 1.1 Coagulation cascade.  
The extrinsic pathway is initiated by the circulating FVIIa binds to exposed TF upon 
vascular injury. Picomolar amount of thrombin is generated as a result of sequential 
activation of FIX and FX. This small amount of thrombin produces FXI, FVIII and FV, 
which create a positive feedback loop to rapidly generate thrombin in sufficient 
amount, and the ultimate formation of a fibrin clot. The intrinsic pathway commence 
from HK/PK contact to the damaged endothelial cell surface, and joins to the 
extrinsic pathway through the formation of FIXa by FXIa.  
 
 
1.1.3 Regulation of the coagulation cascade 
 
Thrombin generation and the subsequent formation of a fibrin clot occur rapidly at 
the site of vessel damage, which occludes the vessel damage and prevents 
deleterious blood leakage. These processes are tightly controlled by several 
anticoagulant mechanisms, which target different components of the coagulation 
cascade, and can control and localise both the formation and activity of thrombin. 
The importance of these regulatory systems is highlighted by the deficiency in many 
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of their components that may result in the impaired response to the vascular injury 
and lead to haemorrhgic or thrombotic diseases [1]. 
 
Initiation of coagulation by TF is regulated by tissue factor pathway inhibitor (TFPI), 
a Kunitz-type serine protease inhibitor. It functions to attenuate FVIIa/TF-catalysed 
FX activation by forming an inactive quaternary complex [15]. TFPI ensures that the 
initial generation of thrombin is under control, and that only a small amount of 
thrombin is generated by limited amount of FXa in the initiation phase of 
coagulation. TFPI ensures that the TF-induced coagulation only proceeds when a 
natural threshold is passed [12]. The initiation phase, where the limited generation 
of thrombin occurs, is highly dependent on the activity of TF/FVIIa and therefore is 
strongly influenced by the inhibitory activity of TFPI. However, during propagation 
phase of coagulation, where positive feedback loops are activated, generation of 
thrombin become TF-independent [16] and hence the antithrombin (AT) and protein 
C inhibitory systems become more prevalent in regulating thrombin formation and 
activity. 
 
AT, a serine protease inhibitor, circulates in plasma [17]. It inhibits free 
procoagulation proteases such as thrombin, FIXa, FXa, FXIa and FXIIa, but is less 
able to inactivate factors in the form of complex (tenase and prothrombinase) 
[18,19]. The inhibitory actions of AT are greatly enhanced by heparin and heparin-
like molecules present on the surface of endothelial cells (ECs) [20]. Binding of 
heparin induces the conformational change in AT molecule, which favours the 
interaction of AT with its target serine proteases [17].  The AT anticoagulant system 
functions to limit the coagulation process to the site of injury and prevents 
unnecessary clot extension.  
 
The protein C anticoagulant pathway commences when thrombin escapes from the 
site of damage and binds to the TM expressed on adjacent endothelium [21]. APC 
generated by thrombin/TM complex, down-regulates thrombin generation through 
inactivation of FVa and FVIIIa. APC pathway is a focus of this thesis and is 
described in section 1.3.  
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The regulation of thrombin (and thereby control of fibrin deposition) is mainly 
dependent on the above anticoagulant systems, however it is worth noting that 
other plasma inhibitors, such as α2-macroglobulin, heparin cofactor II, and protein C 
inhibitor (PCI), also exhibit inhibitory effects against thrombin [22,23]. 
 
1.1.4 Fibrinolysis 
 
As the last step of haemostasis, fibrinolysis represents the proteolytic system by 
which a fibrin clot generated by coagulation is removed once vessel integrity is 
restored [11,14]. Plasmin is the major proteolytic enzyme responsible for cleaving 
fibrin into soluble fibrin degradation products [24]. The formation of plasmin from its 
circulating zymogen plasminogen is achieved through proteolytic cleavage by 
tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator 
(u-PA) [24]. The activity of t-PA in plasma is greatly accelerated by the presence of 
fibrin, which acts as a cofactor in the activation of plasminogen [24]. The activities 
of t-PA and u-PA are regulated by plasminogen activator inhibitors (PAI) and 
thrombin activatable fibrinolysis inhibitor (TAFI), which prevents binding of 
plasminogen to fibrin [25]. 
 
1.2 Thrombin and its multiple functions 
1.2.1 Thrombin structure 
 
Thrombin is a central protease in the coagulation cascade and also plays multiple 
roles in cell proliferation and activation, apoptosis and inflammation [26-30]. It is a 
serine protease that proteolytically generated from prothrombin. Human 
prothrombin (70 kDa), produced in liver parenchymal cells, circulates in the blood 
stream at 1.4 μM [27,31]. It is a glycoprotein zymogen comprised of a Gla-domain, 
two kringle domains, and the serine protease domain that contains a short 
activation peptide [32]. The conversion of prothrombin to thrombin relies on the 
catalytic cleavage of two peptide bonds (Arg320 and Arg271) by FXa, thereby 
releasing the Gla domain and kringle domains [33]. Thrombin activation is 
enhanced by FXa binding to cofactor FVa and forming the prothrombinase complex 
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on negatively charged phospholipid surfaces [34,35]. The resultant thrombin (37 
kDa) is a protein comprised of two polypeptides, an A chain (light chain, 36 aa) and 
a B chain (heavy chain, 259 aa), covalently linked by a disulphide bridge [32,36]. 
The heavy chain is highly homologous to trypsin and contains the catalytic triad 
including Ser195, His57, and Asp102 (chymotrypsin numbering) (Figure 1.2). The 
active site pocket is shaped by two large insertion loops, termed 60-loop and 149-
loop (Figure 1.2) [36]. The residues present on these loops provide important 
interactions with the amino acids adjacent to the cleavage sites of the substrates ; 
they also prevent access of many macromolecular substrate or inhibitors to the 
active site residues, primarily controlling the specificity of thrombin [36]. 
 
A striking feature of the thrombin molecule is its uneven charge distribution on the 
surface of the protein, resulting in highly positive and negative exosites. Two 
surface patches of positively charged residues have received particular attentions 
due to their involvement in the interaction of thrombin with specific inhibitors, 
substrates, and cofactors, allowing the versatility and multifunctional specificity of 
thrombin [32,36]. The first positively charged patch which also include a 
hydrophobic residue, often referred to ‘anion-binding exosite I’, is comprised of 
Lys36, His71, Arg73, Arg75, Tyr76, Arg77a, and Lys109/110 [37]. These charged 
residues have been reported to interact with fibrinogen, FV, FVIII, FXI, FXIII, TM 
and PAR1,3 and 4. The other positively charged cluster of surface exposed 
residues include Arg93, Lys236, Lys240, Arg101, and Arg233, which is termed 
‘anion-binding exosite II’, specifically interact with heparin, FV, and FVIII [37].  
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Figure 1.2 The structure of thrombin.  
A model of thrombin structure is shown. The central catalytic residue Ser195 
(chymotrypsin numbering) comprised in the active site is shown in red. Exosites I 
(green), Exosite II (pink), 60-loop (yellow) and the 148-loop (blue) are highlighted. 
Figure is produced in pyMol based on the information provided in [38]. 
 
1.2.2 Thrombin functions in coagulation 
 
Thrombin plays a central role in the coagulation cascade. As mentioned in section 
1.1.2, a major procoagulant activity of thrombin is to mediate the conversion of 
fibrinogen to fibrin, a process that enhances fibrin clot stabilisation by accelerated 
activation of FXIII [39-41]. Thrombin also amplifies coagulation by feedback 
activating FV [42], FVIII [43] and FXI [44]. Furthermore, fibrinolysis is inhibited by 
thrombin through its activation of TAFI [25]. The role of thrombin is not limited to the 
coagulation cascade. It also has a major role in the primary haemostasis as a 
potent activator of platelets [4,45].  
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1.2.3 Protease activated receptors 
 
Serine proteases such as thrombin, APC, FVIIa, and FXa exert a variety of 
biological activities. Their actions upon cells and tissues can play important 
physiological roles in the body system during inflammation. Their cellular responses 
result from signal transductions that rely on the activation of PARs. PARs belong to 
the subfamily of G protein-coupled receptors (GPCRs) with seven transmembrane 
domains (Figure 1.3) [46]. Rather than being activated by simple ligand occupancy, 
PARs are activated by a unique mechanism involving proteolytic cleavage within 
the extracellular N-terminus [28,46,47]. The newly exposed N-terminal sequence, 
termed as ‘tethered ligand’, interacts with extracellular loop 2 within the same 
receptor and activates the PAR, leading to G protein coupling and subsequent 
signal transductions (Figure 1.4) [46,48,49]. PARs play critical roles in the 
regulation of various pathophysiological functions in mammals, including humans, 
for example, tissue repair, cell survival, inflammation and immune responses 
[29,33,46,47]. So far, 4 types of PARs have been identified and are termed PAR1-4 
(Figure 1.3). PARs are differentially expressed on cells. PAR1 is expressed by a 
wide number of cell types including platelets, epithelial cells, leukocytes, fibroblasts 
and smooth muscle cells; PAR2 is expressed on the same cells (not human 
platelets); PAR3 is detected on platelets, neurons and podocytes; and PAR4 is 
present on platelets, megakaryocytes and monocytes, and this list is progressively 
increasing [29,46,47]. ECs are found to express all the PARs with PAR1 and PAR2 
expressed most abundantly [50-52].  
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H2N
Tethered 
ligand
PAR1 NATLDPR SFLLRN PNDKYEPFWEDEEKNES
PAR2      GTNRSSKGR SLIGKV DG
PAR3 NDTNNLAKPTLPIK TFRGAP PNSFEEFPFSALE
PAR4          LPAPR GYPGQV CANDSDTLELPDSS
Protease cleavage site
Hirudin-like binding site
COOH
PAR1 QTIQVPGLNITTCHDVLNETLLEG
PAR2 QTIFIPALNITTCHDVLPEQLLVG
PAR3 QEYYLVQPDITTCHDVHNTCESSS
PAR4 QTFRLARSDRVLCHDALPLDAQAS
Extracellular loop 2
PAR1 SECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIYKKLT
PAR2 SHDFRDHAKNALLCRSVRTVKQMQVSLTSKKHSRKSSSYSSSSTTVKTSY
PAR3 SKTRNHSTAYLTK
PAR4 SAEFRDKVRAGLFQRSPGDTVASKASAEGGSRGMGTHSSLLQ
C-terminal sequence
 
Figure 1.3 PAR1-4 and the classical mechanism of their activation.  
PAR activation by proteases occurs when they are cleaved at a specific site in the 
N-terminal tail of the receptor, unmasking a ‘tethered ligand’ (red) which interacts 
with the conserved second extracellular loop (orange). Hirudin-like binding site  
presents in PAR1 and PAR3 N-terminal exodomain is highlighted in blue. The 
sequence alignment of intracellular C-terminus of PARs is also given. The figure is 
modified from [47].  
 
1.2.4 Thrombin functions in cell signalling 
 
Thrombin is one of the most extensively studied enzymes that in addition to its well-
recognised role in coagulation cascade and haemostasis, thrombin also exerts 
pleiotropic effects involving intracellular signalling. Most of the thrombin functions 
have been shown by in vitro studies. As examples, it plays important role in 
inflammation and cell proliferation; it exhibits a mitogen activity on both ECs and 
smooth muscle cells. Thrombin displays effects on multiple cell types including 
platelets, ECs, smooth muscle cells, monocytes, fibroblasts and T lymphocytes [27]. 
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Many pleiotropic functions of thrombin rely on the activation of PARs on the cell 
membrane. Of the four members in PAR family, thrombin activates PAR1, PAR3 
and PAR4 [33]. PAR2 is resistant to thrombin cleavage, but it can be trans-
activated by the tethered ligand of PAR1 which is catalytically released by thrombin 
in cultured ECs [51,53]. The activation of platelets by thrombin primarily depends on 
the cleavage of PAR1, whereas at high concentrations thrombin also activates 
PAR4 [45], the latter mechanism is available for haemostasis to arrest bleeding 
when high level of thrombin is generated upon vascular trauma [54]. The difference 
in activating PAR1/3 and PAR4 rests on a hirudin-like binding site which is present 
in the N-terminus of PAR1/3 but not PAR4 (Figure 1.3). It provides an extended 
interaction between the former receptors and thrombin (through exosite I), which 
enables the occurrence of cleavage by thrombin at low concentrations [55-58]. 
Thrombin also binds to the GPIb on platelet surface [54,59], in which thrombin 
exosite II plays a key role in the interaction [60]. However the physiological 
relevance of thrombin/GPIb interaction is not clear and roles of this interaction in 
both prothrombosis and antithrombosis remain possible [60]. 
 
The inflammatory properties of thrombin may be associated with its activity to 
stimulate the release of a number of inflammatory cytokines in varies cell types. In 
cultured ECs and monocytes, thrombin can stimulate the expression and secretion 
of interleukin (IL)-8, IL-6 and monocyte chemoattractant protein-1 (MCP-1) [61,62], 
the latter two of which are also potently produced in smooth muscle cells in 
response to thrombin [63]. Inflammation is characterised by a multistep adhesive 
interaction between endothelium and leukocytes adhesion mediated by various 
families including selectins, integrins, and the Ig superfamily. Thrombin induces the 
expression of P- and E- selectin on ECs, which promotes the initial ‘rolling’ step in 
the adhesion cascade [64,65]. In addition, thrombin-stimulated chemokine 
production may favour the leukocyte activation, second step of adhesion cascade 
[62,64,66]. Lastly, thrombin has also been reported to induce ICAM-1 and VCAM-1 
expression on ECs, which provide the firm interaction with the β integrin in 
leukocytes, enabling their migration across endothelial barrier [65,67].  
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Thrombin also exhibits mitogen properties. For example, it promotes the 
proliferation of ECs, fibroblasts, and vascular smooth muscle cells [68,69], mainly 
dependent on the activation of extracellular signal-regulated kinases (Erk1/2) 
[68,69]. Erks are a subgroup of mitogen activated protein kinase (MAPK) that 
mediates the signal transduction in response to extracellular mitogen. The 
activation of Erk1/2 (p42/p44) is dependent on the sequential activation of raf 
(MAPK kinase kinase) and MEK (MAPK kinase) cascade [70]. They are ultimately 
linked with cell proliferation and differentiation accomplished by their translocation 
to the nucleus and subsequent regulation of the gene expression [71].  
 
Thrombin induces the permeability increase in an EC monolayer and causes 
vascular leakage [72,73]. Vascular barrier integrity disruption remarkable increases 
the permeability to blood fluid and is the central pathophysiologic mechanism of 
many inflammatory disease processes. The mechanism of thrombin-induced EC 
barrier dysfunction has been extensively studied. It involves PAR1-dependent 
coupling to G protein (Gq, G12/13), which lead to activation of Rho GTPase (RhoA) 
and myosin light chain kinase (MLCK). MLCK phosphorylates myosin light chain 
(MLC), causes actin-cytoskeleton contraction which leads to the disassembly of 
adherens junctions between adjacent cells and profound actin stress fiber formation 
[73,74]. In addition, signalling cross-talk between PAR1 and sphingosine kinase 1 
receptor 3 (S1P3) also contributes to the barrier disruptive response of thrombin in 
ECs [75,76]. Sphingosine-1-phosphate (S1P) is a biologically active lipid originated 
from sphingosine through phosphorylation by sphingosine kinases (SK) [77]. In ECs, 
S1P is produced in the cytosol, after which it then translocates extracellularly to 
signal via S1P1-S1P3 [73] and elicits various biological activities including cell 
survival/migration and EC barrier regulation [77-80]. At physiological concentrations 
(< 1-2 μM), S1P preferentially activates the Rho GTPase Rac (sensitive to Gi 
protein) through its ligation to S1P1 and Gi protein coupling, leading to barrier-
protective cellular responses. In contrast, thrombin stimulation usually produces 
supraphysiologic concentrations of S1P, which is associated with Gq and G12/13 
coupled to S1P3, followed by the activation of RhoA, and therefore promoting 
barrier-disruptive signalling effects [75-77].  
 
29 
 
1.3 Protein C and its multiple functions 
 
Protein C, first isolated from bovine plasma by Stenflo [81], is a vitamin K-
dependent serine protease zymogen. It undergoes selective proteolysis by thrombin 
bound to TM to generate APC which plays an important role in regulating 
coagulation and also promotes direct cytoprotection in various cell types [21,82,83]. 
The zymogen protein is predominantly synthesised in the liver, but is also produced 
extrahepatically, such as in kidney, brain, lung and male preproductive tissues 
[82,84]. Protein C is a 62 kDa glycoprotein with the majority of the protein consisting 
of two chains. A small proportion (5-15% in human plasma) of protein C circulates 
in plasma in a single-chain form [85-87]. The mature zymogen is extensively co- 
and post-translational modified (β-hydroxylation, γ-carboxylation, glycosylation), 
and the removal of the dipeptide Lys156-Arg157 through endoproteolytic cleavage, 
resulting in the formation of two-chain molecule [86]. The predominant two-chain 
protein C contains 419 amino acids (aa), and is comprised of a 262-aa heavy chain 
(44kD) and a 155-aa light chain (21kD) held together by a disulphide bond [81,88]. 
It is suggested that the single and two-chain protein C/APC are functionally 
indistinguishable [88].  
 
1.3.1 Protein C structure 
 
Mature protein C contains a γ-carboxyglutamic acid (Gla) domain, a short helical 
hydrophobic aa stack, two consecutive epidermal growth factor (EGF)-like domains, 
and a serine protease domain (Figure 1.4).  
 
The N-terminal Gla domain (aa 1-37) contains 9 Gla residues (position 6, 7, 14, 16, 
19, 20, 25, 26 and 29) resulting from the vitamin K-dependent carboxylation of 
specific glutamic acid residues [89,90]. Coordination of calcium ions by the Gla 
residues is essential for the functional folding of this domain, and they also mediate 
the binding between the Gla domain and negatively-charged phospholipid surface 
[91]. This domain shares a high degree of homology with the corresponding domain 
in other vitamin K-dependent coagulation factors such as prothrombin, FVII, FIX, 
FX [92]. Some residues in the human protein C Gla domain are responsible for the 
30 
 
specific properties of protein C. For example, Leu8 represents a crucial residue for 
the recognition of and subsequent binding to the endothelial protein C receptor 
(EPCR) with high affinity [93]; Asp36/Leu38/Ala39, spanning the Gla domain and 
the helical stack region (aa 38-45), play essential roles in the enhancement of 
protein C anticoagulant activity by its cofactor protein S [94]. Studies done by 
Christiansen et al suggest the helical stack module provides an optimal alignment 
of the enzyme active site with that of the substrate cleavage site on the 
phospholipid surface, enabling an efficient proteolytic activity of APC [95,96]. 
 
EGF1 domain (aa 46-92) is β-hydroxylated at Asp71 (Figure 1.4), and together with 
Asp46 and Asp48, is part of a calcium binding sites [97]. The precise functions of 
EGF1 and EGF2 domains (aa 46-137) are not well understood, but they might 
contribute to the interaction with other proteins, such as protein S [97], FVa and 
FVIIIa [14,21,98]. The entire Gla/EGF1-2 region of protein C is responsible for the 
interaction with thrombin/TM, which is demonstrated by the study using isolated 
domains of protein C. It is shown that fragment consisting of intact Gla/EGF1-2 
domain competes with protein C for binding to thrombin/TM, whereas no inhibition 
was attained by Gla or the two EGF domain fragment alone [99]. The N-linked 
glycosylation at Asn97, which is in the EGF2 domain of protein C, has been shown 
essential for the efficient secretion of the protein [100]. Glycosylation at Asn97 also 
affects the conformation of the heavy chain and therefore influences the 
accessibility for the occurrence of glycosylation at Asn329 [100].  
 
The chymotrypsin-like serine protease domain (SPD, aa 138-419), located at the C-
terminus of protein C, confers catalytic activity. The catalytic triad is composed of 
His211, Asp255 and Ser360 (Figure 1.4), corresponding to chymotrypsin’s 
sequence of His57, Asp102 and Ser195 [92]. This domain contains a high-affinity 
Ca2+ binding segment (aa 225-235), called 70-loop (Figure 1.4). With bound Ca2+ 
ions, this module enhances protein C activation by the thrombin-TM complex and 
also the interaction of APC with FVa [101,102]. The SPD also contains 225-loop (aa 
385-390) (Figure 1.4) that mediates Na+ binding. This loop is allosterically linked 
with the Ca2+ binding 70-loop, such that the presence of Na+ is required for the 
coordination of Ca2+ in the former loop, which ensures the catalytic efficiency of  
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APC [103]. In addition to 70-loop, other loops including 37-loop (aa 190-193), 60-
loop and 148-loop (also called autolysis loop, aa 301-316) (Figure 1.4) also provide 
positively charged surfaces that are critical for the interaction with FVa and FVIIIa 
[102,104-107] and thrombin/TM complex [83,108,109]. Residues Glu330 and 
Glu333 in helix 162 (Figure 1.4) in the SPD have been reported to form part of the 
interaction sites that binds PAR1 [110]. The protein C activation peptide (Asp158-
Arg169) is also contained in the SPD (Figure 1.5, left panel) that is proteolytically 
removed by thrombin/TM, resulting in protein C activation.  
 
N-linked glycosylation sites present in the SPD include Asn248, Asn313 and 
Asn329 [100]. The glycosylation at Asn329 is responsible for the natural α-
glycoform protein C (protein C with all four N-linked glycans) which constitutes 55-
78% of plasma protein C [87,100]. It is suggested that the glycan attachment to the 
unusual Asn-X-Cys consensus sequence at Asn329 is less favourable for 
glycosyltransferase processing than the classical Asn-X-Ser/Thr sequence, and 
thus the percentage of the protein C glycosylation at this site in SPD is at least 
partly associated with the rate of protein synthesis [87]. The significance of 
glycosylation at Asn329 is not clear; however in vitro studies have revealed that β 
APC, in which Asn329 glycosylation is lacking, exhibits enhanced anticoagulant and 
cytoprotective activities [100,111]. Mutating of Asn313 to Gln results in a higher rate 
(2.5-fold faster than WT protein C) of protein C activation by TM bound thrombin 
due to an enhanced affinity of protein C-N313Q to thrombin/TM (indicated by 
reduced Km) [100]. Glycosylation at Asn248 is important for the intracellular 
removal of Lys-Arg dipeptide, and thereby alters the percentage of single-chain 
protein C secreted [100]. Protein C lacking of glycan at both Asn329 and Asn248 
represent γ-protein C, which accounts for ~5% of total plasma protein C [87,100]. 
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Figure 1.4 Protein C domain structure.  
In the left cartoon, blue spheres indicate the calcium ions bound by the Gla domain. 
White circle signify the β-hydroxylation site. The sites of glycosylation are denoted 
in yellow squares. The catalytic triad is highlighted in red ovals. AP represents 
activation peptide, and the important loops are indicated by text. 
In the right model, SPD (wheat)/EGF1-2(grey) structures are based on the x-ray 
model of Gla-domainless APC, the Gla domain (yellow) is based on the x-ray 
structure the FVIIa Gla, and activation peptide (dark red) is introduced using 
homology modelling [88]. Important loops including 60-loop (purple), 37-loop (dark 
blue), 70-loop (green), 148-loop (orange), and 225-loop (light blue) are highlighted 
in distinct colours. Glu330 and Glu333 are in brown and catalytic triad is shown in 
red.  
 
1.3.2 Protein C activation 
 
Thrombin activates protein C through the catalytical cleavage after Arg169, with 
subsequent release of an activation peptide (Lys158-Arg169) [5,112]. The rate of 
activation is approximately 1000-fold enhanced by TM which forms a high-affinity 
complex with thrombin (Kd  0.5 nM) [25,113]. Therefore, physiologically, protein C 
activation by thrombin alone does not occur to any appreciable degree. TM is an 
integral membrane protein that contains a lectin-like N-terminal domain, six EGF-
like domains, an O-linked sugar domain, a single transmembrane domain, and a 
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short cytoplasmic tail at C-terminus (Figure 1.5A) [114-116]. The EGF5-6 domains 
of TM bind to the anion-binding exosite I of thrombin (Figure 1.5A&B), with the 
affinity further enhanced by the interaction of chondroitin sulphate located in the O-
linked sugar region of TM with anion binding exosite II in thrombin (Figure 1.5A) 
[117]. Upon binding to TM, thrombin is more susceptible to inactivation by AT and 
PCI than free thrombin [83,118]. More importantly, binding to TM switches the 
specificity of thrombin from a procoagulant to an anticoagulant through the 
activation of protein C. TM is believed to alter both the environment of active site of 
thrombin and the conformation of the thrombin binding residues adjacent to the 
scissile bond of protein C [117]. This eliminates repulsive interactions that would 
exist between free enzyme and substrate, resulting in the acceleration of protein C 
activation [117]. TM, through its EGF4 domain, also binds the protein C SPD in the 
loops 37, 60, 70, and 148 (minor roles) of protein C (Figure 1.5B) [21,83,109].  
 
 
 
Lectin-like
EGF-like
1
2
3
4
5
6
O-linked sugar
transmembrane
cytoplasmic
TM
Chondroitin sulfate
ABE II
Thrombin
ABE I
 
 
 
 
 
A 
34 
 
 
 
 
Figure 1.5 Thrombin/TM complex and its activation of protein C. 
A), The domain organisation of TM EGF4-6 (purple) with thrombin (red) bound is 
shown [119]. TM domains are identified as labelled. EGF modules are numbered 
and transmembrane region is shown as a typical single helix. Anion-binding exsoite 
(ABE) I and II are shown in thrombin, which ABEI is shown to interact with EGF5-6 
of TM and ABEII is bound by the chondroitin sulphate from O-linked sugar domain 
of TM. B), Thrombin (orange) bound to TM (EGF5-6, blue) activates protein C 
through the catalytic removal of the activation peptide (AP, dark red) in SPD of 
protein C. The loops 60 (purple), 37 (dark blue), and 70 (green) are shown to 
interact with EGF4 domain (purple) of TM. Thrombin/TM and EPCR model were 
made in pyMOL based on their published X-ray structures. For information on the 
structure of protein C, refer to figure 1.4. 
 
 
EPCR binds to protein C and accelerates protein C activation by 20 and 5 fold, in 
vivo [120] and in vitro [120,121], respectively. It is a type 1 transmembrane receptor 
that is homologous to the major histocompatibility complex class1/CD1 family of 
proteins [122].  EPCR is predominantly expressed in large vascular endothelium 
B 
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rather than that in microvasculature [123]. The interaction of protein C with EPCR is 
mediated through the Gla domain. The high affinity binding to EC EPCR (Kd  30 
nM [122]) is unique to protein C, since most of the vitamin K-dependent proteins do 
not bind EPCR  [122]. It has been shown that Leu8 in Gla domain of protein C/APC 
is specifically responsible for this high affinity binding (Figure 1.6) [124]. This 
residue, as buried in the EPCR surface, makes a close hydrophobic contact with 
Leu82 in one of the extracellular helices of EPCR (Figure 1.6) [124]. The critical role 
of Leu8 in binding EPCR is confirmed by its presence in the Gla domain of FVII(a) 
which also binds soluble EPCR (with comparable affinity to protein C/APC [124]. 
However, due to the low plasma concentration of FVII (6 fold lower than protein C), 
it is unlikely that FVII(a) would compete with protein C for EPCR in the physiological 
context. This protein C and EPCR binding is highly dependent on the presence of 
Ca2+ ions coordinated by the Gla residues [125].  
 
Because the Kd of protein C to EPCR is around 30 nM, which is approximately half 
of the plasma concentration of circulating protein C, the majority of EPCR 
expressed on the vasculature endothelium should be occupied by protein C under 
physiological conditions. In fact, in vivo protein C activation is largely dependent on 
EPCR [120]. EPCR is shown to facilitate protein C activation by thrombin/TM 
complex in several ways. Firstly, it decreases the Km for protein C activation 
[120,126]. This potentially protects the thrombin/TM complex from inhibition by 
thrombin inhibitors such as AT and PCI [120]. EPCR might also induce a 
conformational change of protein C through binding to it, since the maximum 
velocity of thrombin/TM-mediated protein C activation is also augmented in the 
presence of EPCR [127]. Lastly, the increase of the local concentration of protein C 
close to thrombin/TM complex might also contribute to the enhanced rate of APC 
generation. This is because EPCR can potently decrease the binding affinity (Kd) of 
protein C to TM to 125~162 nM, from 0.7~1.0 μM in the absence of EPCR [127]. 
Additionally, the observation that colocalisation of EPCR and TM in the same 
subcellular compartment of EC membrane may also suggests that EPCR could 
bring protein C into close proximity to its activation complex [128,129]. Although 
EPCR binds protein C with high affinity, the binding is reversible [130]; and as a 
consequence, bound protein C can be replaced continuously in circulation. The 
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release of APC from EPCR also enables it to fulfil its anticoagulant activities, for 
which its binding to EC/platelet membrane phospholipids is required. The APC that 
remained EPCR-associated, which accounted for at least 30% of the total APC 
generated [131], may play an important role in the cytoprotective signalling.  
 
 
 
 
Figure 1.6 Model of protein C Gla bound to EPCR. 
EPCR consists of two α-helices and an eight-stranded β-sheet, which create a 
groove filled with phospholipids (dark red). Ca2+ coordination in the Gla domain of 
protein C (blue) exposes the N-terminal ω-loop, in which Leu8 (blue spheres) 
specifically interacts with Leu82 (light green) in EPCR. The model of the complex 
contains the residue 7-177 of recombinant soluble EPCR and 1-33 residues of the 
protein C Gla domain, which was made in pyMOL based on the published crystal 
structure of the complex [132]. 
 
 
In human plasma, the zymogen protein C circulates at a concentration of 65 nM 
with a circulating half-life of ~ 8 hours. After activation, APC activity in the plasma 
has a half-life about ~ 20 minutes [133]. The inactivation of APC physiologically is 
majorly mediated by PCI and α-antitrypsin, the activity of the former is enhanced by 
and dependent on heparin [134,135]. Other APC inhibitors exhibit minor inhibitory 
effects on APC include α2-macroglobulin, α2-antiplasmin and PAI-1 [23,136].  
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1.3.3 The anticoagulant function of APC 
 
The natural substrates of APC as an anticoagulant are FVa and FVIIIa [83]. FV and 
FVIII are homologous in domain organisation (A1-A2-B-A3-C1-C2), and are both 
activated by thrombin, which catalyses the proteolytic releases of B domains 
(Figure 1.7A) [137]. FVa and FVIIIa contain two chains, a heavy chain (A1-A2) and 
a light chain (A3-C1-C2), which are Ca2+ (FVa) or Cu2+ (FVIIIa)-dependently linked 
between A1 and A3 domains (Figure 1.7) [137]. While inactivation cleavages only 
occur in the heavy chain, the C domains in the light chain are considered to 
promote phospholipid binding [21]. 
 
1.3.3.1 Inactivation of FVa by APC 
 
The inactivation of FVa by APC involves the proteolysis at Arg306, Arg506 and 
Arg679 (Figure 1.7). While the first two cleavages are important for the inactivation 
of FVa, the cleavage at Arg679 is considered to be of minor importance [138]. This 
is because Arg679 cleavage is only involved in degradation of naturally occurring 
FVa variants that is mutated at Arg306, in the presence of protein S [139]. The 
cleavages at Arg306 and Arg506 differ in terms of kinetics, phospholipid 
dependence, resultant levels of FVa activity, and the influence by other coagulation 
factors such as protein S, FXa and prothrombin [140].  
 
In the absence of its cofactor protein S, cleavage at Arg506 by APC is kinetically 
favoured and occurs 20 fold faster than that at Arg306. This is attributable to the 
positively charged exosites of APC, comprised of the basic residues in loops 37, 70 
and 148, preferably interacting with the negatively charged residues close to 
Arg506 [21]. Dahlback and colleagues have studied individual cleavage at Arg506 
and Arg306 utilising FVa variants, R306Q/R679Q and R506Q/R679Q, which 
enables the cleavage of FVa by APC at individual sites [141]. They found that 
although negatively charged phospholipids can augment FVa inactivation by APC, 
they are not required for the cleavage at Arg506. In contrast, Arg306 cleavage is 
fully dependent on the presence a phospholipid surface, upon which these proteins 
assemble. Whilst the initial cleavage at Arg506 results in partial loss (~70%) of FVa 
cofactor activity [142], Arg306 cleavage induces dissociation of the A2 domain from 
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FVa and leads to its complete inactivation [143]. Protein S enhances the 
inactivation of FVa in several ways (described in section 1.3.3.3). The proteolytic 
degradation of FVa by APC can be impaired in the presence of FXa as well as 
prothrombin [138,141]. FXa is known to specifically protect the cleavage at Arg506, 
probably because FXa binds to the FVa exosite close to Arg506 that is shared by 
APC. As a consequence, the binding of FXa to FVa sterically hinders the docking of 
active site of APC to Arg506 of FVa [138]. In contrast to FXa, inhibition of FVa 
degradation by prothrombin is not confined to one cleavage site [141].  
 
1.3.3.2 Inactivation of FVIIIa by APC 
 
FVIIIa inactivation by APC involves the dissociation of its A2 domain (Figure 1.6) 
[144]. The APC cleavage sites in FVIIIa include Arg336 (in A1 domain) and Arg562 
(in A2 domain) (Figure 1.7B). Unlike to FVa inactivation, cleavage at Arg336 is 
kinetically favoured and occurs 6 fold faster than the cleavage at Arg562 [21]. In 
addition to the degradation by APC, FVIIIa is labile and can lose its activity resulting 
from the spontaneous dissociation of the A2 domain [144]. The formation of the 
tenase complex with FIXa stabilises FVIIIa and protects it from inactivation by APC 
[144]. 
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Figure 1.7 Protein C inactivation of FVa and FVIIIa. 
A), Thrombin-mediated FV activation involves the catalytic cleavage after three 
arginine residues (709, 1018 and 1545) in the B domain of FV, leading to the 
dissociation of B domain. APC inactivates FVa by catalysing the release of A2 
domain as a result of the cleavage after Arg 306, 506 and 679. B), APC 
proteolytically cleaves FVIIIa after Arg336 and Arg562, the subsequent loss of A2 
results in the inactivation of FVIIIa. The circled cross in the APC SPD represents 
the positive charged residues in the surface loops, which are important for the 
catalytic efficiency of APC. Small pink sphere between A1 and A3 domains of FV(a) 
and FVIIIa indicated the bound Ca2+/Cu2+ ions. Figures are adapted from [145] with 
permission. 
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1.3.3.3 The role of protein S in the APC anticoagulant pathway  
 
Protein S, also a vitamin-K dependent protein, is well known as a cofactor for APC. 
The mature protein consists of 635 aa and circulates in the plasma at around 350 
nM [146]. Protein S is a multidomain molecule comprised of a Gla domain, a 
thrombin sensitive region (TSR), 4 EGF-like domains and a sex hormone binding 
globulin-like (SHBG) domain at the C-terminus [146]. The Gla domain, coordinating 
8 calcium ions, serves to bind phospholipid surface with high affinity. The TSR is 
susceptible to cleavage by thrombin in the absence of calcium and phospholipids, 
and therefore it is unclear whether this occurs physiologically [146]. The Gla, TSR 
and EGF1-2 domains of protein S have been reported to be critical for the 
enhancement of APC function. Specifically, it has been shown that Glu36, in the 
Gla domain, and Asp95, in EGF1 domain, are important for protein S enhancement 
of FVa inactivation by APC [147,148]. Protein S forms the complex with C4BP 
through its SHBG domain [146]. Approximately 60% of protein S in plasma is 
associated with C4b-binding protein (C4BP) whereas the remaining 40% circulates 
in a free form [149]. C4BP is a multimeric protein that contains several (6 or 7) 
identical α chains bound together by a β-chain which is capable of binding protein S 
[149]. While only the protein S in free form is generally considered to be a cofactor 
for APC, recent results have suggested that C4BP-bound protein S is also able to 
enhance APC-mediated degradation of FVa, although it is not as efficient as free 
protein S [150].   
 
Protein S enhances APC-mediated inactivation of FVa in the presence of 
phospholipids. The enhancement is approximately 27 fold for Arg306 cleavage, 
whereas the cleavage at Arg506 is increased by only 5 fold [151]. The first 
proposed mechanism by which protein S augments APC inactivation of FVa is 
through binding to APC, protein S inducing an allosteric conformational change in 
APC, thereby orienting the active site of APC more favourably for proteolysis at the 
Arg306 [152]. Another proposal suggests that protein S enhances the efficiency of 
APC-mediated FVa inactivation through increasing the binding affinity between 
APC and the membrane surface (phospholipids) [153]. This mechanism is 
consistent with the observation that protein S can enhance all the FVa cleavages 
(Arg506, Arg306, and Arg679) [151]. It was also supported by the low affinity of 
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APC for phospholipid membrane. The apparent dissociation constant (Kd(app)) is ~ 2-
7 µM, which is much higher than the plasma concentration of APC, whereas the 
Kd(app) of protein S for phospholipids is about 4-15 nM [154,155]. Lastly, protein S is 
also proposed to counteract the FXa-mediated protection of FVa degradation by 
APC that protects Arg506 cleavage [151]. It is, however, unclear if protein S directly 
competes with FXa binding to FVa  [138,156]. 
 
In FVIIIa inactivation by APC, both cleavages are enhanced by protein S, but it has 
been shown protein S has a greater effect at Arg562 [144]. Inactivated FV (FVi) 
also enhances the inactivation of FVIIIa with the priority oriented to the cleavage at 
Arg562 in the presence of protein S [144]. As a consequence, the kinetics of FVIIIa 
inactivation is altered with the presence of protein S and FV, resulting in the 
cleavage rates differing by 2 fold between the two cleavage sites [144].  
 
The anticoagulant protein C system ensures thrombin generation and subsequent 
fibrin clot formation is limited to the site of vascular damage. When thrombin, 
generated during coagulation cascade, escapes from the haemostatic plug, free 
thrombin is either inhibited by AT in circulation or it binds firmly with the TM 
expressed on the intact EC surface adjacent to the damaged area. Therefore, the 
generation of APC at the edge of the fibrin clot ensures this enzyme spatially 
confines the fibrin deposition. The physiological importance of the anticoagulant 
protein C system is demonstrated by the observation that homozygous deficiency of 
protein C results in severe thromboembolic disease in both human and mice, which 
the thrombotic symptoms manifests shortly after birth [157]. Mice with depleted TM 
expression in vascular endothelium, where protein C activation is impaired, exhibit 
spontaneous and fatal thrombosis in the vasculature system [158]. The action of 
APC as an anticoagulant is dependent on protein S, as the in vitro plasma-based 
thrombin generation assay has shown a complete protein S dependence of APC’s 
anticoagulant activity [147]. How heavily protein C system is dependent on protein 
S physiologically is unclear, but humans with congenital partial deficiency in protein 
S are diagnosed with severe recurrent venous thrombosis [159].  
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1.3.4 The cytoprotective pathways of APC   
 
In addition to its anticoagulant activity, APC also exerts potent cytoprotective 
properties, which have been demonstrated in the systems of in vitro cultured cells 
as well as in vivo inflammatory animal models [83,160-174]. The mechanisms of the 
protective cellular responses to APC are not fully understood. However, it has been 
proposed that the binding of EPCR by the Gla domain of APC endows a different 
specificity of this enzyme, enabling APC to activate PAR1 and thereby initiate 
cytoprotective signalling in ECs [129,164,165,175].  
 
1.3.4.1 Anti-inflammatory activity of APC 
 
It has been extensively shown that APC exerts direct anti-inflammatory effects on 
ECs and leukocytes. The major effect of APC on leukocytes is the downregulation 
of cytokine release, which may diminish the initiation of systemic inflammatory 
responses. APC also inhibits the inflammatory mediator secretion from ECs. In 
addition, APC attenuates the expression of adhesion molecules on ECs, thereby 
reducing leukocytes adhesion and infiltration of tissues. Enhancement of 
endothelial barrier by APC also limits the damage to underlying tissue during 
infection triggered inflammatory responses.    
 
In a lipopolysaccharide (LPS)-induced model of endotoxemia, APC has been 
shown to inhibit the production of proinflammatory mediators by monocytes [176-
178]. In vivo animal injury studies suggest APC reduces the cytokine release from 
leukocytes, and their accumulation and chemotaxis, therefore attenuates endotoxin-
induced pulmonary injury and inflammation [179,180]. The mechanism of APC-
mediated anti-inflammatory activities on leukocytes is not completely understood. 
Studies suggest an important role of EPCR for these APC-exhibited cytoprotective 
effects [181,182]. However, other receptors such as β1 and β3 integrins in human 
neutrophils, the apolipoprotein E receptor 2 (apoER2) in human monocytes, and the 
αMβ2 integrin Mac-1 (CD11b/CD18) in murine macrophages are also reported to 
modulate the anti-inflammatory activities of APC [113,183-185]. It is noteworthy that 
soluble EPCR, in which transmembrane helix is lacking, can interact with integrin 
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CD11b/CD18 on activated neutrophils [186]. This raises the possibility that APC 
might also exhibit indirect interaction with Mac-1. APC also extends the lifespan of 
circulating monocytes in vivo, through inhibition of spontaneous monocytes 
apoptosis [182,187]. However it remains controversial whether this is beneficial 
under the circumstance of severe infection disease, for example sepsis; because it 
might also result in the prolonged proinflammatory mediator secretion which 
induces the deleterious tissue damage and amplify proinflammatory response.    
 
On ECs, APC not only attenuates the cell production of pro-inflammatory cytokines 
(i.e. TNF-α, IL-6, IL-8, MCP-1) [176,177], but it also suppresses the expression of 
adhesion molecules expression on the cell surface (i.e. VCAM-1, ICAM-1, E-
selectin and fractalkine) (Figure 1.8) [163,176,188]. APC inhibits nuclear 
transcription factor κB (NF-κB) mediated genes through directly decrease the 
expression and functional activity of NF-κB (Figure 1.8) [163,177,189]. This leads to 
the attenuation of cytokine signalling and adhesion molecules production [190]. 
Inflammatory responses are also diminished by APC through down-regulation of E-
selectin-dependent leukocyte rolling, which limits diapedesis [191-193]. The 
paradigm of the molecular mechanism of APC effects on ECs is established, of 
which the involvement of EPCR/PAR1 axis has been extensively reported [190].   
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Figure 1.8 Anti-inflammatory and anti-apoptotic effects of APC in ECs.  
APC anti-apoptotic/anti-inflammatory activities are dependent on EPCR-binding and 
PAR1 activation in endothelium. These activities include regulation of anti/pro-
apoptotic gene expression and reduction of inflammatory mediator and adhesion 
molecule expression. Arrows indicate stimulation and blocks indicate inhibition. The 
figure was adapted from [190]. 
 
1.3.4.2 Anti-apoptotic activity of APC 
 
Apoptosis, as defined as programmed cell death, is a tightly regulated process 
which is considered a vital procedure under the normal physiological conditions. It 
contributes to various physiological processes including proper development and 
functioning of the immune system, normal cell turnover, embryonic development 
etc.[194]. However, impaired apoptosis (too little or too much) occurs in many 
human diseases such as ischemic damage, stroke, autoimmune disorders and 
numerous types of cancer [194]. This ‘programmed’ cell death can be triggered 
through two distinct pathways, termed intrinsic and extrinsic. In response to cellular 
stress, such as hypoxia, apoptotic signals initiated intracellularly cause the release 
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of cytochrome C from mitochondria and subsequently activate procaspase-9 [195]. 
These represent the key procedures of the intrinsic pathway of apoptosis. The role 
of mitochondria in balancing apoptotic and survival signals is dependent on the 
central regulators, such as p53, tumor suppressor protein and the Bcl-2/Bax family 
proteins [194,196]. Activation of extrinsic pathway of apoptosis occurs in response 
to extracellular stimuli, through the ligation of membrane-expressed death receptors. 
This is dependent on the early activation of initiator caspases (i.e. pro-caspase-8), 
and may also utilise the intrinsic elements such as Bcl/Bax family proteins or may 
directly activate the executioner caspase-3 [194,195]. No matter whether apoptosis 
is processed through intrinsic or extrinsic pathway, the activation of core effector 
caspase-3 is an characteristic of cellular apoptosis [194,195].  
 
In an EPCR and PAR1 dependent manner, APC exhibits anti-apoptotic effects by 
attenuation of DNA degradation, reduction of caspase-3 activation and decrease of 
phosphatidylserine translocation to the outer leaflet of the cell membrane [165,167]. 
It has been suggested APC alters the gene-expression profile of human umbilical 
vascular endothelial cells (HUVECs), through down-regulation of pro-apoptotic 
genes and up-regulation of anti-apoptotic genes [163,164,197]. In human brain 
endothelium subjected to hypoxia, APC is able to inhibit tumor suppressor protein, 
p53, normalise the ratio of Bax/Bcl-2 and reduce activation of caspase 3 (Figure 1.8) 
[165]. Similarly, APC counteracts neurovascular toxicities by interfering with several 
pathways of the apoptotic cascade induced by staurosporine, N-methyl-D-aspartate 
(NMDA) and tPA, such as down-regulation of p53 activation, nuclear translocation 
of apoptosis-inducing factor (AIF), caspase 8 and 3 activation [160,168]. 
Collectively, APC is observed to influence both intrinsic and extrinsic apoptotic 
pathways, although the exact mechanism remains unclear, and future work is 
needed to clarify how exactly APC exerts anti-apoptotic functions.  
 
Activation of Erk1/2 by APC has been observed by many groups (Figure 1.8) 
[164,198,199]. APC-mediated Erk1/2 pathway activation does not only contribute to 
the elevated EC proliferation [198], it is also implicated in the impairment of TNF 
signalling leading to the suppression of TNF-related apoptosis-inducing ligand 
(TRAIL) production [199,200]. 
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1.3.4.3 Endothelial barrier protection by APC 
 
The endothelium that lines the vasculature forms a single-cell layer that controls the 
exchange of water, macromolecules, solutes and white blood cells between the 
blood and extravascular tissues. Endothelial barrier disruption can cause increased 
extravasation of blood components, and in excessive circumstances can result in 
tissue oedema and dysfunction. Endothelial hyperpermeability can be a life-
threatening clinical complication, which is found in pathological conditions 
associated with many serious diseases such as sepsis, ischaemic stroke, diabetes, 
and acute lung injury [201]. Generally speaking, the permeability of the endothelium 
is maintained by an equilibrium between the contractile force of the EC cytoskeleton 
and the adhesive force generated at cell-cell junctions and cell-matrix interactions 
[202].  
 
The major components involved in cytoskeletal contraction are actin and myosin. In 
ECs, the actin-myosin interaction is mediated primarily by MLC phosphorylation 
induced by MLCK. The contractile process can be activated through increasing the 
activity of MLCK by Ca2+/calmodulin signalling, or alternatively via the inhibition of 
MLC phosphatase activity [203]. Rho-like small GTPases are upstream effectors 
involved in the regulation of MLC phosphorylation [73,203,204]. Formation of 
endothelial gaps can also be caused by disruption or rearrangement of the actin 
cytoskeleton, resulting from the formation of stress fibers or local breaks of 
endothelial peripheral actin rim induced by various inflammatory stimuli, including 
thrombin, histamine and VEGF [205].  
 
In addition to a stable actin cytoskeleton, cell-cell adhesion also plays an important 
role for the maintenance of the EC integrity. This is primarily accomplished by the 
assembly of the adherens junctions (AJs), which serves as an intermediary 
connecting the actin cytoskeleton between adjacent cells. AJs are protein 
complexes consisting of cadherin proteins (especially vascular endothelial (VE) 
cadherin) that are associated with the actin cytoskeleton through catenins (α-, β-, 
and γ-catenin and p120). The extracellular domain of VE-cadherin connects 
adjacent ECs through Ca2+-dependent homophilic binding (Figure 1.9) [73], and 
dissociation of VE-cadherin/catenin complex from the cytoskeleton can cause 
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endothelial barrier disruption [73,74].  Tight junctions (TJs) are another type of 
junctions joining together the cytoskeletons of adjacent cells. TJs are formed from 
transmembrane proteins with their extracellular domains joining one another, of 
which the major types are the claudins, occludins and JAM-1 (Figure 1.9). These 
proteins are linked to the actin cytoskeleton by binding to adaptor proteins (i.e. ZO-
1/2/3, cingulin) via their cytosolic domains (Figure 1.9).  Similar to AJs, dissociation 
of TJ proteins interferes with the sealing efficiency of intercellular junctions and lead 
to EC hyperpermeability [206].  
 
The essential role of Rho GTPases in modulating endothelial permeability is 
highlighted by its direct and indirect effects on the myosin-actin interaction and cell 
junction assembly. Rho GTPase consists of Rho, Rac and Cdc42, of which the 
activities are associated with the type of ligands and might have distinct biological 
effects under different conditions. In most cases, Rac1 stabilises cell junctions, 
however it also participates in a barrier-disturbing pathway to generate reactive 
oxygen species through the activation of NADPH oxidase upon stimulation by 
VEGF [207]. Similarly, RhoA is protective in unperturbed cells, however it is strongly 
activated in ECs stimulated by thrombin which leads to endothelial barrier disruption 
[204]. Steady-state stable junctions in ECs are maintained by multiple pathways 
that favour activation of Rac1 and Cdc42 and inhibition of RhoA. The formation of 
AJs provokes intracellular signalling that leads increase of expression and cortical 
translocation of Rac1-specific guanine nucleotide exchange factor (GEF), Tiam, 
and spatial activation of Rac1 [208]. Activation of Rac1 and p190RhoGAP, a Rho 
GTPase regulatory protein, through binding of p120-catenin to junctional complexes 
further inhibit the activity of RhoA [209]. In activated ECs, thrombin induces a 
PAR1-dependent activation of RhoA via Gq/Ca2+/PKCα and G12/13/p115RhoGEF 
pathways [204]. RhoA leads to activation of myosin II, actin-mediated EC 
contraction and disassembly of AJs, resulting in the formation of intercellular gaps. 
This is achieved by the augmentation of MLC level through two independent 
pathways. One pathway relies on the activity of Rho associated kinase (ROCK), 
which functions to inactivate MLC phosphatase; the other pathway depends on the 
phosphorylation of MLC by MLCK [73]. In addition, thrombin stimulation also 
decreases cyclic AMP (cAMP) level, which inhibits Rac1 [204]. 
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The effects of cAMP and cGMP are generally considered to improve endothelial 
barrier function [203]. cAMP causes the dephosphorylation of MLC and thereby 
attenuates actin/myosin contraction, which is through a protein kinase A-dependent 
inhibition of both RhoA and MLCK activities. In addition, binding of Epac, a GEF 
known as exchange protein activated by cAMP, to cAMP activates Rap that 
ultimately strengthens the cell-cell adhesions and promotes polymerisation of the 
cortical band actin [210,211]. Generated by a Ca2+/NO-dependent pathway, cGMP 
improves endothelial barrier function through several mechanisms: it signals 
through activation of cGMP-regulated protein kinases, which is considered to be the 
predominant pathway; it also acts through increasing the cytosolic Ca2+ level and 
inhibiting cAMP degradation [212]. Recent studies, however, also suggest that 
cGMP has a endothelial barrier disruptive effect by promoting cAMP hydrolysis, 
which is predominantly observed at superphysiological concentrations [212].  
 
S1P/S1P1 signalling enhances EC barrier function and cytoskeletal reorganisation 
through stabilisation of cytoskeletal elements [74]. At physiological concentrations, 
S1P preferentially signals through S1P1, which maintains the endothelial barrier. 
S1P stimulates MLCK to translocate to cortical actin, where it phosphorylates the 
MLC. Phosphorylation of MLC at this spatially defined location may induce its 
interaction with filamentous actin and thereby stabilises the actin cytoskeleton and 
promotes the interaction between actin cytoskeleton and adhesive elements  
(Figure 1.9) [74]. In contrast, in response to inflammatory agents (i.e. thrombin), 
MLCK phosphorylates central-located MLCs and thereby induces the profound 
formation of barrier-disrupting cytoplasmic actin stress fibres and spatially-localised 
actomyosin contraction, resulting in paracellular gaps (Figure 1.9) [74]. S1P also 
stimulates the translocation of cortactin, an F-actin binding protein that also 
stimulates actin polymerisation and stabilises the cell periphery filamentous actin 
network [74]. The S1P/S1P1 signalling is mechanically related to the AJ 
assembly/stabilisation and VE-cadherin/β-catenin translocation to the areas of cell-
cell contact. Whereas disruption of AJ assembly, such as in response to thrombin, 
are observed at the sites of intercellular gap formation [73,213].  
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APC promotes EC barrier stabilisation and protects EC barrier from disruption by 
inflammatory agents such as thrombin and TNF-α [110,129,171,190,214]. For this, 
EPCR bound APC activates PAR1, and stimulates SK1-mediated production of 
S1P which signals through S1P1 (Figure 1.9) [129,169,215]. APC induces cortical 
MLC phosphorylation and concomitant actin polymerisation in cortical distribution 
[169]. APC also induces Rac1-dependent cortical cytoskeletal rearrangement that 
leads to EC barrier protection [169,216]. In HUVECs, ZO-1 localised to the cell 
periphery is upregulated by APC. This is dependent on the cross-activation of 
angiopoietin-1 (Ang-1), an anti-hyperpermeability protein secreted by ECs [217].  
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Figure 1.9 Endothelial barrier regulations.  
APC stimulates the S1P synthesis by stimulating SK1 activity. Released S1P binds 
to S1P1 receptor, and induces Gi/Rac1-dependent endothelial barrier enhancing 
effects. These include the translocation of cortactin and phosphorylation of MLC 
localised at cortical actin, formation of the AJs (cadherin, p120 α-, β- and γ-Cat) and 
TJs, leading to the stabilisation of actin cytoskeleton and enhances the adjacent cell 
adhesion. When EC is stimulated by thrombin, Gq and G12/13 are coupled with 
PAR1, resulting in the activation of RhoA and ultimate formation of stress fibre. This 
figure was prepared using information from previous studies [129,169]. 
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Regarding the above described effects of APC and thrombin, it raises the question 
that how does the activation of PAR1 by APC result in enhanced barrier function 
whereas activation of the same receptor by thrombin induces dysfunction of EC 
barrier. Recent studies have shed light on this conundrum, suggesting the critical 
involvement of EPCR in mediating APC-induced cytoprotection, which differs from 
PAR1 activation by thrombin. More specifically, it is revealed the beneficial cellular 
effects of APC on ECs are associated with the activation of PAR1 that colocalise 
with EPCR in glycosphingolipid-rich rafts (caveolae) [128,129].  
 
Lipid rafts are defined as detergent-resistant microdomains of the cell membrane 
that are rich in cholesterol and sphingolipids serving as spatial platforms for the 
assembly of signalling complexes [218]. Caveolae are a subtype of lipid raft that are 
characterised by the expression of caveolin proteins attached to the intracellular 
site of the membrane [218]. Importantly, caveolin-1 depletion in ECs impairs the 
signalling mediated by APC but not thrombin, suggesting the critical role of this 
caveola-associated protein in APC signalling [214]. The evidence of the 
colocalisation of EPCR and PAR1 in caveolae further supports the notion that APC 
activation of PAR1 occurs in this compartment of cell membrane [128]. It is noted 
that in quiescent ECs, caveolin-1 is associated with both PAR1 and EPCR [50].  
When EPCR is occupied by APC, caveolin-1 dissociates from EPCR, at which 
circumstances Gi protein is found to couple to PAR1 [50]. In this case, APC-exerted 
cytoprotective cellular effects are resultant from Gi/Rac1-dependent down-
regulation of NF-κB pathway [216]. In contrast, thrombin activates PAR1 in other 
part of membrane rather than caveolae, and therefore induces Gq and G12/13 protein 
coupling, leading to downstream activation of RhoA, NF-κB, and ultimately inducing 
hyperpermeability [216].  
 
It is shown by a recent study that PAR1 internalisation affects both signal duration 
and different G protein coupling [219]. PAR1 activated by APC/EPCR is retained on 
the cell membrane surface even after prolonged APC treatment and this is related 
with long duration of the increase in cytoplasmic calcium levels [113,214,220]. In 
comparison, thrombin induces rapid PAR1 internalisation and degradation, which is 
accompanied by transient increase of cytoplasmic calcium concentration [113,214]. 
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This further indicates that PAR1 activation by the APC/EPCR complex occurs on a 
subpopulation of PAR1 located in a specific subset of lipid rafts. This results in the 
distinct capability to sustain surface association with PAR1.  
 
It is interesting to note, when EPCR is occupied by active site-mutated protein C 
zymogen (S360A), thrombin-mediated activation of PAR1 shares the same 
downstream signalling pathways with APC and results in cytoprotective responses 
[50,113,215,221]. Furthermore, a chimeric meizothrombin (thrombin intermediate 
which has both Gla and Kringle-1 and -2 domains of prothrombin) with an APC Gla 
domain substitution, which can interact with EPCR, elicits protective signalling 
effects in ECs [50]. It appears that the occupation of EPCR, rather than the type of 
the protease cleaving PAR1, determines the cellular responses in ECs. EPCR 
mediates the caveolin-1–associated rearrangement of the receptor complex, affects 
the duration of PAR1-initiated signal, association of activated PAR1 with specific 
intracellular signalling transducer, thereby leading to modified PAR1-mediated 
responses.  
 
It is worth noting that low concentration (20-50 pM) of thrombin promotes a 
permeability decrease of HUVECs [50,129,215]. The mechanism of this is not clear, 
but could be potentially associated with the low receptor activation rate. At high 
concentrations thrombin is barrier disruptive but is protective below its EC50 (50 pM) 
for PAR1 activation [55]. A study by Bae et al also suggests these EC barrier 
protective effects of thrombin involve the activity of PAR3 [215], with which the 
formation of heterodimers of PAR1 might modulate the signalling specificity of 
PAR1 [222]. These studies further suggest that additional interactions can serve to 
govern the PAR1 response to proteases.  
 
1.3.5 Dissociation of anticoagulant and cytoprotective property of APC  
 
Structure-function studies of protein C/APC have revealed the critical interaction 
sites in this enzyme with its receptors, cofactors and substrates. Through this it has 
been possible to dissociate the functions of APC and further explore the 
mechanism of its multiple activities. Beneficial effects of APC have been observed 
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in various animal injury models, such as LPS-induced endotoxin, pulmonary 
inflammation and injury, stroke, and wound healing/angiogenesis [190]. In light of 
these, it is urged to understand the mechanism of the APC actions in different kinds 
of injury, and to help distinguish the critical or dispensable activities of APC. This 
might inturn facilitate the development of safer yet effective APC derivatives. 
 
The anticoagulant activity of APC relies on the proteolytic inactivation of FVa and 
FVIIIa by the protease in complex with protein S. Inactivation of FVa by APC 
depends on certain interactions between FVa and APC molecules, which the 
positively charged residues in surface loops on APC’s SPD are critical for this 
interaction. As mentioned earlier, these important loops include 37-loop (residues 
190-193) and 70-loop (residues 225-235). Griffin and colleagues have found that 
Ala substitution of positively charged residues KKK191-193 (Figure 1.10) and 
RR229/230 (Figure 1.10) resulted in the APC variant has severely impaired 
anticoagulant activity (4 - 14% of normal activity) [223]. Interestingly, it has also 
found that these APC variants (APC-3K3A and APC-RR229/230AA) have intact 
anti-apoptotic activity which is dependent on PAR1 and EPCR [223].  
 
Based on the mechanism in which the calcium ion coordination in 70-loop is 
required for the interaction of this loop in the APC molecule to FVa, cysteine 
substitution of Asp223 and Arg237 (Figure 1.10) located on the two antiparallel β-
stands generates a disulphide bond between the two beta-sheets [224]. This 
disulphide bond stabilises this loop which is then incapable of Ca2+ binding. This 
prevents interaction with FVa [224]. Likewise, this APC variant has near eliminated 
anticoagulant activity but its cytoprotective activities are not compromised [224].  
 
Previous research conducted in our lab has shown the essential surface residues in 
the Gla domain of APC responsible for the interaction with protein S, which include 
Asp36, Leu38, and Ala39 (Figure 1.10). Substitution of these residues in APC to the 
corresponding residues in prothrombin (Ala36, Asp38, and Val39) results in a 
properly folded Gla domain, but that is no longer enhanced by protein S. Likewise, 
this APC variant (D36A/L38D/A39V) has little activity in inhibiting thrombin 
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generation (< 5% compared to wild type (WT) APC) but normal cytoprotective 
activities (anti-apoptosis and anti-hyperpermeability) [94].  
 
The binding of EPCR is a prerequisite of APC cytoprotective signalling, especially 
on ECs [164,172,198,225]. APC/protein C binds to EPCR via the ω-loop of the Gla 
domain of APC/protein C, in which Leu8 makes a hydrophobic interaction with a 
complementary pocket on EPCR (Figure 1.6 and Figure 1.10) [124]. Although 
prothrombin has a highly homologous Gla domain to that of protein C/APC, it does 
not bind EPCR due to the presence of a valine at the corresponding position. 
Consequently, the L8V mutation results in the protein C variant with a correctly 
folded Gla domain and normal phospholipid binding, but that is unable to bind 
EPCR [124]. The APC-L8V is shown to have comparable FVa hydrolysis to WT 
APC [124]. 
 
Two residues, Glu330 and Glu333 (Figure 1.10) located in helix 325-333, have 
been reported to form the exosite responsible for recognising PAR1 [110]. The 
APC-E330A and APC-E333A generated by Yang et al exhibited normal 
anticoagulant activity but it failed to cleave PAR1, and was therefore unable to 
exhibit cytoprotective effects on ECs [110].  
 
Given the above mutagenesis studies of APC, It appears that genetic engineering 
of APC can generate APC variants that preserve the cellular beneficial effect but 
with reduced anticoagulant activity. APC variants, of which their cytoprotective 
effects are maintained but anticoagulant properties were ablated, might have great 
therapeutic potential such that the adverse effects accompanied, such as bleeding, 
could be prevented. 
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Figure 1.10 Important residues for the anticoagulant or cytoprotective 
properties of APC.  
The crucial residues are highlighted in colours with each function is given in text 
(section 1.3.5). 
 
1.4 Inflammation and Coagulation 
 
Inflammation and coagulation are essential parts of the innate host-defence 
systems that interact closely with each other. They collaborate in the recognition 
and elimination of invading pathogens and in control of the tissue/vascular damage. 
Extensive cross-talk between these two systems has been evident, whereby 
inflammation activates coagulation, and coagulation also considerably regulates 
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inflammation in many ways. Generally, activation of coagulation by inflammation 
includes the induction of TF expression, down-regulation of certain anticoagulant 
systems and endogenous fibrinolysis. Conversely, the coagulation-driven 
modulation of inflammation involves affecting specific cellular receptors on 
inflammatory cells and ECs by activated coagulation factors. 
 
1.4.1 Overview of inflammation 
 
Inflammation is an adaptive response to any type of bodily injury. Acute 
inflammatory response is considered to be beneficial as it aims to neutralise 
invading pathogens/irritants and repair tissue damage. However, dysregulation or 
persistence of inflammatory response, often observed in various types of diseases, 
may lead to loss of organ function and become detrimental [226,227]. In response 
to infection or trauma, the acute inflammation is triggered and involves a rapid yet 
coordinated delivery of leukocytes into the site of infection or injury, and followed by 
the tissue repair after infectious agents are eliminated [227]. Acute inflammation in 
response to microbial infection (i.e. bacterial infection) commences when it is 
recognised by receptors of the innate immune system, for example, toll-like 
receptors [226,228,229]. This is mainly mediated by neutrophils, resident 
macrophages, dendritic cells and mastocytes, which response as a rapid release of 
inflammatory mediators (chemokines, cytokines). Proinflammatory cytokines such 
as IL-1 and TNF-α activate ECs [230]. Activated ECs also produce inflammatory 
mediators, for example, secretion of IL-8 and chemoattractant protein-1 (MCP-1) 
and expression of EC adhesion molecules (E-,P- selectins, ICAM and VCAM) on 
EC surface, and their permeability is also increased [231]. Most of these events are 
mediated by the activation of NF-κB, a transcription factor that controls the gene 
expression of many pro-inflammatory mediators [232]. These adhesion molecules 
recruit the activated neutrophils while elevated permeability enhances neutrophil 
extravasation and migration to the site of injury/infection [64,65,67]. The delivery of 
neutrophils to the inflamed tissue allows the destruction of microbial agents through 
releasing the toxic contents of their granules. Finally, a successful and controlled 
acute inflammatory response includes the resolution and repair phase. This is 
mainly mediated through phagocytosis by tissue-resident macrophages or recruited 
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monocytes in response to the anti-inflammatory mediators, which are released at 
this stage [227]. However, if elimination of the pathogen is not achieved by the 
acute inflammatory response, for example, the persistence of pathogens or self-
antigens, inflammatory process continues and may result in chronic inflammatory 
disease [226]. 
 
1.4.2 Inflammation activates coagulation 
 
The activation of coagulation and deposition of fibrin induced by acute inflammation 
responses can be considered instrumental in limiting inflammatory activities to the 
site of injury or infection, reflecting the physiological efficiency of the relationship 
between coagulation and inflammation. However, inflammation-trigger coagulation 
may also contribute to disease in the case of severe infection, such as sepsis.  
 
Firstly, inflammation can initiate activation of coagulation by inducing TF expression. 
In vivo, IL-6 is mainly responsible for inflammation-induced TF expression. This is 
supported by the evidence showing that blocking IL-6 completely prevents TF-
dependent thrombin generation in animal model of endotoxemia [233]. In cultured 
ECs, TF expression can be induced by proinflammatory cytokines such as TNF-α, 
IL-1, monocyte MCP-1 [9,234]. The up-regulated TF synthesis is found in ECs, 
monocytes/macrophages and dendritic cells during innate inflammation responses 
to low dose experimental endotoxemia [72].  Inflammation also stimulates the 
formation of microparticles from a variety of blood-exposed cells [72]. Microparticles 
arising from stimulated monocytes also carry great amounts of TF which can be 
transferred into other cells during the process of microparticles fusion to their cell 
surfaces [72]. 
 
The natural anticoagulant systems are down-regulated during inflammation, 
particularly the protein C and AT pathway [235]. In severe inflammatory disease, 
the AT system is impaired as a result of a decreased synthesis and up-regulated 
degradation of the AT by elastase secreted by activated neutrophils [235]. The 
reduced synthesis of glycosaminoglycans, which functions as heparin-like cofactor 
of AT also contributes to impaired AT function [235]. The protein C pathway is 
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greatly impaired in inflammatory disease such as sepsis [236]. First, the plasma 
level of protein C is diminished due to the impaired synthesis and increased 
degradation [235]. Down-regulation of TM by proinflammatory cytokines also results 
in the lessened APC generating potential [237,238]. The acute inflammatory 
processes enhance the production of α1-antitrypsin, an inhibitor of APC [236]. 
Moreover, the plasma level of C4BP is also elevated, which results in a decrease of 
free protein S. A reduction in EPCR expression is also found in inflammatory 
disease such as sepsis [239,240], which further compromises a proper function of 
protein C system. 
 
Finally, fibrinolysis is also severely impaired during inflammation, which results in 
the extensive fibrin deposition. During inflammation, although tPA and uPA are 
rapidly released through the stimulation of inflammatory cytokines (ie. TNFα and IL-
1β) [241], more sustained PAI secretion by ECs counterregulates the tPA/uPA 
effect and thereby resulting in the inhibition of fibrinolysis which may aggravate 
organ damage in sepsis [72,241].  
 
1.4.3 Coagulation influences inflammation 
 
The regulation between inflammation and coagulation is bidirectional, such that 
coagulation also stimulates inflammatory activity. Activated coagulation 
factors/cofactors activate specific cell receptors such as PARs to trigger intracellular 
signalling transduction, thereby affecting the inflammatory cell responses. FXa, 
thrombin and fibrin can induce the synthesis of proinflammatory cytokines, including 
IL-6 and IL-8, by ECs and mononuclear cells [242]. TF expression is essential for 
FVIIa signalling through PAR2 in vascular cells, leading to the secretion of 
proinflammatory mediators and expression of leukocyte adhesion proteins [235]. 
FXa as a free protease, or in TF/FVIIa/FXa ternary complex, is found to signal to 
the cells through PAR1 and PAR2, which results in production of cytokines (IL-1β, 
macrophage inflammatory protein MIP-2α), synthesis of adhesion molecules, 
mediation of adhesion and migration of leukocytes [72]. Thrombin is the most 
versatile coagulation protease implicated in inflammation and its actions are 
described previously in section 1.2.4.  
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Although coagulation modulates inflammation in several different ways, blocking 
coagulation by anticoagulants is not by itself guaranteed to limit inflammation. APC 
can control inflammation in several ways, however, the administration of other 
anticoagulants, such as AT, TFPI, and heparin, do not show comparable efficacy 
[201]. It is suggested that the anti-inflammatory effects of APC perhaps is not due to 
its anticoagulant functions [94,223], which further suggests pure inhibition of 
coagulation does not control inflammation. 
 
1.5 Protein Kinase C 
 
Protein kinase C (PKC) is a super-family of serine/threonine-related kinases that 
are implicated in a wide variety of G protein-coupled receptor and other exogenous 
activated cellular responses [243,244]. This family comprises multiple isoforms, and 
according to their structures and modes of activation, are divided into 3 subgroups. 
The classical PKCs (α, β1, β2, and γ) are activated by Ca
2+, diacylglycerol (DAG) 
and phosphatidylserine; novel PKCs (ε, δ, θ, and η) are activated by DAG and 
phosphatidylserine but are independent of Ca2+; atypical PKCs (ζ, and ι/λ) are 
activated independently of either Ca2+ or DAG [244,245]. 
 
1.5.1 PKC structure and activation 
 
PKC isozymes are members of the AGC kinase (PKA, PKG and PKC) family that 
share the same basic structure: an N-terminal regulatory domain and C-terminal 
kinase domain linked by a flexible hinge segment (Figure 1.11). The inactive state 
of PKC is maintained through occupying the substrate-binding cavity (in the 
catalytic domain) by the autoinhibitory pseudosubstrate sequence (in the regulatory 
domain) [246]. The C1 domain is present in both classical and novel PKCs and 
contains the DAG-binding motif [244,247,248]. The C2 domain confers the binding 
to anionic lipids in a Ca2+ sensitive manner [244,247,248]. Novel PKCs lack the 
critical calcium-coordinating acidic residues in their C2 region and, as a result, their 
activities are independent of calcium [248]. The variant contained in the C1 domain 
and absence of C2 domain render the atypical PKC insensitive to either DAG or 
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calcium, but the activity of these PKC isozymes is mainly regulated by protein-
protein interactions through PB1 domain [247,248].  
 
The occurrence of a series of events marks the activation of PKC. Upon stimulation 
of GPCR or receptor tyrosine kinase, the generation of DAG and Ca2+ recruits PKC 
to the membrane through tethering the C1 and C2 domains on the membrane [248]. 
This engagement of C1/C2 domain with membrane causes a conformational 
change in the protein that leads to the loss of autoinhibiton, allowing their activation 
and subsequent substrate binding and phosphorylation [245]. Notably, the expelling 
of psedosubstrate segment can be also mediated by non-conventional ligands such 
as short chained phosphatidylcholines [249] and protamine [250,251]. The 
phosphorylation motifs in PKCs are highly conserved among PKC isozymes (Figure 
1.11) and are termed activation loop, turn motif and hydrophobic motif. The 
phosphorylation of activation loop requires an upstream kinase and that this role is 
fulfilled by the phosphoinositide-dependent kinase-1 (PDK-1) in all three subgroups 
of PKCs [252-255]. The phosphorylation of the activation loop leads to subsequent 
autophosphorylation at the turn and hydrophobic motifs. However, the 
phosphorylation on the latter sites is mainly responsible for stabilisation of the 
protein and aligns residues more favourably for catalysis [256], whereas 
phosphorylation on the activation loop is critical to render the enzymes catalytically 
competent [245]. Activated PKCs then continues to phosphorylate and activate a 
plethora of kinases and thereby modulate diverse cellular responses, such as 
regulating membrane structure events, cell proliferation and many inflammatory 
responses [244,257-261]. 
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Figure 1.11 Domain structure of PKC isoforms.  
PKCs have a conserved catalytic domain (kinase domain) and comparatively 
variable regulatory domains. A pseudosubstrate (PS) motif is present in regulatory 
domain of all PKCs. The mutation in the C2 domain of novel PKCs and C1 domain 
of atypical PKCs disables the calcium binding and DAG binding, respectively. The 
lack of C2 domain in atypical PKCs also determines the activity of these PKC 
isozymes are independent of calcium.  
 
1.5.2 PKC functions 
 
PKC has been implicated in the regulation of a range of cellular events including 
proliferation, differentiation, apoptosis/survival and many inflammatory responses 
[244,257-261]. However, remarkable heterogeneity exists regarding their 
intracellular distribution, activation profiles, and functional roles [243]. Due to the 
diverse profile of protein expression in different kinds of cells, effects of PKC are 
usually cell-type specific.  
 
In ECs, PKC α, β, ε, δ, ζ, η, θ, λ, and μ are expressed and play different and 
sometimes redundant roles in EC function, dependent on the stimulus. For example, 
VEGF, of which the EC signalling has been extensively studied, elicits potent anti-
apoptotic effects through the activation of PKCε, leading to the downstream 
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induction of anti-apoptotic protein Bcl-2 and inhibition of caspase-3 activation [262]. 
In contrast, PKCβ plays an important role in VEGF-induced EC hyperpermeability 
[263]. Interestingly, PKCα, β and θ are shown to be responsible for VEGF-induced 
EC proliferation, through activation of Erk1/2 pathway [264,265].  
 
As this project is associated with the regulation of EC barrier permeability, the 
functions of PKC described herein only involve their modulation in EC barrier 
functions. PKCα [263,266-270], PKCβ [263,271-275] and PKCδ [276-279] are 
thought to be barrier disruptive, such as in response to vascular endothelial growth 
factor (VEGF), thrombin, and phorbol 12-myristate 13-acetate (PMA). In contrast, 
PKCε activation is usually associated with endothelial barrier protective responses 
[270,280-283]. PKCζ differs to these PKC isozymes and plays a role in both 
endothelial barrier protection [284-286] as well as disruption [287-289]. The 
mechanism of PKC involved in the regulation of barrier function has been 
extensively studied. Activation of PKC can cause Rho pathway activation 
[266,290,291], actin polymerization [292], activation of actin-binding proteins 
[292,293], and it also triggers endothelial contractile response [290,293] as well as 
disassembly of VE-cadherin junctions [268,294]. Indirectly, PKC activation may alter 
the EC barrier function by cross talk with other intracellular signaling cascades such 
as nitric oxide (NO) [295-297] and S1P [78,79] pathways. 
 
1.6 Aims of my project 
 
APC and thrombin evoke opposing cellular responses in ECs through the activation 
of the same receptor, PAR1. It has been proposed that APC and thrombin target 
different subpopulations of PAR1 on ECs. APC selectively activates the PAR1 
compartmentalised in caveolae, whereas the localisation of PAR1 in the caveolae is 
not essential for thrombin-mediated signalling [214]. As a result, distinct active 
receptor conformations are likely attributable to the different G protein coupling, 
resulting in triggering different signalling pathways [50,73,128,298]. While the EC 
membrane distribution of PAR1 gives a framework for considering the molecular 
basis of cellular stimulation by APC and thrombin, the detailed mechanisms, 
responsible for protease-selective signalling through PAR1 remains to be 
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completely elucidated. The overall aim of my project was to identify the down-
stream modulators in ECs contributing to the divergent signalling pathways 
mediated by APC and thrombin. Considering the participation of different PKC 
isozymes in the diverse signalling responses, the potential involvement of PKC was 
of particular interest.   
 
The first aim of my project was to examine the receptor/coreceptor specificity of 
APC signalling in ECs, using APC variants and receptor blocking Abs. To do this, 
four protein C variants were generated. Wild type (WT) protein C and protein C 
variants were expressed in mammalian cell lines, followed by purification and 
activation (chapter 3). Their anticoagulant activities were examined (chapter 4). The 
ability of APC and thrombin to cleave PAR1 was determined in chapter 5. PAR1 
and EPCR dependency of APC-mediated activation of Erk1/2 and enhancement of 
EC barrier integrity were investigated (chapter 6). Finally, I aimed to investigate the 
mechanism of which APC and thrombin exhibited distinct cellular responses with 
particular relevance to PKC involvement (chapter 7).   
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Chapter 2 Methodology  
 
PAR1exo peptide cleavage
Protein C variant preparation
• Site-directed mutagenesis
• DNA sequencing
• Transformation of competent cells
• Plasmid extraction
• Expression of protein C variants in HEK 293 cells
• Protein C purification
• Protein C activation and quantification
APC anticoagulant activity 
(CAT assay)
• Erk1/2 phosphorylation assay
• Permeability assay
• PKC translocation detection
• PKC phosphorylation detection
Cell signalling assays
 
 
Figure 2.1 Flow chart of the methods in this thesis.  
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2.1 Generation of human Protein C variants 
2.1.1 Construction of WT protein C vector 
 
The vector pRc/CMV/human protein C which contains WT human protein C cDNA 
was kindly provided by Prof. Bjorn Dahlback (University of Lund, Malmo, Sweden). 
Human protein C cDNA was ligated with restriction enzyme site of HindIII and Notl 
at each end before it was cloned into pRc/CMV vector (Invitrogen) (Figure 2.2). The 
pRc/CMV/protein C vector contains SV40 origin of replication, cytomegalovirus 
(CMV) and T7 and Sp6 promoters. It is also resistant to Ampicillin (Amp) and 
Neomycin. The resultant pRc/CMV/human protein C plasmid was used as a 
template to produce single point or composite mutations by site-directed 
mutagenesis.  
 
Figure 2.2 Protein C expression vector.   
The pRc/CMV/human protein C vector contains human protein C cDNA flanked by 
HindIII and Notl restriction sites. The CMV promoter enhances the expression of 
protein C in the mammalian cells. The Amp-resistant gene and Neomycin gene 
were used for the vector selection in the bacteria transformation and mammalian 
cell transfection, respectively. T7 and Sp6 promoters enabled the sequencing of the 
insert using T7 and Sp6 primers.  
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2.1.2 Generation of protein C mutants by site-directed mutagenesis 
 
Protein C variants were generated by site-directed mutagenesis using 
QuickChange II XL site-directed mutagenesis kit (Stratagene) (overviewed in Figure 
2.3). In detail, the complementary primers containing desired mutation(s) were 
designed (Primer sequences refer to Appendix) and manufactured by Thermo 
Scientific. The sample reactions were prepared at 25 μl scale with the composition 
listed in Table 2.1 before adding 1.25U of PfuUltra HF DNA polymerase. The 
mutated dsDNA was produced and amplified using the polymerase chain reaction 
(PCR) with cycling parameters outlined in Table 2.2. The end product was treated 
by 5U of Dpn 1 restriction enzyme for 1 hour at 37 ºC to digest the parental dsDNA 
before transforming bacteria cells. 
 
 
 
 
 
Figure 2.3 Overview of the site-directed mutagenesis method.  
The procedure of site-directed mutagenesis includes introduction of mutation(s) by 
PCR using base pair substituted primers, Dpn1 digestion of template and 
transformation into competent cells for nick repair. 
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Component Volume/µl 
10×reaction buffer 2.5 
WT human PC vector (20 ng/μl) 1 
Forward primer (10 µM) 0.75 
Reverse primer (10 µM) 0.75 
dNTP mix 0.5 
QuickSolution 1.5 
ddH2O 21 
Total 25 
 
Table 2.1 Site-directed mutagenesis PCR reaction composition.  
PCR reaction composition (except for the polymerase) to generate protein C 
mutants were listed. 
 
 
Segment Temperature (°C) Time Cycles 
1 95 1 minute 1 
2 95 50 seconds 18 
 60 50 seconds  
 68 7.5 minutes  
3 68 7 minutes 1 
 4 ∞  
 
Table 2.2 PCR cycling parameters.  
PCR cycling parameters for generating protein C mutants are outlined. 
 
 
2.1.3 Transformation of XL10-Gold competent cells 
 
Transformation of XL10-Gold ultracompetent cells (New England Biolabs) with 
mutated human protein C vector was performed according to the manufacturer’s 
instruction. In detail, an aliquot of 45 μl cells was thawed on ice before incubation 
with 2 μl β-mercaptoethenol for 10 minutes with gentle swirling every 2 minutes. 
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Dpn I-treated DNA (2 μl) was gently mixed with the cells, and the transformation 
mixture was incubated on ice for another 30 min. The cells were heat-pulsed at 42 
ºC for 30 seconds before incubating on ice for 2 minutes. Five hundred μl 
prewarmed S.O.C. medium (Invitrogen) was added to the reaction before the cells 
were allowed to grow at 37 ºC with shaking for 1 h. Transformed cells (100 µl) was 
plated on a LB - Amp (100 μg/ml) agar plate (Invitrogen) following incubation at 37 
ºC overnight. Amp-resistant colonies were picked and each was grown in 5 ml LB 
broth (Invitrogen) containing 100 μg/ml Amp overnight at 37 ºC with shaking at 225 
rpm.  
 
2.1.4 Plasmid minipreps and mutation verification 
 
Plasmid DNAs of both WT and variant protein C were extracted using Plasmid 
Miniprep kit (Qiagen) according to the manufacturer’s protocol. The introduction of 
desired mutations and no unwanted mutations were confirmed by Sanger 
sequencing method performed by MRC CSC Genomics Core Laboratory of Imperial 
College London. These were done with T7, hSP and Sp6 primers (table 2.3) that 
together covered the whole sequence of protein C insert.   
 
ID Sequence 
T7 5’- TAA TAC GAC TCA CTA TAG GG - 3’ 
hSP 5’- ACA GAA GAC CAA GAA GAC CAA - 3’ 
Sp6 5'- GAT TTA GGT GAC ACT ATA G - 3' 
 
Table 2.3 Sequencing primers for protein C vector.  
The combination of the three primers listed was used to confirm the success of 
mutagenesis and ensure the absence of error in the inserted protein C sequence. 
 
2.1.5 Plasmid maxipreps and quantification 
 
A larger quantity of verified plasmid DNA was prepared using Qiagen Maxiprep kit 
in order to obtain sufficient amount of DNA for the mammalian cell transfection.  
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The yield of each maxiprep was quantified by spectrophotometer (JENCONS-PLS). 
Absorbance was read at the wavelength of 260 nm with the absorbance parameter, 
260:280 ratio, between 1.8 and 2.0. 
 
2.1.6 Preparation of glycerol stocks 
 
Of the 500ml bacteria culture prepared for Maxiprep (section 2.1.5), 800 μl were 
mixed with 200 μl of sterile glycerol (Sigma) to obtain a homogenous mixture, which 
was stored at -80 °C.  
 
2.2 Expression of recombinant human protein C 
 
2.2.1 Cell Culture 
 
Human embryonic kidney (HEK) 293 cells (ATCC) were used for the stable 
transfection of protein C vector. Cells were cultured in the humidified incubators at 
37 °C with 5% CO2. Complete medium for HEK293 cells was minimum essential 
medium (MEM, Invitrogen) supplemented with 10% fetal calf serum (FCS) (Biosera), 
2 mM of L-glutamine (Invitrogen), 1 × non-essential amino acids (Invitrogen), 1 U/ml 
penicillin and 0.1 mg/ml streptomycin. Cells were grown in the medium which was 
changed every 3 days. Whenever confluent, cells were washed with phosphate 
buffered saline (PBS; 10 mM phosphate buffer, 2.7 mM potassium chloride, 137 
mM sodium chloride) (Invitrogen) and were split 1: 3 using 500 μl TrypLE Express 
(GIBCO) per 175 cm2 flask. 
 
2.2.2 Stable transfection of HEK 293 cells 
 
A stable HEK293 cell line expressing protein C was achieved by transfecting cells 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions 
with modifications. In detail, cells were seeded in a 6-well plate in complete MEM 
medium and were grown until reaching 90-95% confluence. Protein C DNA (4 μg) 
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and Lipofectamine 2000 (10 µl) were individually diluted into 250 μl OptiMEM 
medium (Gibco-BRL). After 5 minute incubation at room temperature, DNA solution 
was added drop-wise to the Lipofectamine 2000 solution before being mixed and 
further incubated for 5 minutes at room temperature. The resultant transfection 
mixture was dispensed equally over the surface of the cells with 2.5 ml of OptiMEM. 
Treated cells were incubated for 4-6 hours at 37°C, 5% CO2, after which the 
medium was removed and replaced with complete MEM medium. Cells were split 
1:10 after 24 hours and selected in complete MEM medium containing 1 mg/ml 
G418 sulfate (Calbiochem) for ~10 days. Stably transfected HEK293 cells were 
maintained in complete MEM medium supplemented with 200 μg/ml G418 sulfate.   
 
2.2.3 Cell line cryopreservation and revival 
 
HEK293 cells, protein C stable cell lines and EA.hy926 cells were cryopreserved in 
liquid nitrogen. When cells reached confluence, they were washed twice in PBS 
and detached using trypsin (500 μl per 175 cm2 flask). Around 10 ml complete 
medium was used to neutralise the typsin. After centrifuging at 1200 rpm for 5 
minutes, cells were resuspended in cold complete medium to reach a cell density of 
6×106/ml. An Equal volume of cold complete medium containing 10% dimethyl 
sulfoxide (DMSO) was added drop-wise to the cell suspension. Immediately after 
mixing, cells were aliquoted in cryovials at 1 ml/vial and stored in a cryo freezing 
container at - 80 °C overnight before being transferred to liquid nitrogen. 
 
When reviving cells from liquid nitrogen, vials were transiently carried on ice prior to 
be thawed in 37 °C water bath. Cells were suspended in ~20 ml of warm complete 
medium and centrifuged to remove DMSO. Resuspended cells in 4 ml complete 
medium were cultured in a 25 cm2 flask until confluent before culturing was scaled 
up.  
 
2.2.4 Protein C expression and harvest 
 
Stably transfected HEK293 cells were cultured in triple- or hyper- 175 cm2 flasks 
with 75 ml or 500 ml of OptiMEM medium containing 20 μg/ml of vitamin K (Roche), 
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respectively. The conditioned medium (CM) was collected after 3 days, which was 
centrifuged and filtered to remove cell debris prior to being concentrated ~ 10 fold 
by tangential flow filtration (TFF, Millipore). Concentrated CM was buffer exchanged 
against 5 L TBS pH 7.4 (20 mM Tris-HCl, pH 7.4; 150 mM NaCl) overnight at 4 °C 
before proceeding to purification. 
 
2.3 Protein C purification 
 
2.3.1 Purification of protein C using anion-exchange chromatograpy 
 
Fast protein liquid chromatography (FPLC) was performed to purify WT protein C 
and protein C variants from the CM prepared in section 2.2.4. This was conducted 
using an AKTA purifier (GE healthcare) with a 5 ml anion exchange Q-Sepharose 
Fast Flow (QFF) column (Amersham Biosciences).  
 
Concentrated, dialysed CM supplemented with 5 mM ethylenediaminetetraacetic 
acid (EDTA) was loaded to the column equilibrated with TBS (pH 7.4)/ 5mM EDTA. 
The column was then washed with TBS (pH 7.4) to elute weakly bound proteins. 
The elution of protein C was performed using TBS (pH 7.4)/ 50 mM CaCl2. 
Thereafter, the column was stripped with 20 mM Tris-HCl (pH 7.4)/ 1 M NaCl and 
was finally washed with ddH2O prior to being kept in 20% ethanol. To avoid cross-
contamination, the column was only reused for purification of the same variant. 
 
2.3.2 Analysis of purified protein C 
 
2.3.2.1 SDS-PAGE 
 
The proteins in each purification fraction was separated using sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), which was performed in 
the XCell SureLock Mini Cell (Invitrogen). Briefly, samples were prepared in 1× 
NuPAGE LDS sample buffer (Invitrogen), and additional 10% β-mercaptoethanol 
was supplemented if reducing condition was required. Prepared samples were 
heated at 95 °C for 5 minutes before electrophoresis on 4-12% pre-casted NuPAGE 
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Novex Bis-Tris gels (Invitrogen) at 200 V for 40 minutes or self-casted 10% SDS-gel 
(recipe refer to Appendix) at 130V for 10 minutes and then at 200V for 1 hour. 
 
2.3.2.2 Coomassie Staining 
 
SDS-PAGE gels were washed 3×5 minutes with ddH2O and stained with 10 ml 
Coomassie stain (Thermo Scientific) for 1 hour. To destain, the gel was washed for 
multiple times with ddH2O for ~ 1.5 hours or until clear bands were obtained. 
 
2.3.2.3 Western Blot 
 
After SDS-PAGE, the gel was washed briefly with ddH2O before proteins were 
transferred on to a Hybond-ECL nitrocellulose membrane (Amersham Biosciences) 
in transfer buffer (25 mM Tris base, 190 mM glycine and 20% Methanol) at 30 V for 
60 minutes in the XCell II Blot module (Invitrogen). Membranes were blocked in 
blocking buffer, 5% fat-free milk/PBS (mass/volume; m/v), for 1 hour at room 
temperature or overnight at 4 °C.  
 
To detect protein C, the membrane was incubated with 2.2 μg/ml polyclonal rabbit 
anti-human protein C Ab (Sigma Aldrich) diluted in blocking buffer for 1 hour. This 
was followed by the incubation with polyclonal goat anti-rabbit chemiluminescent 
horseradish peroxidise (HRP) conjugated Ab (2 μg/ml) (Sigma Aldrich) in the same 
buffer for an additional hour. Alternatively, to detect γ-carboxylated protein C, 
monoclonal mouse anti-human Gla antibody (1/500, American Diagnostica INC) 
and 0.5 μg/ml goat anti-mouse lgG-HRP antibody (Dako) were used as the primary 
and secondary Ab, respectively.  
 
The membrane was washed 3 × 5 minutes with 0.1% Tween/PBS (PBS-T) between 
primary and secondary Abs and washed 3 × 10 minutes after secondary Ab 
incubation. After 5 minute treatment with HRP substrate Immobilon (Millipore), the 
membrane was developed on Amersham Hyperfilm ECL (GE healthcare). 
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2.4 Primary characterisation of the protein C variants 
 
2.4.1 Protein C Enzyme-linked immunosorbent assay (ELISA) 
 
A human protein C ELISA was established to determine protein C concentration. 
Purified protein C fractions were pooled and dialysed, similarly as described in 
section 2.2.4 to remove calcium ions. A 96-well microtiter plate (NUNC) was coated 
with 100 μl rabbit polyclonal anti-human protein C (10 μg/ml, Sigma) diluted in 
sodium carbonate buffer (50 mM, pH 9.6) overnight at 4 ºC. Wells were washed 
three times with PBS-T between each step to remove nonspecifically bound 
proteins or Abs. All the following incubations were performed in a low-speed plate 
shaker at 37 ºC for indicated time. Wells were blocked with 200 μl 2% bovine serum 
albumin (BSA, Sigma)/PBS (m/v) for 2 hours. One hundred ul of Protein C 
standards and samples prepared in 1% BSA/PBS were applied to wells in duplicate 
and incubated for 1 hour. Protein C bound to each well was detected using a 
polyclonal HRP-labelled sheep anti-protein C Ab (1/1500, Affinity Biologicals) which 
was incubated for 1.5 hours. Following this, the plate was developed by incubating 
with 170 µl O-phenylenediamine dihydrochloride (OPD, Sigma) diluted in water for 
up to 10 minutes prior to the colour being fixed with 50 µl of 3 M H2SO4. The 
absorbance was measured at 492 nm with μQuant microplate spectrophotometer 
(BioTek instrument). 
 
Plasma purified protein C (Haematologic Technologies Inc, HTI) ranging from 0 to 1 
nM was applied, with the linear range from 0-0.5 used as a standard reference to 
determine the concentration of protein C. The analysis was performed using 
GraphPad Prism 4.03. The intra assay variability was obtained as the coefficient of 
variation (CV) from different  dilutions from one plate, and inter assay variability was 
expressed as CV between plates. 
 
2.4.2 Evaluation the total amount of proteins using BCA protein assay 
 
The total protein concentration in different protein C preparations was assessed 
using BCA assay according to manufacturer’s instruction with minor modifications. 
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Briefly, 10 µl of BSA standards diluted in ddH2O (0-2 mg/ml) and purified protein C 
samples were loaded in 96 well plate. Two hundred µl of BCA working reagent 
(50:1, Reagent A:B) was added and mixed before the plate was incubated at 37 °C 
for 30 minutes in a low-speed plate shaker. The plate was cooled to room 
temperature and was read at absorbance of 562 nm. 
 
2.4.3 Protein C activation 
2.4.3.1 Protein C activation by Protac 
 
Protein C and its variants were initially activated by Protac. For this, 100 nM protein 
C was incubated with Protac (0, 0.1, 0.2, or 0.3 unit / ml) (Hyphen BioMed) in TBS 
(pH 7.4) buffer. The activation was performed at 37ºC for 1 hour and then at 4 ºC 
for additional 16 hours for storage before use. 
 
2.4.3.2 Activation by human thrombin 
 
In addition to the use of Protac, thrombin was also used to activate protein C. Firstly, 
the proteolytic activation efficacy of thrombin to convert protein C to APC was 
assessed in the presence and absence of Ca2+ to demonstrate the effect of calcium 
ions on the activation. The time-course activation of plasma-purified human protein 
C (500 nM) by human α-thrombin (50 nM, Thermo scientific) was monitored in 
0.1%BSA /TBS (pH 7.4) supplemented with 2.5 mM CaCl2 or 1 mM EDTA in a 96-
well plate at 37 °C. Aliquots were taken at various times and were supplemented 
with 500 nM hirudin (Lepirudin, Refludan® from CSL Behring GmBH) to neutralise 
thrombin activity. Activation of protein C at each time interval was quantified using a 
chromogenic substrate S2366 specifically cleaved by APC, which is described in 
section 2.4.4. 
 
Secondly, I sought to optimise protein C activation by thrombin. Briefly, various 
concentrations of thrombin (25-100 nM) were incubated with 450 nM WT protein C 
in 0.1%BSA / TBS (pH 7.4) / 1 mM EDTA. The reaction was carried out at 37 °C for 
2 hours before thrombin activity was quenched by 10 fold concentration of hirudin. 
The rate of protein C activation was assessed in the S2366 assay. 
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2.4.4 APC quantification using S2366 assay 
 
The concentration of APC in the reaction mixture was determined by an assay 
based on the steady-state hydrolysis of an APC-specific chromogenic substrate, 
S2366 (Chromogenix), as previously described [110]. Prior to the measurement in 
the S2366 cleavage assay, the activation reaction was recalcified. 
 
In a 96-well plate, 100 μl working buffer (20 mM Tris, pH7.4; 100 mM NaCl; 0.1% 
BSA and 1mg/L polyethylene glycol (PEG) 8000) containing a series of 
concentrations of commercial recombinant APC ( 0, 0.5, 1, 2, 5 nM; Xigris, Eli Lily) 
was applied. The rate of the substrate hydrolysis (final concentration 400 μM) by 
APC at each concentration was measured at 405 nm at room temperature 
continuously for 20 minutes in the uQuant microplate spectrophotometer. The 
absorbance value was plotted against APC concentration to generate a linear 
reference standard curve using Graphpad Prism 4.3. Dilutions of WT APC and APC 
variants were made to ensure they fell into the range of reference standard, 
allowing the quantification of APC. Due to the lack of activity of APC-S360A, 
confirmation of activation of this variant was assessed using a monoclonal antibody 
ELISA as described below in Section 2.4.5. 
 
2.4.5 Determination of protein C activation efficiency by ‘APC ELISA’ 
 
The activation efficiency of WT protein C and its variants was determined by 
comparing the calculated APC concentration to the protein C ELISA (Section 2.4.1), 
with the exception of S360A mutant. To confirm the complete activation of protein C 
under the optimised conditions and to demonstrate a comparable activation in 
S360A variant an ‘APC ELISA’ was performed. A monoclonal Ab that only 
recognises human protein C but not APC served as a detection Ab in this ELISA. 
By using this approach, non-activated protein C could be detected, therefore, 
protein C activation was detected as a loss of signal. The standard procedure of 
this ELISA was the same as that described in Section 2.4.1 with the exception that 
‘APC ELISA’ used a reference standard of 0 - 2 nM of plasma-derived protein C. In 
addition, mouse monoclonal anti-human protein C Ab (HTI, 1.5 μg/ml) was used as 
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the detection Ab in this ELISA, which is followed by the goat anti-mouse IgG-HRP 
Ab (Dako, 3 μg/ml).  
 
2.5 Calibrated automated thrombography (CAT) assay 
 
2.5.1 Principle of the CAT assay 
 
The CAT assay (Figure 2.4) was used in this project to assess the anticoagulant 
functions of APC and its variants based on their ability to reduce thrombin 
generation. This is a plasma-based assay in which the coagulation cascade is 
initiated by the addition of TF [299]. The amount of thrombin generated is 
determined through the cleavage of a thrombin-sensitive fluorogenic substrate over 
time, which is quantified by reference to the standard calibrator [299]. Phospholipids 
are added to the reaction to provide the surface where coagulation occurs. Plasma 
is collected in sodium citrate, and the coagulation reaction starts only when CaCl2 is 
supplemented. To ensure that the initiation of thrombin generation is dependent on 
TF addition, contact activation is inhibited by the addition of corn trypsin inhibitor 
(CTI), an inhibitor to FXIIa. A number of parameters are derived from the 
fluorescence curves and are used to quantify thrombin generation. They are lag 
time, the time to the burst of thrombin generation (equivalent to clotting time); 
thrombin peak height (maximum concentration of thrombin generated); and 
endogenous thrombin potential (ETP), represented by the area under the curve, 
which is the total amount of thrombin generation over time. 
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Figure 2.4 Thrombin generation curve.  
A thrombin generation curve is displayed with the parameters including lag time, 
peak thrombin and ETP. 
 
2.5.2 Preparation of normal pooled platelet poor plasma 
 
Blood from 16 healthy donors was individually collected in glass vials with 18 μg/ml 
CTI (correspond to 40 μg per ml of plasma, CTI was from HTI) and 10 µM sodium 
citrate (Sigma). Platelet poor plasma (PPP) was obtained by centrifugation of the 
blood first at 3500 g for 15 minutes (without break) followed by another 
centrifugation at 11 000 g for 10 minutes. PPP was stored at - 80°C until use. 
 
2.5.3 Preparation of phospholipid vesicles 
 
In the plasma-based CAT assay, phospholipid vesicles made in the composition 
that mimics the membrane of activated platelets that serve as the platform to 
assemble coagulation factors. Phospholipid vesicles were made from synthetic 
phospholipid stocks dissolved in 10/90 (v/v) methanol/chloroform solution (Avanti 
Polar Lipids) as previously described [147]. Essentially, phospholipid mixtures 
comprised of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-
glycero-3-phosphoserine (DOPS), and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were prepared in a glass vial at a molar ratio of 
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60:20:20. The mixture was allowed to dry under N2 stream in the fume hood before 
being reconstituted in TBS (pH 7.4) buffer and was vortexed for 3 minutes. Finally, 
extrusion treatment was performed by applying the mixture through a 100 nm pore 
size membrane 19 times in an extruder. The resultant unilamellar phospholipid 
vesicles (final concentration of 1.25 mM) were stored at 4 °C and used within 3 
days. 
 
2.5.4 Evaluation of the anticoagulant activity of APC variants using CAT 
 
To assess the anticoagulant activity of WT APC and APC variants, the CAT assay 
was performed according to the manufacturer instructions with minor modifications 
[300]. The thrombogram was measured using fluorometer (Fluoroskan Ascent Plate 
Reader, Thermo Lab System) equipped with a 390/460 filter set and a solution 
dispenser in the combination with Thrombinscope software (SYNAPSE BV). Round-
bottom 96-well microtiter plates (Thermo scientific) were used for the reaction. 
 
In the assay using normal human plasma, each well was loaded with 100 μl mixture 
of the following components: 80 μl PPP, 50 μM phospholipid vesicles (section 2.5.3), 
4 pM TF (Dade Innovin) and 0-3 nM recombinant human APC. In the assay using 
protein C-deficient plasma (Affinity Biologicals), same conditions were used,  except 
that it was supplemented with 40 μg CTI (HTI) per ml of plasma, and incubated with 
0-20 nM recombinant human APC. Coagulation was initiated by automatic 
dispensation of 20 µl of a fluorogenic substrate solution, containing 2.5 mM 
substrate (Z-Gly-Gly-Arg-AMC·HCl, Bachem), 2.5% DMSO, 18 mM HEPES (PH7.4), 
60 mg/ml BSA and 100 mM CaCl2, into each well. The thrombin generation was 
quantitated using a thrombin calibrator (Synapse) prepared in either normal or 
protein C-deficient plasma. Measurements were performed at 37 °C and taken at 
20 second intervals for 60 minutes at wavelengths 390 nm (excitation) and 460 nm 
(emission).  
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2.6 PAR1 cleavage assessment 
 
2.6.1 HUVEC extraction 
 
HUVECs were isolated from human umbilical cord by a collagenase treatment to 
separate the cells from umbilical vein vascular wall. Human umbilical cords were 
obtained from London Hammersmith hospital with ethical approval and were under 
consent of the donors and hospital. Human umbilical cords were collected in Hank’s 
Balanced Salt Solution (HBSS, +Ca2+ and Mg2+, GIBCO) containing 50 μg/ml 
Gentamicin (Sigma) and 110 mg/L Na-pyruvate (GIBCO) and stored at 4 °C up to 4 
days if not used immediately.  
 
The cord isolation process was performed under sterile condition in Laminar flow 
cabinet. The umbilical cord was transferred into the flat-bottom glass container 
sealed by foil before it was wiped clean with fizz-free paper towels. Both ends of the 
cords were neatly cut using a scalpel and excess blood was wiped off. A three-way 
stopcock was inserted into the vein at one end of the cord and secured in place with 
double-knotted cotton string. A 50 ml syringe filled with ~20 ml warm HBSS was 
connected via the tap and the buffer was flushed through the cord to check the 
leaks. Thereafter, a 3-way stopcock was attached to the other end. HBSS (~ 20 ml) 
was flushed through the cord to wash out any blood retained in the vein. 
Collagenase (0.5 mg/ml, Roche) diluted in 20 ml HBSS was injected into the cord 
using a syringe, which was retained in the cord by closing both 3-way stopcock and 
incubated at 37 °C for 10 minutes which was followed by the massage of cord to 
help to detach venous ECs. The cell suspension was collected by flushing with 
HBSS. 
 
The cell suspension was centrifuged at 1200 rpm for 5 minutes and was 
resuspended in 12 ml HUVEC culture media (see section 2.6.2) and seeded into a 
1% gelatine-(Sigma) coated 75 cm2 flask (see Section 2.6.2). Medium was replaced 
one day after the initial seeding and these cells were considered at passage 0. 
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2.6.2 HUVEC culture and passage 
 
HUVECs were cultured in 1% gelatine coated 75 cm2 flask with M199 Medium (MP 
Biomedicals) containing 50 unit/ml penicillin and 50 µg/ml streptomycin (Invitrogen), 
2 mM L-Glu, 20% FCS (v/v), 10 U/ml heparin and 30 µg/ml endothelial cell growth 
factor (ECGF, Sigma). Once confluent, the cells were split 1:2 or 1:3. Essentially, 
cells were washed with HBSS prior to be detached by incubating 200 µl TrypLE 
Express for 1 minute. Trypsin was neutralised with 10 ml complete medium and 
removed by spinning the cell suspension at 1200 rpm for 5 minutes. Once 
resuspended, cells were split into 75 cm2 flasks.  
 
2.6.3 HUVEC cryopreservation 
 
The cryopreservation of HUVECs up to passage 3 was performed the same as 
other cell lines described in 2.2.3 with the exception that cells were stored in FCS 
containing 5% DMSO.  
 
2.6.4 Total RNA extraction 
 
Total RNA was extracted from HUVECs using the RNeasy mini Kit (QIAGEN) 
according to the manufacturer’s instructions. Each preparation in the mini kit was 
capable of purifying RNA from up to 4 × 106 cells and generally yielded 40-140 µg 
RNA according to cell types. Briefly, up to 1 × 107 cells (1 × 75 cm2, 3 preparations) 
were lysed in buffer RLT, and the lysate were homogenised by passing through a 
blunt 20-gauge needle 5 times. One volume of 70% ethanol was applied, allowing 
appropriate binding conditions for the subsequent binding of RNA to the RNeasy 
membrane in the spin column. Contaminants were washed away using buffer RW1 
before the RNA was eluted in 30 µl RNase-free water.  
 
2.6.5 Determination of RNA concentration 
 
The concentration of the total RNA extracted as described in section 2.6.4 was 
measured using the NanoDrop ND-1000 spectrophotometer according to the 
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manufacturer’s instructions (Labtech International). A 260/280 ratio of ~2.0 and 
260/230 ratio between 2.0-2.2 indicated an isolation of the high-quality RNA. 
 
2.6.6 Generation of cDNA coding fragment of PAR1exo peptide 
 
The PCR cDNA coding sequence for Arg27-Pro85 of the N-terminal domain was 
obtained by reverse transcriptional PCR using HUVEC mRNA followed by a second 
round PCR. First, a cDNA fragment with a corresponding aa sequence of Leu20-
Ile121 was generated by reverse transcription. Then, a second round PCR allowed 
the generation of the desired Arg27-Pro85 coding sequence with nucleotides CACC 
and a stop codon (TGA) flanked at its N terminus and C terminus, respectively, to 
ensure an orientation specific ligation into the pET100 expression vector (Section 
2.6.7). The reverse-transcription PCR was performed using QIAGEN OneStep RT 
PCR kit with the reaction composition and thermal cycler conditions outlined in 
Table 2.4 and Table 2.5, respectively. Enzyme mix in the kit is comprised of both 
Omniscript/Sensiscript reverse transcriptases and HotStarTaq DNA polymerase 
blend which allowed the reverse transcription and cDNA amplification in ‘one step’.   
 
Component Volume / µl 
5×QIAGEN OneStep RT-PCR Buffer 5 
RNA (100 ng/µl) 1 
Forward primer (10µM) 1.5 
Reverse primer (10µM) 1.5 
dNTP Mix 1 
QIAGEN OneStep RT-PCR Enzyme Mix 1 
RNase-free water 14 
Total 25 
 
Table 2.4 Reverse transcriptional PCR reaction composition.  
PCR reaction to obtain DNA fragment spanning Leu20-Ile121 of PAR1 N-terminus 
from the mRNA extracted from HUVECs. 
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Segment Temperature (°C) Time (minute) Cycles 
1 
 
50 
95 
30 
15 
1 
 
2 94 1 30 
 58 1  
 72 1  
3 72 10 1 
 4 ∞  
 
Table 2.5 Reverse transcriptional PCR cycling parameters.  
PCR cycling parameters for generating DNA fragment corresponding to aa Leu20-
Ile121 in PAR1. 
 
Second round PCR was performed using Platinum Taq High Fidelity polymerase 
and sequence-verified DNA product from the PCR reaction (Table 2.6) and thermal 
cycler parameters (Table 2.7). The final PCR product was a cDNA fragment, 
spanning from Arg27-Pro85, with four bases (CACC) added to the 5’ terminal and 
three bases (TGA) to the 3’ terminal.  
 
Component Volume / µl 
10×High Fidelity PCR Buffer 2.5 
Template DNA (20µM) 2 
Forward primer (10µM) 0.5 
Reverse primer (10µM) 0.5 
dNTP Mix 
50 mM MgSO4 
2 
1 
Platinum Taq High Fidelity 0.2 
Autoclaved, distilled water 16.3 
Total 25 
 
Table 2.6 PCR reaction composition.  
The PCR reaction compositions for DNA fragment corresponding to PAR1 N-
terminal aa Arg27-Pro85 were listed. 
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Segment Temperature (°C) Time Cycles 
1 94 1 minute 1 
2 94 30 seconds 30 
 60 30 seconds  
 68 12 seconds  
3 68 7 minutes 1 
 4 ∞  
 
Table 2.7 PCR cycling parameters.  
PCR cycling parameters for generating DNA fragment corresponding to PAR1 N-
terminal aa Arg27-Pro85. 
 
2.6.7 PAR1exo peptide expression vector construction 
 
The PCR product was electrophoresed on an agrose gel from which the desired 
DNA band was cut and extracted for the cloning. The coding sequence for aa 
Arg27-Pro85 was cloned into pET100TOPO vector (Invitrogen) using the Champion 
pET Directional TOPO Expression Kit according to the manufacturer’s protocol 
(Figure 2.5). Briefly, cloning reaction comprised of 1 µl Salt Solution, 1 µl insert (5 
ng/µl) and 1 µl TOPO vector in water (3 μl) were incubated at room temperature for 
5 minutes before the vector was transformed into TOP10 competent cells by 
standard protocol. Five colonies were selected, cultured and isolated by mini prep 
before being sequenced using a T7 primer.  
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Figure 2.5 PAR1exo peptide expression vector.  
The pET100/D/TOPO/PAR1exo Arg27-Pro85 vector contains cDNA spanning the 
desired sequence of PAR1 N-terminus. The Amp-resistant gene is used for the 
vector selection in the bacteria transformation and expression. T7 promoter enables 
the sequencing of the insert using T7 primer. Polyhistidine sequence attachment 
allows the subsequent purification of the peptide. 
 
2.6.8 PAR1exo peptide expression and analysis 
 
Plasmid DNA was isolated with a Mini prep kit before being expressed in Rosetta 
(DE3) cells. The cells (25 µl) were firstly transformed with the construct (5 ng) as 
described previously in section 2.1.3 followed by incubating cell in S.O.C media 
(250 µl) at 37 °C for 30 minutes with shaking. The entire transformation reaction 
was added to 10 ml of LB broth containing 100 µg/ml Amp and the culture was 
grown overnight at 37 °C with shaking (200 rpm). Overnight-grown culture (500 μl) 
was inoculated into 10 ml LB broth (+Amp), which was allowed to grow for further 2 
hours before it was split into 2×5 ml cultures. Isopropyl β-D-1-thiogalactopyranoside 
(IPTG, at final concentration of 1 mM) was added to one culture and the incubation 
continued as above. Five hundred µl aliquots were taken from each culture at time 
intervals of 0 hour (starting at the point of adding IPTG), 3 hours and 6 hours. 
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Samples taken from induced and noninduced cultures at different time points were 
lysed in BugBuster buffer (Novagen), frozen in liquid nitrogen or thawed at 42 °C 
repeatedly for 3 times prior to be centrifuged for 10 minutes. The supernatant was 
considered to contain soluble cytoplasmic protein and the pellet to contain insoluble 
protein (inclusion bodies). Inclusion bodies were solubilised in buffer containing 20 
mM Tris (pH 7.8), 500 mM NaCl and 8 M urea before SDS-PAGE analysis. 
 
Equal volume (5 μl) of both fractions were mixed with LDS-loading buffer and 
subjected to SDS-PAGE before the gel was stained with Coomassie blue. The 
cloning into pET100/D-TOPO vector was expected to result in the peptide 
expression with a His6 tag and Xpress epitope fused to the PAR1 N–terminus 
(Arg27-Pro85). 
 
The pilot expression of the His6-PAR1 exodomain (PAR1exo) peptide was scaled 
up to obtain sufficient amounts to purify. For this, 10 ml LB broth (+Amp) was 
inoculated with 500 µl of the transformation reaction, culture was grown at 37°C 
with shaking until the absorbance at 600 nm reached 0.6-1.The resultant culture 
was used to inoculate 1L 2×YT broth and further gown until the large culture 
reached absorbance600  0.5 before IPTG (1 mM) was added to induce the 
expression. Cells were harvested by centrifugation at 3 000 g for 10 minutes. 
Inclusion bodies were extracted essentially as described for small scale expression. 
 
2.6.9 PAR1exo peptide purification using IMAC 
 
PAR1exo peptide was purified from solublised inclusion bodies using Immobilised 
metal ion affinity chromatography (IMAC), which took advantage of the affinity of 
the His6 tag for nickel ions. Essentially, inclusion bodies were solublised in buffer 
comprised of 20 mM Tris (pH 7.8), 500 mM NaCl and 8 M urea. The solute was 
then loaded with the same buffer supplemented with 25 mM imidazole on the 
nickel-equilibrated Chelating HP column (Amersham Biosciences). After washing 
with solubilisation buffer containing 40 mM imidazole, the peptide was specifically 
eluted with solubilisation buffer containing 250 mM imidazole. Finally, the column 
was stripped with buffer containing 20 mM Tris (pH 7.8), 500 mM NaCl, 6 M Gdn-
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HCl, and 50 mM EDTA before it was washed and stored in 20% ethanol. Purified 
peptide was dialysed into TBS (pH 7.4) buffer for 24 hours with multiple changes of 
the buffer to remove denaturing reagent before PAR1exo peptide was quantified 
using BCA assay (protocol refer to 2.4.2) used in the cleavage assay. 
 
2.6.10 PAR1exo peptide cleavage assay 
 
PAR1exo peptide (10 μg/ml) was incubated with 100 nM, or otherwise stated, 
concentration of APC (HTI), Xigris APC or recombinant APC that I had prepared) in 
TBS (pH 7.4) buffer containing 10 mM CaCl2 at 37 °C. Aliquots were taken out at 
various times, which were treated with 1 mM Pefabloc SC (AEBSF (4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride), Sigma) to inhibit proteolytic activity of APC 
or thrombin. To assess the peptide cleavage by Protac or thrombin, the same 
conditions were used except the peptide was incubated with either 0.17 U/ml Protac 
or 20 pM thrombin. Aliquots were then subjected to SDS-PAGE, followed by the 
immunoblotting using monoclonal anti-His6 peroxidase conjugate antibody (Sigma) 
or the gel was stained using Coomassie blue stain. Protein inhibitors used in the 
assay also included PMSF (phenylmethylsulfonyl fluoride), obtained from Sigma, 
and ATIII (Kybernin 500) from SCL Behring. 
 
2.7 Cell signalling assays 
 
2.7.1 EA.hy926 cells culture 
 
EA.hy926 cells were purchased from ATCC, and maintained in 75 cm2 flasks in 
complete EC medium, which was composed of  Dulbecco’s Modified Eagle Medium 
(DMEM, high glucose, +L-Glu, Invitrogen) supplemented with 10% FCS, 50 
U/ml/μg/ml penicillin/streptomycin and 1 X HAT supplement (contains 100 μM 
sodium hypoxanthine, 0.4 μM aminopterin, 16 μM thymidine, Invitrogen). Cells were 
passaged twice every week with the splitting procedure same as that of HUVECs 
described in 2.6.2. This cell line was established by hybridization of HUVECs with 
the human lung carcinoma cell line A549. They were used as an EC model in the 
cellular assay (Erk1/2 phosphorylation assay and permeability assay).  
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2.7.2 Materials  
2.7.2.1 Blocking Antibodies 
 
Rabbit polyclonal H-111 (IgG1) raised against aa 1-111 of human PAR1, was from 
Santa Cruz Biotechnology and used at 25 µg/ml. Mouse monoclonal ATAP2 (Santa 
Cruz Biotechnology), which binds to PAR1 N-terminal sequence Ser42-Phe55, was 
used at 20 µg/ml alone or 10 µg/ml in combination with WEDE15. WEDE15 
(Beckman Coulter), binds to an epitope Phe51-Glu64 (hirudin-like binding domain) 
of PAR1, was used at 25 µg/ml together with ATAP2. Monoclonal anti-EPCR (RCR-
252, Sigma) was used at 25 µg/ml to block APC binding to EPCR. 
 
2.7.2.2 Protein inhibitors 
 
Pharmacological PKC inhibitors used in this project included GF109203X (2-[1-(3-
Dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) maleimide) and  Gö6976 (5,6,7,13-
Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-
propanenitrile), both were obtained from Tocris Bioscience.  
 
Cell permeable pseudosubstrate peptide inhibitor (PSI) used in the project were as 
follows: Antennapedia (Anp)-PSIζ was from Tocris Bioscience; Myristorylated (Myr)-
PSIζ and -PSIθ were from Calbiochem; Myr-PSIα/β was from Promega. 
 
U0126 (1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), the MEK1/2 
inhibitor,  was used at 10 µM unless otherwise stated, which was obtained from 
Tocris Bioscience.  
 
2.7.3 Erk1/2 phosphorylation assay 
 
EA.hy926 cells were seeded at 1.4×105 cell/well in a 12 well plate and allowed to 
grow in complete DMEM medium. After 64 hours, cells were washed twice with 
HBSS (+Ca/Mg, Invitrogen), incubated in serum-free DMEM for 5 hours before the 
addition of indicated agonists for various times. The APC used was Xigris, protein C 
was from HTI, PAR1-AP (H-SFLLRN-OH) was from Bachem, and PMA was 
obtained from Sigma. Where indicated, pharmacological or PSI inhibitors for PKC, 
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EPCR Ab, or PAR1 Ab(s) were added 30 minutes prior to the agonist. In all 
experiments, control groups were treated with agent vehicle controls (DMSO, 
ddH2O or PBS/1%NaN3). 
 
After treatment, cells were washed twice with ice-cold PBS and incubated with lysis 
buffer (Appendix, 70 μl per well) with gentle sharking at 4 °C for 10 minutes. The 
lysates were transferred into Eppendorfs and vortexed at 4 °C for 5 minutes before 
they were centrifuged at 10,000 rpm 4 °C for 10 minutes. Total protein 
concentration in each sample was determined using BCA assay to ensure equal 
loading. Each sample (25 μg) was subjected to SDS-PAGE as described in section 
2.3.2. Proteins on the membrane were incubated with Phospho-p44/42 MAPK 
(Erk1/2) rabbit mAb (1:1000; Cell Signalling) overnight at 4 °C followed by 1 hour 
incubation with goat anti-rabbit HRP antibody (2 μg/ml; Sigma Aldrich) at room 
temperature. After developing, the membrane was washed with PBS-T (3 × 5 
minutes), and Abs were stripped by incubating in 50 mM Glycine/ 1 mM EDTA (pH 
2.3) for 20 minutes. The membrane was washed again before reprobing using 
p44/42 MAPK mouse mAb (1:3000; Cell Signalling) for 1 hour at room temperature 
prior to an additional hour incubation with goat anti-mouse lgG-HRP antibody (0.5 
μg/ml; Dako). 
 
The intensity of phosphorylated Erk1/2 and total Erk1/2 was determined by 
densitometry using Image J programme. The results were expressed as fold 
changes of phosphorylated Erk1/2 normalised against total Erk1/2 to untreated 
group which was set to 1. 
 
2.7.4 EC permeability assay  
 
Macromolecular cell monolayer permeability was analysed using a two-chamber 
compartment and Fluorescein isothiocyanate (FITC) – dextran (Sigma Aldrich) as 
previous described [129], but with minor modification (Figure 2.6). EA.hy926 cells 
were seeded on the semi-permeable membrane (polyethylene terephthalate, 1 µm 
pore size) attached at the bottom of the insert that was seated in a 24-well receiver 
plate (BD Falcon). Cells were left to attach and form a monolayer on the membrane. 
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To obtain a confluent cell monolayer, 1.2×105/well of cells were seeded; if a newly-
confluent cell monolayer was needed, cells were seeded at 4×104/well. Cells were 
then allowed to grow in complete DMEM medium (200 µl in the transwell and 700 µl 
in receiver plate well) for 40 hours. On the day of experimentation, cells were 
washed with HBSS and incubated in serum-free DMEM for 3 hours before APC 
(Xigris) or thrombin treatment. After treatment, cells were washed and the medium 
was replaced with 1% BSA/DMEM containing 1 mg/ml FITC-dextran (40 kDa) in the 
upper chamber and 1% BSA/DMEM in the lower chamber. After incubation for 30 
minutes, the medium in the lower chamber was collected and excitation at 485 nM 
and emission at 538 nm was measured in a fluorometer (Fluoroskan ascent FL) as 
a measure of FITC-dextran passage across the cell monolayer. Where indicated, 
pharmacological and peptide inhibitors or PAR1 Abs were added 30 minutes prior 
to addition APC or thrombin. In all experiments, control groups were treated with 
agent vehicle controls (DMSO, ddH2O, or PBS/1%NaN3). 
 
Permeability was expressed as the measured fluorescence in the bottom chamber 
if experiments were performed on confluent cells. When newly-confluent cells were 
used, permeability was expressed by the percentage of measured fluorescence of 
treated group to vehicle-treated group. When PSIs were used to pretreat cells prior 
to thrombin treatment, permeability was determined using the following equation 
 
P = (TPSI-CPSI) / (T-C) × 100% 
 
Where P is permeability (percentage), T is the fluorescence of thrombin-treated 
cells, C represents for the fluorescence of untreated cells, and subscripted PSI 
refers to ‘with PSI pretreatment‘. 
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Figure 2.6 Schematic representation of the dual-chamber EC permeability 
assay.  
ECs were cultured in the upper chamber insert and were allowed to grow until 
desired confluence of cell monolayer was achieved. Cells were treated as indicated, 
after which FITC-dextran was applied to the upper chamber and were allowed to 
accumulate in the lower compartment by incubating for 30 minutes. The 
permeability was determined by the measured fluorescence in the lower chamber. 
 
2.7.5 PKCδ small interfering RNA (siRNA) transfection 
 
siRNA (sc-36253, 10 µM) specifically targeting human PKCδ mRNA  and control 
siRNA (sc-37007, 10 µM) were both obtained from Santa Cruz Biotechnology. 
EA.hy926 cells were plated at 8×104/well in a 24-well plate, which were grown for 
24 hours in complete DMEM media without antibiotics. Cells were than transfected 
with 10 nM siRNA duplexes per well using Lipofectamine 2000 according to 
manufacturer’s instructions. Briefly, 1 µl Lipofectamine 2000 and 10 nM siRNA were 
diluted in 50 µl OptiMEM separately, which were gently mixed and incubated at 
room temperature for 5 minutes. The diluted siRNA and transfection reagent were 
combined and mixed again followed by additional 20 minute incubation at room 
temperature prior to their addition to the well containing cells. After 4 hours, 
transfection medium was replaced with fresh complete DMEM medium and cells 
were allowed to grow for 72 hours before experiments.  
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2.7.6 PKC translocation assay 
 
To detect PKC translocation from cell cytosol to membrane, soluble (cytosolic) and 
particulate (membrane) protein fractions were separated as previous described with 
minor modifications [301]. EA.hy926 cells were seeded at 1.4 × 106 in a 25 cm2 
flask, and were allowed to grow for 48 hours before serum starvation overnight. 
Cells were treated with thrombin (5 nM) or APC (50 nM) for various times (0 - 3 
hours). After treatment, cells were washed with ice-cold PBS and scraped into 200 
μl ice-cold homogenization buffer containing 25 mM Tris, 2.5 mM EDTA, 2.5 mM 
ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol, cocktail protease 
inhibitor (final concentration equals to that in lysis buffer given in appendix). All 
subsequent steps were performed at 4 °C. After vortexing briefly, 20 μl aliquots 
were taken out and mixed with an equal volume of homogenization buffer 
containing 1% Triton before being centrifuged at 14,000×g for 10 minutes. The 
supernatant was collected, which represented the total PKC, and total protein was 
measured using a BCA assay (section 2.4.2) that ensures equal sample loading. To 
obtain the cytosolic fraction, the remaining 180 μl were vortexed and centrifuged at 
14,000×g for 15 minutes. The supernatant (cytosolic fraction) was removed and the 
pellet was washed in homogenization buffer before centrifuging at 14,000×g for 10 
minutes. The supernatant was discarded, and the pellet was solubilised in 180 μl 
homogenization buffer containing 1% Triton. After 5 minute vortexing, another 
centrifugation step was carried out at 14,000×g for 15 minutes, and the supernatant 
(solubilised membrane fraction) was obtained.  
 
2.7.7 Immunodetection of PKC or phosphorylated PKC isozymes 
 
The BCA assay was performed for each sample subjected to Western blotting 
similar as described in section 2.4.2.  
 
To detect PKC in membrane and cytosolic fractions, 20 μg protein per sample was 
prepared in 1× NuPAGE LDS sample buffer. SDS-PAGE and subsequent 
immonodetection was carried out as described in section 2.3.2 but the following 
PKC Abs and corresponding secondary Abs were used. The primary Abs which 
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detected PKC isozymes include PKCα (C-20) 1/2000, PKCβ1 (C-16) 1/200, PKCζ 
(H-1) 1/2000, PKCε (C-15) 1/5000, and PKCδ (C-20) 1/5000, all of which were 
obtained from Santa Cruz Biotechnology. Primary Ab incubation was performed for 
1 hour at room temperature, except for PKCβ1, which was incubated overnight at 
4 °C. Corresponding secondary Abs were incubated for 1 hour at room temperature 
as usual.  
 
To detect phosphorylated PKC isozymes, 30 µg proteins from whole-cell lysate 
were prepared in 1× NuPAGE LDS sample buffer with 10% β-mercaptoethanol. 
Phosphorylation of PKCε at serine 729 was detected using rabbit polyclonal anti-
phospho-PKCε (Ser729) from Millipore and phosphorylation of PKCζ at threonine 
410 was detected by rabbit polyclonal p-PKCζ (Thr 410)-R obtained from Santa 
Cruz Biotechnology. Primary (p-PKCε 1/1000, p-PKCζ 1/2000) and secondary Ab 
incubations were performed for 1 hour each at room temprature. 
 
2.8 Statistical analysis 
 
The GraphPad Prism 4.03 programme was used to perform the statistical analysis 
of the results obtained in the cellular assays. Two-tailed unpaired t-test with 95% 
confident intervals were used to calculate statistical significant P values between 
compared groups.  
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Chapter 3 Preparation of APC variants 
 
To explore the cell signalling functions of APC in ECs, I first needed to set up and 
characterise the expression, purification and activation of recombinant human 
protein C. In addition, I aimed to produce 4 protein C mutants in parallel to provide 
essential controls for the APC cell signalling studies. The rational of using such 
variants to study the specificity of APC signalling was based on previous 
mutagenesis studies, which illustrated a structure-function relationship of APC such 
that certain residues were required for exerting specific properties of APC 
[101,223,224,302-306]. Whereas the exact molecular mechanisms underlying APC-
mediated cytoprotective function was not completely understood, it has been shown 
that, particularly in ECs, both EPCR and PAR1 are critical elements 
[129,164,165,167,172,198,225,307-310]. Therefore, the following PC variants were 
generated: protein C-L8V devoid of EPCR binding, protein C-E330A/E333A with 
reported PAR1 binding impairment, active-site mutated protein C-S360A, and finally, 
protein C-D36A/L38D/A39V with severely attenuated protein S-dependent activities 
(Table 3.1). The background information about these variants can be found in 
section 1.3.5. 
 
The first part of this chapter includes a description of the generation and 
mammalian cell expression of protein C variants (section 3.1.1) and their 
purification using ion-exchange chromatography (section 3.1.2). The second part 
describes the preliminary characterisation of these protein C variants, including the 
determination of the concentration (Section 3.2.1), optimisation of their activation 
using two different approaches, and subsequently the quantification of generated 
APC (Section 3.2.2).  
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Variant ID Influence of Substitutions 
Plasma 
Anticoagulant 
Activity 
In vitro 
Cytoprotective 
Activity 
WT -  (100%)  (100%) 
L8V 
Loss of EPCR binding 
(no PAR1 signalling) 
 (100%*) [124]  (0%) [124] 
E330A/E333A 
Loss of PAR1-binding exosite 
(no PAR1 signalling) 
 (100%) [110]  (0%) [110] 
S360A 
Loss of active-site serine 
(no enzyme activity) 
 (< 25%) [303]  (0%) [223] 
D36A/L38D/A39V 
Loss of protein S binding 
(no anticoagulant activity) 
 (< 5%) [94]  (100%) [94] 
 
Table 3.1 Lists of protein C variants generated.  
Variants with the corresponding function modulation as well as their reasons are 
demonstrated. The anticoagulant or cytoprotective activities predicted or provided 
from publications are also given. 
 
3.1 Preparation of protein C variants 
3.1.1 Generation and expression of protein C variants 
 
All protein C mutations were introduced to the WT human protein C/pRc/CMV 
vector by site-directed mutagenesis using primers containing the desired nucleotide 
substitutions (Section 2.1.2 and Appendix). Sequencing of the entire protein C 
coding region confirmed the successful introduction of mutations and ensured there 
were no unwanted mutations introduced by PCR. Verified vectors were 
subsequently amplified by Maxiprep to enable transfection of mammalian cells for 
expression and purification of protein C and its variants.   
 
The expression of all four protein C variants as well as WT protein C was performed 
initially by transient transfection in HEK 293T cells cultured in the presence of 
vitamin K to ensure post-translational modification of protein C (i.e. γ-carboxylation 
of the Gla domain). CM and cell lysates from each transfection were analysed by 
Western blotting using a rabbit polyclonal anti-human protein C Ab (Figure 3.1). 
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Western blot results showed that transfected protein C was present in both CM and 
cell lysates. The recombinant WT protein C and protein C mutants in the medium 
had the same mobility as plasma-derived protein C (Control in Figure 3.1). The 
protein C in CM has higher molecular weight (MW) than that in the cell lysates, 
since the nascent protein C detected in cells is not glycosylated. The protein C 
variants were expressed and secreted normally compared to WT protein C, except 
for a reduced secretion observed for protein C-E330A/E333A. 
 
 
Figure 3.1 Protein C expressions in HEK293T cells.  
The expression vectors for each protein C variant were transfected into HEK 293T 
cells in a 6-well plate. OptiMEM media containing 10 μg/ml vitamin K was incubated 
on cells for 3 days before CM was harvested and cells were lysed. Equal volumes 
of CM and cell lysate of each variant were subjected to Western blot. Protein C was 
detected using polyclonal rabbit anti-human protein C Ab as described in section 
2.3.2. 
  
Stable expression of proteins allows sustained production of recombinant proteins. 
Therefore, protein C was stably expressed in HEK293 cells using Lipofectamine 
2000 for transfection and G418 sulphate for selection of clones. Stable cell lines for 
all protein C variants were generated, except for protein C-D36A/L38D/A39V, which 
was previously generated in our lab by Dr. Roger Preston. Stably transfected 
colonies were selected in G418 (section 2.2.2) and ~ 20 colonies per variant were 
selected, of which the 3 or 4 colonies that expressed the highest levels of protein C 
were preserved. Western blot analysis (Figure 3.2) confirmed the expression of 
protein C in selected clones. The two-band form of protein C detected represents 
variable glycosylation of protein C, termed the α and β forms, in which β protein C 
has slightly lower MW than that of α protein C, since the former is not glycosylated 
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at position Asn329 [85,87]. The cells from a single clone were expanded, and large-
scale expression was performed for each protein C variant. CM were harvested 
after cells were incubated for 3 days, concentrated by TFF, and dialysed against 
TBS (pH7.4) buffer to remove most Ca2+ ions prior to purification. 
 
 
Figure 3.2 Western blot analysis of CM from HEK293 cells stably expressing 
WT and mutated protein C.  
Several colonies from each mutant transfection were picked and single colony was 
grown confluence into one well of a 24-well plate. OptiMEM media (+ 10 μg/ml 
vitamin K) incubated on cells for 3 days were harvested and analysed by Western 
blot using polyclonal anti-human protein C Ab (section 2.3.2). The doublet bands 
(indicated by arrows) in each lane demonstrated the known heterogeneity of 
expressed protein C. Number 1-4 stands represents different clones selected for 
each protein C variant.  
 
3.1.2 Purification of protein C 
 
Having established an expression system for protein C and its variants, purification 
of protein C from CM was performed which allowed subsequent functional analysis. 
The concentrated CM was first dialysed into TBS buffer (pH 7.4) and then 
supplemented with 5 mM EDTA. This ensured the absence of Ca2+ in protein C 
containing solution and allowed the efficient purification by anion exchange 
chromatography. The post-translational vitamin K-dependent γ-carboxylation of 9 
residues in protein C Gla domain is essential for the biological activity of protein C. 
The mammalian cell expression system usually provides the post-translational 
modification of a recombinant protein. However, γ-carboxylation in protein C Gla 
domain is not always complete in recombinant protein C preparations [311-313]. 
For this reason, protein C mutants were subsequently purified to selectively isolate 
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the fully γ-carboxylated protein C as well as to remove major contaminants present 
in the medium.  
 
The principle of the protein C purification was to bind protein C in absence of Ca2+ 
ions to an anion-exchange QFF column through its negatively charged Gla domain 
and then elute the γ-carboxylated protein C from the column using CaCl2 [311,312]. 
It is known that Gla residues in the Gla domain of protein C bind calcium ions with 
high affinity, whereas non-γ-carboxylated Glu residues are incapable of this binding. 
The application of CaCl2 leads to the binding of Ca
2+ ions to the γ-carboxylated 
protein C Gla domain, which in turn induces a conformational change, resulting in 
the elution of γ-carboxylated protein C. The method has also been used 
successfully to purify other Gla-domain containing recombinant proteins, such as 
protein S and prothrombin [314]. 
 
An example of this protein C purification strategy is shown in Figure 3.3A, which 
was performed as described in section 2.3.1. The concentrated and dialysed CM 
containing WT protein C supplemented with 5 mM EDTA was loaded to the QFF 
column equilibrated with TBS (pH 7.4). After washing in the same buffer, the elution 
of protein C was studied in TBS (pH 7.4) buffer containing 50 mM CaCl2, which was 
initially applied as two linear gradients (from 0-20 mM and 20-50 mM). The final 
step removed tightly bound proteins using high salt containing buffer (TBS, pH 7.4, 
1M NaCl). The ion-exchange chromatogram of WT protein C shows the majority of 
proteins (blue line) did not bind to the column and were therefore present in the flow 
through. Bound proteins were eluted by 0-20 mM CaCl2 and 20-50 mM CaCl2, 
which generated two broad peaks. Proteins that remained bound to the column 
were stripped in the end which yielded a small peak.   
 
After purification, CM, flow through, elution and stripping fractions were analysed by 
SDS-PAGE and Coomassie staining (Figure 3.3B). Compared to plasma-derived 
protein C control (very faint, Figure 3.3B ‘C’ lane), a band with similar mobility was 
observed in CM and elution fractions from 0-20mM CaCl2, whereas no clear bands 
were present in 20-50 mM CaCl2 elution fractions. In addition, a strong band with 
higher MW than protein C was present in both CM and flow through, however that 
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was not detected in the elution fractions. This indicated a successful removal of the 
major contaminant by this chromatography. These fractions were also analysed by 
Western blotting using a rabbit anti-human protein C Ab (Figure 3.3C), which 
showed protein C was present in 0-20 mM CaCl2 elution peak (Figure 3.3C ‘E’ 
lanes) and was not detected in 20-50 mM CaCl2 elution peak (not shown). This 
suggested that 20 mM CaCl2 was efficient to elute protein C. The absence of 
protein C in the flow through (Figure 3.3C ‘F’ lane) and stripping (not shown) 
fractions further suggested an efficient binding between protein C and the anionic 
QFF column.  
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Figure 3.3 Optimisation of protein C purification using a QFF column with the 
analysis of fractions by Coomassie staining and Western blotting.  
A). Absorbance at 280nm was plotted against the volume (ml) of liquid passed 
through the column. The blue line represents the absorbance and the green line 
stands for the change of the buffer. Each fraction was analysis by SDS-PAGE 
followed either by Coomassie staining (B), or the protein C was specifically 
detected by polyclonal rabbit anti-human protein C Ab on a Western blot (C) C: 
control (Plasma-derived protein C from HTI), F: flow through, E: elution (0-20 mM 
CaCl2), S: stripping.   
 
A 
B 
C 
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As protein C was eluted efficiently between 0 - 20 mM CaCl2, in subsequent work 
20 mM CaCl2 was used to purify protein C and its variants. Chromatography was 
performed as above, except protein C was step eluted by 20 mM CaCl2/TBS (pH 
7.4) to obtain a more concentrated preparation. A representative chromatogram of 
protein C purification using step elution is shown in Figure 3.4A. As before, a large 
and broad flow through peak was observed suggesting most of proteins in the CM 
did not bind to QFF column. A sharper elution peak (Figure 3.4A ‘Elution’) 
compared to that from a gradient elution (Figure 3.3A ‘Elution’) implicated a more 
concentrated protein preparation was achieved by step elution.  
 
The fractions of each peak were analysed by Western blotting using rabbit 
polyclonal anti - human protein C Ab (Figure 3.4B). From this, the majority of protein 
C was found to be eluted by 20 mM CaCl2 (Figure 3.4B ‘E lanes’), whereas a small 
amount of protein C was detected in the stripping fraction (Figure 3.4B ‘S’ lane). 
This was probably due to this proportion of protein C lacking complete γ-
carboxylation in its Gla domain. To detect the Gla domain γ-carboxylation in each 
peak, Western blotting was performed on each fraction using the mouse anti-
human Gla Ab under reducing conditions. This demonstrated that the eluted protein 
C was γ-carboxylated (Figure 3.4C, ‘E’ lane). However no band was observed in the 
stripping fraction (not shown) suggesting that the minor proportion of protein C 
observed in Figure 3.4B was indeed non-γ-carboxylated and was successfully 
separated from γ-carboxylated protein C by this approach. In Figure 3.4C, the band 
migrating between 20-30 kDa represents the light chain of two-chain protein C, and 
the upper band at 50-60 kDa represents the single chain-form of protein C. In 
normal plasma, approximately 5-15% of protein C is in single chain form [85-87]. 
Using mammalian cell expression systems, this percentage can increase up to 70%, 
but varies among different cell lines. Cultured HEK293 cells typically express ~20% 
protein C as single chain [315]. Both the single chain and the two chain forms are 
fully functional [88]. It is worth noting that the lower MW of protein C (~55 kDa) 
observed on the blot or stained gel was probably due to the nature of the ladder 
which is comprised of polypeptides, migrating slower on the gel than the folded 
protein with the same MW. 
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The analysis of the same fractions on Coomassie stained SDS-PAGE gel (Figure 
3.4D) suggested good protein purity using this approach. However, due to the low 
sensitivity of Coomassie staining method, the elution fraction of protein C was also 
analysed with BCA (Section 2.4.2) and ELISA (Section 2.4.1) assays to determine 
the total protein concentration and protein C concentration, respectively. It was 
found the protein C: total protein ratios were between 50%-70% among protein C 
variants. 
 
 
 
 
           
 
B 
C 
A 
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Figure 3.4 Chromatogram of protein C purification using QFF column and the 
analysis of fractions by Coomassie staining and Western blotting.  
A: Absorbance at 280 nm was plotted against the volume (ml) of liquid through the 
column. The blue line represents the absorbance and the green line stands for the 
change of the buffer. The analysis of WT protein C purification was done using 
polyclonal anti-protein C Ab (B) or monoclonal anti-Gla Ab (C). The purity of each 
fraction was analysed by Coomassie staining (D). CM: conditioned medium, F: flow 
through, E: elution, S: stripping 
 
3.2 Characterisation of protein C variants 
3.2.1 Protein C quantification by ELISA 
 
To assess protein C concentration obtained after purification, the quantity of each 
purified protein C variant was determined by “in-house” ELISA. To optimise the 
detection of protein C, I titrated the concentrations of capture and detection Ab to 
obtain a standard curve that was linear within a certain range. Plasma-derived 
human protein C diluted between 0-1 nM was fitted into a one-site binding curve 
(Figure 3.5). The linear range, generally from 0 to 0.5 nM, was used as the 
reference standard curve for calculating purified protein C samples which were 
diluted to ensure they fell within this range. Each variant had three different dilutions 
and was measured in duplicates within one ELISA plate. This was repeated five 
times and obtained an intra- and inter- CV both below 15%. Concentration of each 
variant was determined from the sum of the ELISAs. Protein C was expressed in 
batches based on demand. In general, 3 triple flasks (in total 225 ml) of WT and 
variant protein C stable cell lines were grown in optimum for 3 days and CM were 
D 
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collected, dialysed, from which protein C was purified. Normally, the yield of protein 
C from each preparation was 300-700 µg (i.e. ~ 1.3-3.1 µg/ml). 
 
 
Figure 3.5 Human protein C ELISA.  
Absorbance values (492 nm) of duplicate readings were fitted against known 
concentration (0-1 nM) of APC (HTI). A representative reference standard curve is 
shown. 
 
3.2.2 Protein C activation 
 
Protein C is a serine protease zymogen that must be activated before it can exert 
its biological functions. This activation occurs through the proteolytic cleavage after 
Arg169, which, in two chain protein C, also leads to the removal of a small 
activation peptide from the N-terminus of the heavy chain (Section 1.3.2) In vivo, 
protein C is activated by thrombin-TM complex, in which TM is an essential cofactor 
for thrombin in this activation reaction. In vitro, human protein C activation can be 
achieved using certain proteases derived from snake venoms [316] or using 
thrombin alone [110]. In this thesis, I explored the activation of protein C with both 
agents to generate APC for subsequent functional analyses. 
3.2.2.1 Protein C activation by Protac 
 
Protac is a commercially available protein C activator extracted from the venom of 
the southern copperhead snake, Agkistrodon c. contortrix. It is a single chain 
glycoprotein with a MW of 37 kDa that rapidly converts protein C to its active form in 
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either purified systems or in plasma [317]. In the past decade, it has been broadly 
adopted in diagnostic labs to identify disorders in the protein C pathway and also 
used in blood coagulation research.  
 
To optimise activation of my recombinant protein C using Protac, 100 nM WT 
protein C was incubated with 0-0.3 unit/ml Protac for 1 h at 37 °C, followed by a 
further 16 h at 4 °C [85,93].  
 
The concentration of APC generated during activation was subsequently assessed 
using an amidolytic assay that employed a synthetic chromogenic substrate, S2366. 
The mechanism of this quantification is based on the ability of APC to proteolytically 
cleave S2366, releasing the chemical group (4-nitroaniline) that gives rise to a 
yellow colour. The change in absorbance at 405 nm is measured which is 
proportional to the catalytic activity of the enzyme. In this thesis, the absorbance 
values derived from S2366 cleavage by known concentration of plasma-derived 
APC (0-5 nM) was measured from 0 to 20 minutes. The absorbance values of 
different APC concentrations were plotted against time, in which a linear correlation 
was observed between 0 – 10 minutes (Figure 3.6A). To enable the quantification 
of Protac-activated APC, a standard curve was developed using the rate of 
changes in absorbance plasma-derived APC (reflected by the gradient of each 
linear curve from Figure 3.6A) against APC concentration, which is shown in Figure 
3.6B. Different dilutions of the activation reactions that fell into the standard curve 
were measured at the same time with known concentration APC, and the APC 
generated was determined in the reference to the standard curve. Protac did not 
hydrolyse the S2366 substrate (data not shown), therefore the absorbance change 
was only attributable to the cleavage by the APC in activation reaction. 
 
Using this method, the APC generated using 0-0.3 unit/ml Protac was quantified. 
From this, full activation of WT protein C was achieved at 0.3 unit/ml (Figure 3.7). 
Protein C variants were activated in the same way using 0.3 unit/ml Protac, and 
they were found to have the comparable conversion efficiency to that of WT protein 
C. As expected, no appreciable cleavage activity was observed for APC-S360A 
variant towards the chromogenic substrate within measuring period (0-20 min). 
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Consequently the activation of this variant was assessed using a monoclonal 
protein C ELISA described in section 3.2.2.3.  
 
 
       
Figure 3.6 Quantification of APC using S2366 substrate.  
Absorbance at 405 nm (mAU) derived from S2366 cleavage by plasma-derived 
APC (0-5 nM) was plotted against time (minutes) (A), and the gradient (mAU/min) of 
the curve was plotted against the known APC concentration (nM) (B). The rate of 
substrate hydrolysis is proportional to the concentration of APC and recombinant 
protein C activation was quantified with the reference to the standard curve.  
 
 
 
 
Figure 3.7 Titration of Protac to activate 100 nM of WT protein C.  
WT protein C preparation (100 nM) was activated with various concentrations of 
Protac. The concentrations of generated APC from each activation reaction were 
determined using amidolytic assay. These were presented as percentage of 
activation efficiency which was plotted against the concentrations of the activator.  
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3.2.2.2 Activation by thrombin 
 
In the latter stage of my project, it was found although Protac has negligible activity 
in the plasma-based CAT assay, it could potentially interfere with the assays 
involving PAR1, as Protac was able to cleave the PAR1 peptide (Section 5.3). 
Therefore, the activation of protein C was also performed using thrombin as a 
neutralisable activator. The APC generated from thrombin activation was then used 
in the cytoprotective assays (PAR1 exo peptide cleavage and Erk1/2 activation).  
3.2.2.2.1 Effect of Ca2+ on protein C activation by thrombin 
The presence of calcium ions is obligatory in the thrombin-TM mediated protein C 
activation. In contrast, they are inhibitory to the activation of protein C by thrombin 
in the absence of TM [121,318]. Therefore, the effect of calcium ions in protein C 
activation by thrombin was initially evaluated. Plasma-derived human protein C 
(500 nM) was incubated with thrombin (50 nM) for 0-1 h. Using the APC activity 
S2366 assay, I found that thrombin activated protein C at an average rate of ~ 2.5 
nM/min in the absence of Ca2+, whereas protein C generation rate as low as 0.0128 
nM/min was observed in the presence of 2.5 mM Ca2+ (Figure 3.8). In agreement 
with the literature, the finding confirmed that Ca2+ functioned as a potent inhibitor of 
thrombin in regard to the protein C activation. 
 
 
Figure 3.8 The effect of calcium ions in protein C activation by thrombin.  
Plasma-derived protein C was incubated with thrombin in TBS buffer containing 0.1% 
BSA in the presence (   ) or absence (   ) of 2.5 mM CaCl2 at 37°C. Aliquots were 
taken from the reaction at the indicated time points and quenched with hirudin 
before APC was quantified by S2366 assay. 
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3.2.2.2.2 Titration of thrombin in the protein C activation 
Having confirmed the inhibitory tendency of Ca2+ in thrombin-mediated APC 
activation, recombinant human protein C variants were activated by thrombin in the 
absence of Ca2+. Purified WT protein C was buffer exchanged to remove the 
majority of calcium ions and 1 mM EDTA was supplemented in the reaction mixture 
to chelate any residual Ca2+ ions. First, WT protein C (450 nM) activation by human 
α-thrombin (25-100 nM) was studied in TBS (PH 7.4)/BSA/EDTA buffer at 37 °C for 
2 hours. Hirudin (10 fold molar excess to thrombin) was added in the end to stop 
the reaction. This also stops thrombin present in the reaction mixture from 
interfering in the APC quantification assay, since S2366 is sensitive to thrombin 
hydrolysis. Figure 3.9 showed the concentration of APC generated had a positive 
correlation with thrombin dosage, and full activation was attained when 75 nM 
thrombin was used. Consequently, the activation of protein C variants was achieved 
by the incubation of 450 nM protein C with 75 nM thrombin at 37°C for 2 hours. 
Protein C variants - L8V, E330A/E333A and D36A/L38D/A39V were activated at a 
comparable efficiency to that of WT protein C (Table 3.2). Since, APC-S360A did 
not hydrolyse S2366 peptide (not shown), its activation was determined by the 
monoclonal protein C ELISA described in section 2.4.5. Essentially, this ‘APC 
ELISA’ used monoclonal protein C Ab that only binds to protein C but not APC, and 
therefore APC-S360A was quantified by the concentration of total protein C 
subtracted by unactivated proteins.  The activation efficiency for protein C is 
expressed as the percentage of APC to total protein C, which is listed in Table 3.2. 
As shown, essentially all protein C (WT and variants) was activated using Protac 
and thrombin. 
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Figure 3.9 Optimisation of recombinant WT protein C activation by thrombin. 
 WT protein C (450 nM) was incubated with 25-100 nM thrombin at 37 °C for 2 
hours before the reaction was inhibited by the addition of hirudin. The APC 
generation was determined by S2366 assay and the activation efficiency (APC 
generated %) was plotted against thrombin concentration using one site hyperbola 
curve fitting. Values were expressed as the mean of duplicates. 
 
 
 
Variants Activation efficiency 
(Mean±S.D.)% 
WT 98.1±2.3 
L8V 99.7±0.2 
D36A/L38D/A39V 98.6±1.8 
E330A/E333A 99.9±0.1 
S360A 99.6±0.4 
 
Table 3.2 Activation efficiency of protein C WT and mutants. 
Protein C (WT and variants) was activated by thrombin or Protac in the conditions 
given in section 2.4.3. Concentration of APC was determined by S2366 cleavage 
assay for all protein C variants except S360A. For S360A, unactivated protein C 
was determined by ‘APC ELISA’ and APC-S360A was obtained by subtracting the 
unactivated protein C from the total protein C concentration. Activation efficiency 
was represented as the percentage of APC to total protein C.   
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Chapter 4 Evaluation of APC anticoagulant activity 
 
Protein C plays a vital role in the natural anticoagulant pathways which help to 
counterbalance thrombin formation and maintain a normal controlled haemostatic 
response. The influence of APC on thrombin generation involves FVa and FVIIIa 
inactivation, requiring cofactor functions of protein S and FV/FVi [140]. The initiation 
stage of coagulation leads to a trivial amounts of thrombin generation, which 
subsequently feedback activates FV and FVIII. Since APC down-regulates these 
coagulation cofactors, it mainly acts to control excessive amount of thrombin 
generation in the propagation phase of coagulation. In vitro, the anticoagulant 
activity of APC is usually assessed in two ways - either by purified protein system 
such as FVa inactivation assay or through the CAT assay where the APC effect is 
measured in the plasma milieu. 
 
In this chapter, the anticoagulant activity of APC and the variants generated in 
chapter 3 were determined using CAT.  As mentioned in Section 2.5.1, the CAT 
assay, in which coagulation was initiated by TF, measures the total thrombin 
generation in plasma in real time. It provides a global measure of the thrombin 
generation capacity of a sample rather than simply measuring the isolated reactions. 
Therefore, it can be regarded as more physiological and, in this case, a reflection of 
APC activity in vivo. Parameters including lag-time, thrombin peak height, and ETP 
were analysed. 
 
Included in this chapter are the titration of TF (Section 4.1) and Protac (Section 4.2) 
in normal pooled plasma, and subsequently the anticoagulant activities of APC 
variants were determined in both normal plasma (Section 4.3) or protein C-deficient 
plasma (Section 4.4) performed in the CAT assay. 
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4.1 TF titration in normal plasma 
 
Prior to the assessment of the anticoagulant activity of APC and its variants, TF 
concentration was titrated to enable optimal analysis of APC function. TF 
concentrations from 1 - 8 pM were used to initiate coagulation in normal PPP 
including 50 μM phospholipid vesicles (Figure 4.1). Consistent with previous 
findings [319,320], thrombin generation correlated with TF concentration, which was 
observed as increases in ETP and peak height, and decrease in lag-time (Figure 
4.1). While low TF concentration (~1 pM) is generally employed to study 
coagulation factor deficiencies [299,319], higher TF concentrations which generate 
larger thrombin peaks are more appropriate for investigation of anticoagulant 
activities. I have observed that inter assay variability increased at lower TF 
concentrations (1 pM and 2 pM). Therefore, 4 pM TF was chosen to use in my CAT 
assays since substantial thrombin generation was obtained, and it is also within the 
concentration range (1 - 5 pM) that commonly used in the literature to trigger 
coagulation in plasma [321-325]. 
 
 
 
Figure 4.1 TF titration in normal plasma.  
Thrombin generation in human PPP (Section 2.5.2) was initiated with either 1, 2, 4 
or 8 pM TF, 50 μM phospholipid vesicles (PS/PC/PE, 20%/60%/20%) and 16.7 mM 
CaCl2.  
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4.2 Titration of Protac in normal plasma 
 
Recombinant APC and its variants generated by Protac in chapter 3 were assessed 
in the CAT assay. Protac does not only activate protein C in purified system but it is 
also capable of converting endogenous protein C in plasma [326]. Therefore to 
examine whether thrombin generation was influenced by Protac present in my APC 
preparations, Protac was titrated from 0 - 0.1 U/ml in normal PPP under conditions 
as previously established (4 pM TF, 50 µM phospholipids and 16.7 mM CaCl2). 
Results presented in Figure 4.2 showed thrombin generation was inhibited with 
increasing concentrations of Protac. This inhibition was associated with changes in 
ETP and peak height but the lag-times remained unaltered, indicating the activation 
of endogenous protein C. Importantly, Protac at concentrations below 0.02 U/ml, 
which is equivalent to the amount present in 6-7 nM APC, did not interfere with the 
assay. Thus, providing that recombinant APC variants were assessed at 
concentrations from 0 - 6 nM, the Protac would not interfere with the assay allowing 
the assessment of APC-specific anticoagulant functions. 
 
Figure 4.2 The effect of Protac in human normal plasma.  
Different concentrations of Protac (0-0.1U/ml) were incubated with human normal 
PPP. Thrombin generation was initiated by 4 pM TF, 50 μM phospholipid vesicles 
(PS/PC/PE, 20%/60%/20%), and 16.7 mM CaCl2. 
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4.3 Anticoagulant activity of APC in normal plasma 
 
To determine the anticoagulant activity of each APC mutant, WT and variant APC 
activated by Protac were assayed for their abilities to inhibit TF-induced thrombin 
generation. This was first studied in normal PPP containing 50 μM PS/PC/PE 
(20%/60%/20%) vesicles, in which the coagulation pathway was initiated by the 
addition of 4 pM TF. In the absence of APC, a thrombin peak of 371 ± 12 nM and 
an ETP of 1460 ± 58 nM were generated. When WT APC was incubated in the 
normal PPP, both peak height and ETP were reduced in a concentration-dependent 
manner (Figure 4.3A). APC, at the highest concentration used (3 nM), almost 
completely inhibited thrombin generation, with only 1.0 ± 0.6 % peak height and 1.6 
± 1.2% ETP when compared to that in the absence of APC (Figure 4.3 B, ETP not 
shown). Although APC had a major effect on the decrease of thrombin peak and 
ETP, the lag-time was not affected by APC (Figure 4.3 A), demonstrating that APC 
primarily influences the propagation phase of coagulation, regulating both the total 
and maximum amount of thrombin generated rather the initiation phase of 
coagulation (determined by the lag-time), in agreement with the literature [327]. The 
inhibitory effect of thrombin generation observed by the addition of APC was 
abolished when a rabbit polyclonal protein C/APC Ab was used at 20 fold molar 
excess to the APC concentration, suggesting the anticoagulant effect was specific 
to APC. 
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Figure 4.3 Recombinant WT APC and thrombin generation in normal human 
plasma.  
A), WT APC (0-3 nM) was incubated with normal human PPP. Thrombin generation 
was initiated by 4 pM TF, 50 μM phospholipid vesicles (PS/PC/PE, 20%/60%/20%), 
and 16.7 mM CaCl2. A representative experiment was shown.  
B), The peak height of each concentration of WT APC was determined using 
Thrombinoscope software and presented as the percentage to the peak in the 
absence of APC. Values were expressed as the mean ± S.E.M. (n=3). 
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Variants APC-L8V, APC-E330A/E333A, APC-S360A, and APC-D36A/L38D/A39V 
were tested in parallel with WT APC. A similar inhibition of thrombin generation was 
observed for APC-L8V and APC-E330A/E333A compared to WT APC (Figure 4.4 
upper panels), and a comparable reduction of thrombin peak was attained for each 
concentration of these three preparations (Figure 4.5). The IC50 of WT and the two 
mutated APC (L8V and E330A/E333A) of thrombin generation inhibition were 
determined for normal PPP from three independent experiments, and were found to 
be indistinguishable (~ 1.3 nM) (Table 4.1). This suggested APC-L8V and APC-
E330A/E333A both have normal anticoagulant activity. In contrast, active site 
mutated APC-S360A and protein S-independent APC-D36A/L38D/A39V had 
negligible or no effect on thrombin generation even at 3 nM, a concentration at 
which WT APC almost completely ablated thrombin generation (Figure 4.4 lower 
panels and Figure 4.5). It is worth noting that when 3 nM APC is used, inhibition of 
thrombin generation is entirely dependent on its cofactor, protein S [124,147], which 
was confirmed by the finding that the protein S binding-impaired APC variant 
D36A/L38D/A39V exhibited no detectable anticoagulant activity in the CAT assay at 
the concentrations tested. 
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Figure 4.4 APC variants anticoagulant activities in normal plasma.  
Varying concentrations (0-3 nM) of APC variants (L8V, E330A/E333A, S360A and 
D36A/L38D/A39V) were incubated with the human normal PPP. Thrombin 
generation was initiated with 4 pM TF, 50 μM phospholipid vesicles (PS/PC/PE, 
20%/60%/20%), and 16.7 mM CaCl2. A representative experiment for each APC 
variant was shown. 
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Figure 4.5 Comparison of the anticoagulant activities of APC variants in 
human normal plasma.  
Different APC variants (WT, E330A/E333A, L8V, S360A and D36A/L38D/A39V, 
from 0-3 nM) were assessed in the CAT assay. Thrombin peak height was 
determined and expressed as % of that in the absence of APC. Data were 
presented as mean ± S.E.M. (n=3). 
 
 
 
Variant name IC50 (nM) 
WT 1.35 ± 0.07 
L8V 1.33 ± 0.08 
E330A/E333A 1.30 ± 0.05 
S360A N/A 
D36A/L38D/A39V N/A 
 
Table 4.1 The IC50 (nM) of each APC variants in human normal plasma.  
IC50 was determined from their abilities to reduce thrombin peak and expressed as 
mean ± S.E.M. (n=3). 
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4.4 Anticoagulant activity of APC variants in protein C-deficient plasma 
 
To confirm that the anticoagulant activity obtained from normal plasma did not arise 
from endogenous protein C activation, APC variants were also assessed in human 
protein C-deficient plasma with 50 µM phospholipids, 65 µg/ml CTI, and coagulation 
was initiated by 4 pM TF, as before. Under these conditions, a thrombin peak of 
405 ± 16 nM and an ETP of 1592 ± 77 nM were obtained, similar to those in normal 
plasma. 
 
WT APC (0 - 10 nM) dose-dependently inhibited thrombin generation, such that 10 
nM APC was able to reduce the thrombin peak and ETP to <1% of that in the 
absence of APC (Figure 4.6).  There was also no significant effect of WT APC on 
lag-time, consistent with finding in normal plasma (data not shown). APC-L8V and 
APC-E330A/E333A exerted normal inhibition of thrombin generated in protein C-
deficient plasma, comparable to WT APC (Figure 4.6). As expected, both APC-
S360A and APC-D36A/L38D/A39V exhibited severely impaired inhibition of 
thrombin generation (Figure 4.6). Compared to WT APC (which conferred an almost 
complete inhibition of thrombin production at 10 nM) APC-S360A and APC-
D36A/L38D/A39V, even when concentration was increased by 2 fold, only reduced 
thrombin peak by 14.8 ± 0.8% and 20.1 ± 7.7% (compared to that in the absence of 
APC), respectively. The IC50 was determined for each APC variant evaluated in 
protein C-deficient plasma and is given in Table 4.2. This also showed WT APC, the 
E330A/E333A variant and the L8V variant had similar abilities to inhibit thrombin 
generation. Protac addition did not produce any inhibitory effect upon thrombin 
generation even at 0.4 U/ml (data not shown), confirming the absence of any 
endogenous protein C in the protein C-deficient plasma used for these experiments. 
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Figure 4.6 Comparison of the anticoagulant activities of APC variants in 
human protein C-deficient plasma.  
Thrombin generation was performed with the addition 0-10 nM APC variants (WT, 
E330A/E333A and L8V) and 0-20 nM APC variants (S360A and D36A/L38D/A39V). 
Thrombin peaks were expressed as % of that in the absence of APC. Data were 
present as mean ± S.E.M (n=3). 
 
 
 
Variant name IC50 (nM) 
WT 2.33 ± 0.28 
L8V 2.62 ± 0.35 
E330A/E333A 3.05 ± 0.70 
S360A N/A 
D36A/L38D/A39V N/A 
 
Table 4.2 The IC50 (nM) of each APC variants in human protein C-deficient 
plasma.  
The IC50 was calculated from the ability of each APC variant to reduce thrombin 
peak and expressed as mean ± S.E.M (n=3). 
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4.5 Discussion 
 
The CAT assay represents an in vitro model which allows the study of the kinetics 
of coagulation reactions in which coagulation factors and cofactors are at or near 
the physiological concentrations. In the current study, CAT assay was used to 
evaluate the anticoagulant activity of APC. Contact activation-inhibited and TF-
initiated thrombin generation was performed in human PPP with 15 μM 
phospholipid vesicles. TF was first titrated in normal PPP and showed a positive 
correlation to thrombin generation within the tested concentration range of TF (1 - 8 
pM). This suggested that the coagulation was dependent on the amount of TF, 
which agrees with literature [299,319,320]. The titration of Protac in normal PPP 
also indicated the concentration limit of prepared APC to use in the assay without 
contaminant interference, which is 0 – 6 nM.  
 
I next evaluated the anticoagulant activity of APC variants in both human normal 
PPP and protein C deficient plasma. The initial titration of WT APC in normal PPP 
revealed that a near ablation of thrombin generation was achieved with 3 nM APC. 
Furthermore, the specificity of APC was confirmed by using polyclonal Ab against 
protein C/APC that completely inhibited the reduction of thrombin generation upon 
APC administration.  
 
At each tested concentration, APC-E330A/E333A and APC-L8V both exhibited a 
similar level of reduction in generation of thrombin compared to WT APC in both 
plasma, suggesting their anticoagulant property is not affected by the loss of PAR1 
binding and EPCR binding, respectively. This is in agreement to the literature 
demonstrating a normal anticoagulant activity is attained by these variants 
[93,110,124].  
 
At 3 nM, the anticoagulant activity of APC in normal PPP is dependent on the 
activity of cofactor, protein S [124,147], which is consistent with my observation that 
APC-D36A/L38D/A39V conferred no capability in attenuating thrombin generation 
in the tested range (0 – 3 nM). In contrast, some protein S-independent activity is 
observed when APC is used at or above 10 nM [124,147]. Indeed, APC-
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D36A/L38D/A39V was able to reduce thrombin generation in protein C-deficient 
plasma, however the reduction (~ 20%) was severely impaired when compared to 
WT APC (>99% at 10 nM). APC-S360A had little or no effect at 3 nM in normal PPP, 
and was able to inhibit thrombin generation by ~15% at 20 nM in protein C-deficient 
plasma. The remaining anticoagulant activity of APC-S360A has been reported by 
Nicolaes et al who demonstrate that this is mainly due to the high affinity binding of 
Arg506 side chain of FVa to the substrate-binding region close to the active site of 
APC-S360A [328]. This variant competes with FX for binding to FVa, hence 
reducing the generation of thrombin [328]. However, this effect is not attained by 
zymogen protein C-S360A which is not allosterically oriented for an optimal 
substrate binding provided by the removing of the activation peptide in protein C 
molecule [328].  
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Chapter 5 PAR1 cleavage activity of APC 
 
One characteristic of APC/EPCR- mediated cytoprotective activity on the 
endothelium is the activation of PAR1 [129,165,167,307-310], which depends on 
the cleavage after Arg41 in the N-terminal extracellular tail of this receptor. Prior to 
investigating the signalling pathways mediated by APC through PAR1 activation, 
the ability of APC to cleave the receptor was assessed. The direct analysis of the 
cleavage employed a PAR1exo peptide as an APC substrate. This 59-mer peptide, 
spanning the N-terminal sequence from residue 27 to 85 of PAR1, was expressed 
in bacteria with a His6 tag attached at its N-terminus and, thereafter, purified. The 
cleavage reaction was analysed by visualisation of cleavage products by SDS-
PAGE or by the disappearance of the full length peptide on a Western blot. 
 
This chapter includes the generation (Section 5.1) and purification (Section 5.2) of 
the PAR1exo peptide, optimisation of the peptide cleavage assay and the analysis 
of peptide cleavage by both APC and thrombin (Section 5.3). 
 
5.1 PAR1exo peptide generation 
 
The coding region of the PAR1exo peptide, spanning from Arg27 to Pro85 in PAR1 
N-terminal exodomain, was produced by RT-PCR using total mRNA extracted from 
HUVECs. The PCR product was then ligated into pET100TOPO expression vector 
(Section 2.6.7), followed by the expression of the His6-peptide (Section 2.6.8). The 
tagged peptide had a predicated MW of ~11 kDa determined using ProtParam 
programme (http://web.expasy.org/protparam/) from ExPASy Proteomics Server 
online. 
 
A pilot experiment was first performed to check the peptide expression in Rosetta 
E.coli cells. A small volume of transformant culture was split into two, and before 
incubating both cultures at 37°C with shaking, one culture was induced with IPTG. 
Aliquots were taken from each culture at time intervals of 0, 3 and 6 hours, where 
inclusion bodies were extracted (Section 2.6.8) and analysed by SDS-PAGE with 
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Coomassie staining (Figure 5.1). The profile of the bands appeared to be similar in 
induced and uninduced cultures, reflecting the presence of bacterial proteins. In 
addition, a band migrating between 10-15 kDa was readily detected in the induced 
fractions (Figure 5.1 indicated by the arrow). This indicates the likely position of the 
expressed PAR1exo peptide.  
 
 
 
Figure 5.1 PAR1exo peptide pilot expression.  
PAR1exo/pET100/D-TOPO vector (section 2.6.7) was transformed into Rosetta 
(DE3) cells and allowed to grow in a 5 ml culture. Culture was equally split and 
incubated with or without the presence of 1 mM IPTG. Aliquots were taken at 
various times (0, 3 or 6 hours).Inclusion bodies were extracted, solubilised and 
proteins were analysed on stained gel as described in section 2.6.8.  
 
 
5.2 PAR1exo peptide purification using IMAC 
 
After the small scale expression test, a large scale expression of the PAR1exo 
peptide was performed as described (Section 2.6.8). Inclusion bodies containing 
the PAR1exo peptide were extracted and solubilised in buffer containing 20 mM 
Tris (pH 7.8), 500 mM NaCl and 8 M urea. To separate the PAR1exo peptide from 
the proteins originating from the bacterial host cells, IMAC was used (Section 2.6.9) 
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[329,330]. The purification approach took advantage of the high affinity of His6 tag 
for nickel ions immobilised on a HiTrap chelating HP column, whereas the affinity 
was rather weak between nickel ions and the most naturally occurring proteins.  
 
Solubilised inclusion bodies were supplemented with 25 mM imidazole prior to 
loading on the nickel-equilibrated chelating HP column. This low concentration of 
imidazole in the loading sample was added to reduce binding between bacterial 
proteins and nickel ions. The column was then washed in the TBS/Urea buffer 
containing 40 mM imidazole before elution of recombinant proteins with 250 mM 
imidazole in 20 mM Tris (pH 7.8)/500 mM NaCl/8 M urea which competed with the 
binding of His6 to nickel ions on the column to displace the His6-tagged PAR1exo 
peptide.  
 
Samples, from the PAR1exo peptide purification were analysed by Coomassie 
staining (Figure 5.2A). This showed that the majority of bacterial proteins did not 
bind to the Ni2+-equilibrated column and were therefore present in the flow-through 
fraction (Figure 5.2A ‘F’ lane). The 40 mM imidazole washing step resulted in the 
removal of loosely bound proteins, which constituted only a small amount of protein 
(Figure 5.2A ‘W’ Lane). In the elution fraction, a protein band between 10-15 kDa 
was detected suggesting an elution of the relatively pure PAR1exo peptide (Figure 
5.2A ‘E’ Lane). To confirm the presence of PAR1exo peptide, Western blotting 
employing an Ab specific for the His6 tag was performed. The band detected was 
consistent with the Coomassie-stained gel, which suggested the PAR1exo peptide 
was successfully purified (Figure 5.2B). This elution fraction was dialysed into TBS 
(pH7.4) buffer to remove imidazole and urea before the peptide cleavage was 
assessed. A total of ~ 1 mg purified PAR1exo peptide was obtained by this method, 
and the amount of purified peptide was determined using nanodrop. 
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Figure 5.2 PAR1exo peptide purification.   
PAR1exo peptide containing solution from the large scale IPTG-induced bacteria 
culture pellet was loaded on a Ni2+-chelating HP column with 25 mM imidazole 
followed by washing and the elution of the tagged peptide using 250 mM imidazole. 
Each purification fraction was analysed by SDS-PAGE and Coomassie staining (A) 
or Western blotting using mouse monoclonal anti-His6 Ab (B). SIB: solubilised 
inclusion bodies; F: flow through; W: washing; and E: elution. 
 
 
5.3 Cleavage of the PAR1exo peptide  
 
The ability of APC to cleave PAR1exo peptide was initially investigated by 
incubating 10 μg/ml peptide with 100 nM plasma-derived APC (HTI) at 37°C in TBS 
(pH7.4), 10mM CaCl2. Aliquots were taken at various times (0-2 hours), and these 
were mixed with the serine protease inhibitor, Pefabloc (1 mM), to terminate the 
reaction. Subsamples were analysed by a Western blotting using mouse 
monoclonal anti-His6 Ab. Over time, the intensity of PAR1exo peptide band 
decreased (Figure 5.3A), suggesting the cleavage of the peptide by APC. The lack 
of detection of newly generated cleavage products was probably due to their small 
size, making them difficult to detect by Western blotting. To confirm specific 
cleavage, subsamples of the cleavage reaction taken at various times were also 
assessed by Coomassie staining that revealed two cleavage fragments (Figure 
5.3B ‘APC’ lanes).  
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However, I also found that PAR1exo peptide was cleaved by 0.17 U/ml Protac 
(Figure 5.3B ‘Protac’ lane). As the cleavage products from Protac hydrolysis had 
similar MWs as those from APC degradation, the Protac cleavage site is likely also 
after Arg41. This is perhaps not surprising as Protac is a serine protease with 
substrate specificity for Arg or Lys at P1 position [331,332]. This finding presented a 
problem for analysis of APC variants in the assay for PAR1exo peptide cleavage, 
due to the presence of Protac in these variant preparations. To investigate the 
ability of WT APC and APC variants to cleave the peptide, any potential 
interference of Protac needed be eliminated. I attempted to separate Protac from 
APC using anion exchange chromatography.  APC activated by Protac was loaded 
on the column at pH 7.4 followed by the elution with various concentrations of NaCl. 
The majority of Protac was found in the flow through, whereas APC was in the 
elution fraction (eluted by 200 mM NaCl). However, residual Protac in the elution 
fraction was still detected, which was sufficient to cleave PAR1exo peptide (data 
not shown). Importantly, and consistent with the literature [317], Protac was not 
readily inhibited by serine protease inhibitors such as Pefabloc and PMSF. 
Furthermore, in contrast to the reported complete inhibition of Protac using AT III 
and heparin together [333], I found that Protac was only partly inhibited by these 
inhibitors. It is also noteworthy that it seems impossible to abolish the enzymatic 
property of Protac without suppression of APC activity. Because of these problems 
with contaminating Protac, I decided to investigate an alternative method of protein 
C activation that did not involve this protease. The method I have used to 
generation APC was to use thrombin (Section 3.2.2.2). 
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Figure 5.3 PAR1exo peptide cleavage by HTI APC and Protac.  
A), Peptide (10 μg/ml) was incubated with HTI APC (100 nM) for various times 
before the reaction was terminated by the addition of 1 mM Pefabloc. Samples 
were subjected to Western blotting and detected by mouse monoclonal His6 Ab. B), 
PAR1exo peptide (30 μg/ml) was incubated with 100 nM HTI APC or 0.17 U/ml 
Protac cleavage under the conditions described in section 2.6.10. The cleavage 
was then assessed on a Coomassie-stained gel. 
 
The PAR1exo peptide cleavage assay was performed using WT APC under the 
same conditions as for plasma-derived APC (HTI). However, no cleavage was 
observed even after 2 hour incubation (data not shown), which was incompatible 
with the results where HTI APC was used. The ability of HTI APC to cleave the 
PAR1 peptide was reassessed, and this time in parallel with a commercial 
recombinant APC preparation (Xigris) and thrombin. The results, presented in 
Figure 5.4, showed that PAR1exo peptide cleavage was detected using plasma-
derived APC (HTI), but not Xigris, and the peptide cleavage by 20 pM thrombin was 
readily detected after 90 minutes. These results might indicate the plasma-derived 
APC (HTI) was contaminated by thrombin. 
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Figure 5.4 Western blot of PAR1exo peptide cleavage by thrombin or APC 
(HTI or Eli Lilly).  
PAR1exo peptide (10 μg/ml) was incubated with Xigris APC (180 nM), HTI APC 
(180 nM) or thrombin (20 pM) at 37 °C. Subsamples were taken at different time 
intervals (0, 45, 90 minutes) and supplemented with 1 mM Pefabloc. PAR1exo 
peptide cleavage was analysed using mouse monoclonal Ab against His6 on a 
Western blot. 
 
To specifically test whether APC (HTI) was contaminated with thrombin, this APC 
preparation was incubated with PAR1exo peptide at 37°C in the presence or 
absence of hirudin. The results showed hirudin completely inhibited PAR1exo 
peptide cleavage by APC (HTI) (Figure 5.5). Since hirudin is specific for thrombin, 
these results strongly suggested thrombin contamination of APC (HTI), and that it 
was thrombin, rather than APC, that hydrolysed the peptide. This finding was 
supported following contact with its manufacturer, who indicated that the APC had 
been activated by thrombin followed by a cation exchange chromatography, which 
may not remove all trace of thrombin. In contrast, Xigris appears to have a much 
higher purity and lacks thrombin contamination. Because of this, Xigris was used as 
an APC standard in the following assays.  
 
 
Figure 5.5 Western blot of PAR1exo peptide cleavage by HTI APC with or 
without hirudin.  
PAR1exo peptide was incubated with HTI APC (180 nM) in TBS (pH 7.4)/10mM 
CaCl2 at 37 °C, subsamples were taken at various times (0, 30 and 60 minutes) 
before the addition of Pefabloc (1 mM). Peptide cleavage was detected on a 
Western blot using mouse monoclonal anti-His6 Ab. 
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Xigris at 180 nM fails to hydrolyse the PAR1exo peptide after 90 minutes (Figure 
5.4), and consequently, the cleavage assay was optimised using high 
concentrations of APC and prolonged incubation times. As depicted in Figure 5.6 A, 
PAR1exo peptide cleavage by 1 μM Xigris was detected after 4 hours, and 
substantial hydrolysis was found after 7.5 hours. This confirmed that the ability of 
APC to cleave the peptide but with much lower efficiency to that of thrombin (Figure 
5.4).  
 
After validation of PAR1exo peptide cleavage using Xigris, recombinant WT APC 
prepared using thrombin activation was studied. WT PC (450 nM) was activated by 
thrombin (75 nM) under the condition described in section 2.4.3.2, which was 
followed by the addition of 750 nM Hirudin to neutralise thrombin activity. The 
activation reaction mixture was recalcified with 10 mM CaCl2 before mixing and 
incubating with PAR1exo peptide (10 μg/ml) at 37 °C, where subsamples were 
taken at various times. Subsamples analysed by Western blotting showed that 450 
nM WT APC did not appreciably cleave the peptide at 6.5 hours (Figure 5.6B).  
 
 
 
Figure 5.6 PAR1exo peptide cleavage in the presence of APC (Xigris, WT and 
S360A) or in buffer only.  
PAR1exo peptide (10 μg/ml) was incubated with APC (Xigris, 1uM) plus hirudin (A), 
450 nM WT APC (B) at 37°C in TBS (pH 7.4) buffer containing 10 mM CaCl2. 
Subsamples were taken at indicated time points followed by the addition of 1mM 
Pefabloc. Cleavage was analysed on a Western blot using monoclonal Ab against 
His6. 
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5.4 Discussion 
 
The initial goal of the PAR1exo cleavage assay performed in this chapter was to 
assess the capability of APC variants in cleaving PAR1. The assay was designed to 
utilise a soluble exodomain (R27-P85) of human PAR1 as a model for the full-
length receptor, which could unambiguously examine the cleavage of this receptor 
by the proteases and this method was also adopted in the previous study [223]. The 
expression of the PAR1exo peptide was performed in competent E.coli cells. 
Bacteria expression system enables a rapid, low cost and high productivity of 
heterologous protein although the resultant peptide would be lack of the 
posttranslational modification such as glycosylation. However, unlike PAR2 which 
the glycosylation close to the scissile bond is shown to affect its activation by mast 
cell tryptase [334,335], N-linked glycosylation of the PAR1 N-terminal exodomain 
(at Asn 35, 62, 75) is rather important for the receptor’s expression but does not 
affect the efficacy of its cleavage by thrombin [336,337]. Consequently, a non-
glycosylated peptide spanning the N-terminal sequence of PAR1 could serve as a 
model of the full length receptor, which allowed the assessment of PAR1 cleavage 
in soluble condition. 
  
The cleavage of the peptide was optimised using Xigris, a commercial human 
recombinant APC preparation. It was found that an extremely high concentration of 
APC as well as prolonged incubation was required to attain the cleavage of 
PAR1exo peptide. In contrast, in cultured cells low concentration of APC (ie 5-20 
nM) is able to mediate PAR1 activation-dependent signalling transduction [111,224]. 
On ECs, this augmented rate of PAR1 cleavage by APC was associated with the 
binding of the protease to EPCR, which presents APC into close proximity to PAR1 
and thereby facilitating the cleavage. The PAR1exo peptide cleavage assay 
designed in current study can measure the direct cleavage in the purified system. 
However, it is less valuable in terms of helping one understand the APC effects in 
the physiological context, especially on ECs where EPCR expression is readily 
detected. A similar model used to measure the cleavage of PAR1 employs a PAR1 
chimera, which is comprised of an alkaline phosphatise tagged N-terminal 
extracellular domain of PAR1 fused with transmembrane domain of TF (since TF 
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only has one transmembrane domain) [110,224,338]. This chimera vector is 
transfected into ECs and PAR1 N-terminus cleavage is assessed by measuring the 
amounts of alkaline phosphatise accumulated in medium [110,224,338]. APC is 
found to cleave PAR1 with 104 fold lower efficacy than thrombin using this model, 
which led to the conclusion by the authors that the cleavage of PAR1 by APC under 
physiological conditions is unlikely [338]. However, this conclusion is challenged by 
the studies of Schuepbach et al, in which the endogenous PAR1 cleavage by APC 
was assessed using a PAR1 cleavage sensitive Ab [220]. They have shown that 
efficiency of endogenous PAR1 cleavage by APC is 500 fold lower than that by 
thrombin, and this PAR1 cleavage is dependent on EPCR [220]. It is suggested that 
the decreased efficacy towards PAR1 cleavage by APC of the transfected PAR1 
chimera is probably due to the lack of availability of EPCR colocalised with PAR1 in 
the same subcellular compartment [128]. Collectively, my results suggest that 
soluble PAR1 peptide cleavage is likely to be of limited use. Because a very high 
concentration of APC (1 µM) was needed in this assay, APC variants were 
alternatively assessed in assay involving ECs where EPCR is expressed. 
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Chapter 6 EC signalling responses of APC and thrombin 
 
In ECs, APC and thrombin have been shown to induce distinct cellular effects 
through activation of the same receptor, PAR1. This paradox has been partly 
explained by a recently proposed mechanism in which APC and thrombin activate 
PAR1 that is differentially compartmentalised on EC membranes. However, the 
down-stream intracellular transducers of those signals remain unclear. I proposed 
the differential involvement of PKC isozymes might transduce the opposing signals 
in response to APC and thrombin. To establish an EC model that was responsive to 
these two proteases, the activation of MAPK (Section 6.1) and modulation of EC 
barrier permeability (Section 6.2) were investigated in this chapter.  
 
6.1 Activation of Erk1/2 MAPK by APC and thrombin in ECs 
 
Before exploring PKC participation in APC- or thrombin-induced cellular effects on 
ECs, I first examined the influence of the proteases on activation of the MAPK 
pathway, as analysed by the phosphorylation of Erk1/2 (p42/p44). EA.hy926 cells 
are an immortal EC line derived from the fusion of HUVECs with lung carcinoma 
A549 cells. These cells have been used as an EC model to study their responses to 
APC and thrombin by many groups [50,110,111,128,129,214,223,224]. Confluent 
EA.hy926 cells were serum starved for 5 hours before incubating with APC for 10 
minutes. Thereafter, phosphorylation of Erk1/2 was detected by Western blotting 
using a phospho-specific Ab as described in section 2.7.3. The recombinant APC 
used in this chapter was Xigris (Eli Lily) unless otherwise stated. As shown in Figure 
6.1, APC induced Erk1/2 phosphorylation in EA.hy926 cells in a dose-dependent 
manner, with the maximal intracellular level of phosphorylated Erk1/2 attained by 40 
nM APC (Figure 6.1A). Similar results were obtained using HUVECs (Figure 6.1B), 
indicating the cellular responses in EA.hy926 cells reflected those in HUVECs, at 
least in this system.  
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Figure 6.1 Phosphorylation of Erk1/2 by APC.  
A), Confluent EA.hy926 cells were serum deprived for 5 hours prior to APC 
treatment (0-80 nM, 10 minutes). Erk1/2 activation was detected using Western 
blotting described in section 2.7.3. The figure shows a representative experiment. 
The histogram result shows the quantification of Erk1/2 activation from repeated 
experiments. Values representing densitometric analysis results of p-Erk1/2 
normalised by total Erk1/2, and are expressed as mean ± S.E.M (n=3). The 
unstimulated cultures are set to 1. *, p<0.05 compared to untreated control (one-tail 
t test) B), Same as A but HUVECs were used, figure showed one representative 
Western blot (n=2). 
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The effect of thrombin on Erk1/2 phosphorylation was also investigated. As 
expected, thrombin (5 nM, 10 minutes) induced phosphorylation of Erk1/2 in 
EA.hy926 cells (Figure 6.2A). Simultaneous administration of hirudin at 4 fold molar 
excess to thrombin abolished this phosphorylation, indicating this cellular response 
was specific to thrombin activity (Figure 6.2A). The Erk1/2 activation by the PAR1-
activating peptide (PAR1-AP) was also evaluated. PAR-APs are short synthetic 
peptides mimicking the tethered ligand domains of PARs. These peptides are able 
to stimulate PAR activation in a protease-independent manner through direct 
binding to the receptors [339]. Treatment with PAR1-AP (SFLLRN, 10 µM) for 10 
minutes increased the Erk1/2 phosphorylation level in confluent EA.hy926 cells 
(Figure 6.2B), which suggested activation of PAR1 is capable of stimulating Erk1/2 
phosphorylation.  
 
 
 
Figure 6.2 Phosphorylation of Erk1/2 by thrombin and PAR1-AP.  
A), Confluent EA.hy926 cells were serum-deprived for 5 hours prior to the treatment 
with thrombin (5 nM, 10 minutes) in the presence or absence of hirudin (5 or 20 nM). 
B), Confluent EA.hy926 cells were serum-deprived for 5 hours before cells were 
treated with thrombin (5 nM), PAR1-AP (10 µM), or APC (40 nM) for 10 minutes. 
Erk1/2 phosphorylation was detected as described in Section 2.7.3. Th: thrombin. 
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The time kinetics of Erk1/2 activation in response to APC and thrombin were 
examined next. For this, serum-starved EA.hy926 cells were incubated with either 
40 nM APC or 5 nM thrombin, and the cells were harvested at different time points 
(0-120 minutes). Thrombin was used at 5 nM based on the previously studies 
[129,340]. Phosphorylated Erk1/2, as determined by immunoblotting, is shown in 
Figure 6.3. Rapid phosphorylation of Erk1/2 was induced by APC after 5 minutes, 
and this persisted until 60 minutes before it gradually decreased after 120 minutes 
(Figure 6.3A). In comparison, the maximal level of phosphorylated Erk1/2 induced 
by thrombin was detected after 5 minutes of stimulation (Figure 6.3B). However, the 
duration of Erk1/2 activation was rather transient such that the phosphorylation 
level rapidly declined and returned to the basal level after 60 minutes (Figure 6.3B).  
 
 
Figure 6.3 The time course of phosphorylation of Erk1/2 by APC and thrombin. 
Serum-starved EA.hy926 cells were treated with either 40 nM APC (A) or 5 nM 
thrombin (B) for 0-120 minutes. Erk1/2 phosphorylation levels were detected as 
described in section 2.7.3. Upper panels show one representative Western blot of 
APC or thrombin treatment. Lower panels show the quantifications results from 3 
independent experiments. Values representing densitometric analysis results of p-
Erk1/2 normalised by total Erk1/2 and are expressed as mean ± S.E.M (n=3), which 
the unstimulated cultures were set to 1.  
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6.2 Modulation of EC barrier permeability by APC and thrombin 
 
The permeability of the EC barrier plays a vital role in controlling the interchange of 
cells and plasma constituents between the blood and underlying tissues. APC and 
thrombin play important but distinct roles in the modulation of EC barrier integrity. 
To examine this, a two-chamber compartment system was used (Section 2.7.4). 
The permeability of EA.hy926 cell monolayers was determined by quantification of 
the fluorescence of FITC-dextran that passed across the cell barrier. In this system, 
fluorescence of accumulated FITC-dextran in the absence of cells was 179±1 FU, 
newly confluent EA.hy926 cells had a markedly reduced permeability level (~45-75 
FU), whereas confluent cells resulted in a cell monolayer that effectively prevented 
FITC-dextran passage (≤ 10 FU). Serum-starved confluent cells in the transwells 
were treated with thrombin (5 nM, 10 minutes), which triggered a dramatic increase 
in the permeability of EA.hy926 cells (Figure 6.4A). Pre-incubating cells with APC 
for 3 hours attenuated thrombin-induced hyperpermeability in a dose-dependent 
manner and a complete prevention was achieved with 50 nM APC (Figure 6.4B). 
This is consistent with cell morphology observations using a light microscope. 
Serum-starved confluent monolayer of EA.hy926 exhibits the typical EC 
cobblestone-like shape (Figure 6.4C top panel). Whereas, after thrombin 
stimulation (5 nM, 10 minutes), cells retracted and became rounded-up, and 
formation of intercellular gaps is clearly visible (Figure 6.4C middle panel). However 
these cellular effects were prevented by the administration of APC, as no disruption 
on cell monolayer was observed if cells were pretreated with 50 nM APC for 3 hours 
prior to thrombin challenge (5 nM, 10 minutes) (Figure 6.4C bottom panel). It has 
been reported that this APC-induced protection of EC integrity was not due to its 
prevention of PAR1 cleavage by thrombin [129,220], since APC and thrombin have 
been shown to target different PAR1 populations on cell membrane [216,218].  
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Figure 6.4 APC opposes thrombin-induced hyperpermeability.  
EA.hy 926 cells were seeded in the 24-well transwell inserts and grown until 
confluent. A), Cells were treated with thrombin (5 nM) in serum free DMEM for 10 
minutes and permeability (fluorescence) was measured as previously described in 
section 2.7.4. B), Cells were treated with various concentrations of APC in serum 
free DMEM for 3 hours prior to thrombin treatment (5 nM, 10 minutes). Permeability 
(fluorescence) was measured as above. Values are expressed as the mean ± 
S.E.M for 4 (A) or 2 (B) independent experiments with each performed in duplicate. 
C), A representative set of pictures showing the cell morphologies of untreated, 
thrombin treated and APC pretreated before thrombin challenge groups. 
 
 
In addition to protecting ECs from thrombin-mediated barrier dysfunction, APC also 
promotes stabilisation the permeability integrity of non-perturbed, newly-confluent 
ECs [129]. To examine this effect, I first needed to establish the optimal cell 
seeding density enabling a cell monolayer profile that had a less established cell-
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cell contact (i.e. newly-confluent cells) and without well-formed intercellular 
junctions. EA.hy926 cells were seeded at 2×104, 3.5×104 or 5×104 per transwell 
insert. They were left to attach and grow for ~40 hours before they were serum 
starved or supplemented with APC for 3 hours followed by the permeability analysis 
described in section 2.7.4. When cells were seeded at 2×104 cell density, gaps 
were clearly visualised under the microscope after 40 hours, and APC failed to 
diminish cell permeability (Figure 6.5A); whilst when 3.5-5×104 cells/well were 
seeded, an EC monolayer with a loose cell-cell connection or a discontinuous EC 
monolayer was established after 40-hour growth, the measured permeability 
(Figure 6.5A) which was found to be similar to that of thrombin-perturbed confluent 
EA.hy926 cells (Figure 6.4A). APC reduced the EC permeability of EA.hy926 cells 
seeded at these densities (Figure 6.5A). Therefore, the conditions, including 
seeding of 4×104 EA.hy926 cells per well and 40 hour growth in complete DMEM 
medium, were chosen to evaluate APC EC barrier enhancing effects. As shown in 
Figure 6.5B, treatment of APC for 3 hours dose-dependently decreased the 
permeability of the newly-confluent-cell monolayer with 50 nM APC reducing EC 
permeability by ~50%. 
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Figure 6.5 EC barrier integrity was enhanced by APC in newly-confluent cells.  
A), EA.hy926 cells were seeded at various densities in the transwell inserts and 
allowed to grow for 40 hours. Thereafter cells were incubated in vehicle control or 
50 nM APC in serum-free DMEM for 3 hours before the permeability is analysed as 
described in section 2.7.4. Values were expressed as mean ± S.E.M (n=2) from 
duplicate samples. B), 4×104 EA.hy926 cells were seeded and grown for 40 hours 
before cells were treated with APC (20 or 50 nM) in serum-free DMEM for 3 hours 
prior to the permeability analysis. The permeability of untreated cells was set as 
100% to which treated cells were compared as stated in section 2.7.4. Values were 
expressed as mean ± S.E.M (n=3) for three independent experiments in triplicate.  
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6.3 The involvement of PAR1 and EPCR in APC-mediated cell signalling 
 
The cellular models responsive to both APC and thrombin have been established 
and described in the above sections. Thrombin induced hyperpermeability, whereas 
APC enhanced EC barrier function and protected cell monolayer integrity from 
disruption. In addition, both APC and thrombin activate a downstream signalling 
pathway-Erk1/2, although in response to APC a prolonged duration of the activation 
is observed. To understand the molecular specificity of the two proteases on EC 
surface, which would initiate different intracellular signal transduction, I next 
investigated the signalling dependence of APC/thrombin to EC receptors PAR1 and 
EPCR.  
 
First, the Erk1/2 phosphorylation assay was performed using conditions optimised 
previously but with the recombinant APC variants (Figure 6.6). Serum starved 
confluent EA.hy926 cells were treated with 40 nM of Xigris, WT APC or APC 
variants for 10 minutes, and the Erk1/2 phosphorylation was detected as before. As 
expected, WT APC increased the level of phosphorylated Erk1/2 similarly to 
commercial APC (Xigris) (Figure 6.6A&B). A comparable level of phosphorylation of 
Erk1/2 was also attained by the non-anticoagulant APC-D36A/L38D/A39V (Figure 
6.6 A&B), suggesting this variant elicited normal signalling capability.  
 
APC-L8V, which cannot bind EPCR, failed to induce Erk1/2 phosphorylation (Figure 
6.6A&B), indicating the requirement for EPCR binding to enable signalling. This 
result was also confirmed by employing an EPCR-blocking Ab (RCR252) which 
completely blocked APC-initiated Erk1/2 phosphorylation (Figure 6.7 A&B).  
 
The Erk1/2 phosphorylation in cells treated with active site-mutated APC-S360A or 
WT zymogen protein C was indistinguishable from that of the untreated group 
(Figure 6.6 A&B), which indicated that APC protease activity is essential for its 
signalling function.  
 
Surprisingly, Erk1/2 phosphorylation in response to APC-E330A/E333A was 
comparable to that of WT APC (Figure6.6A&B).  Mutation of these residues has 
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been previously reported to abolish PAR1 cleavage and thus ablate signalling 
(Figure 6.6 A&B). My results suggested that either E330A/E333A substitutions do 
not disrupt APC signalling or that the effect induced by this variant was not 
dependent on PAR1. 
 
 
Figure 6.6 The effect of APC variants on Erk1/2 phosphorylation.  
Confluent EA.hy926 cells were treated with commercial APC (Xigris), WT APC, 
APC variants or commercial protein C from HTI (40 nM, 10 minutes) before Erk1/2 
phosphorylation level was analysed (section 2.7.3). A), A representative Western 
Blot is shown. B), Histogram shows the quantifications of corresponding Western 
blot results repeated experiments. Values representing densitometric analysis 
results of p-Erk1/2 normalised by total Erk1/2 and are expressed as mean ± S.E.M 
(n=4), where the unstimulated cultures were set to 1. *, p<0.05; **, p<0.01; ***, 
p<0.001, N.S., not significant, compared to untreated cultures or otherwise 
indicated.  
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Figure 6.7 The effect of EPCR blocking Ab (RCR252) on APC-mediated Erk1/2 
phosphorylation.  
Confluent EA.hy926 cells were incubated with anti-EPCR Ab, RCR252 (25 µg/ml, 
30 minutes) before treatment with 40 nM APC for 10 minutes. Erk1/2 
phosphorylation was analysed (section 2.7.3). A), A representative Western blot is 
shown. B), The quantification of Western blot results from repeated experiments. 
Values representing densitometric analysis results of p-Erk1/2 normalised by total 
Erk1/2 and are expressed as mean ± S.E.M (n=2) from 2 independent experiments 
performed in duplicate. The unstimulated cultures were set to 1. 
 
Based on the previous finding, I endeavoured to rationalise my findings by further 
exploring the PAR1 dependency of APC triggered signalling using a PAR1 blocking 
Ab. Anti-human PAR1 Ab H-111 is a polyclonal IgG1 against PAR1 residues 1-111. 
Serum-starved confluent EA.hy926 were incubated with H-111 (25 μg/ml, 30 
minutes) prior to be treated with either 5 nM thrombin (Figure 6.8A) or 40 nM APC 
(Figure 6.8B) for 10 minutes. The results showed that H-111 only moderately 
inhibited both thrombin- and APC- induced Erk1/2 phosphorylation. The bands 
indicated by the arrows in Figure 6.8 A and B were probably due to H-111, a rabbit 
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Ab being detected with the anti-rabbit HRP labelled Ab used to detect 
phosphorylated Erk1/2 (the primary Ab against which was raised in rabbits). 
 
Alternatively, confluent cells plated in transwell inserts were treated with the Ab (25 
μg/ml, 30 minutes) prior to the same thrombin treatment (Figure 6.8 C). Similarly, H-
111 also exhibited minor inhibition on thrombin-mediated EC hyperpermeability 
(Figure 6.8C). This Ab was successfully used to bind human or mouse PAR1 or 
block PAR1 signalling [166,168,215,224,341], however the failure of this Ab to bind 
mouse PAR1 in a recent study suggested a change in the properties of recent 
batches [171]. The failure to effectively block the signalling responses afforded by 
APC or thrombin could potentially be due to the lack of PAR1-blocking efficiency or 
these signalling responses are not PAR1 dependent. Therefore, the involvement of 
PAR1 in APC and thrombin signalling was explored using other PAR1 Abs.  
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Figure 6.8 The effect of H-111 Ab on thrombin and APC-induced EC signalling. 
Serum-starved confluent EA.hy926 cells were incubated with rabbit polyclonal Ab 
(H-111, 25 µg/ml) for 30 minutes prior to be treated with thrombin (5 nM, 10 minutes) 
(A) or incubated with H-111 (25 µg/ml) for 1 hour before APC treatment (40 nM, 10 
minutes) (B). Erk1/2 phosphorylation was analysed as described in section 2.7.3. 
C), Confluent EA.hy926 cells grown in the transwell inserts were incubated with 25 
µg/ml H-111 for 30 minutes before treated with 5 nM thrombin for additional 10 
minutes. Permeability was analysed as in section 2.7.4. 
 
 
ATAP2 is a monoclonal Ab that binds to the ‘tethered ligand’ in the newly released 
N-terminus of PAR1 (amino acid 42-55) [342]. However, a better characterised and 
more widely used way to block catalytic PAR1 cleavage was to use ATAP2 in 
combination with WEDE15 [51,129,164,183,343], an anti-PAR1 monoclonal Ab 
against the hirudin-like binding sequence [344,345].  
 
Successful inhibition of PAR1 cleavage has been shown using ATAP2 alone [198], 
but the study by Shi, X et al have also suggested that this inhibition effect is modest; 
conversely, a strong inhibitory effect has been shown using combination of ATAP2 
and WEDE15 Abs [53]. My findings suggested that ATAP2 alone (20 μg/ml, 30 
minutes) cannot inhibit either thrombin- or APC-induced Erk1/2 phosphorylation 
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(Figure 6.9). In contrast, a mixture of both WEDE15 and ATAP2 together 
completely ablated thrombin-induced Erk1/2 activation (Figure 6.10A) and EC 
hyperpermeability (Figure 6.10B), in agreement to the literature [51]. 
 
 
 
Figure 6.9 The effect of ATAP2 on thrombin or APC induced Erk1/2 
phosphorylation.  
Confluent EA.hy926 cells were incubated with a mouse monoclonal anti-PAR1 Ab, 
ATAP2 (20 μg/ml), for 30 minutes followed by APC (40 nM) or thrombin (5 nM) 
treatment for 10 minutes. P-Erk1/2 was analysed as described in section 2.7.3. Thr, 
thrombin; p-Erk1/2, phosphorylated Erk1/2. 
144 
 
 
 
Figure 6.10 The effect of ATAP2 and WEDE15 Ab mixture on thrombin-
induced Erk1/2 phosphorylation and hyperpermeability in EA.hy926 cells. 
Confluent EA.hy926 cells were incubated with ATAP2 (10 µg/ml) and WEDE15 (25 
µg/ml) mixture for 30 minutes before cells were treated with 5nM thrombin for 10 
minutes, followed by Erk1/2 phosphorylation analysis (A) or permeability analysis 
(B). A shows a representative Western blot from two independent experiments. In B, 
the permeability was expressed as fluorescence and values represent mean ± 
S.E.M (n=2). 
 
 
Based on the effect of ATAP2+WEDE15 on thrombin-mediated PAR1 signalling, 
PAR1 dependency in APC-mediated cytoprotective signalling was assessed using 
the optimised PAR1-cleavage blocking approach. Confluent EA.hy926 cells were 
incubated with control carrier or 10 μg/ml ATAP2 and 25 μ/ml WEDE15 for 30 
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minutes before subjected to APC (40 nM, 10 minutes). As shown in figure 6.11A, 
the Erk1/2 phosphorylation triggered by APC was remarkably attenuated in the cells 
pretreated with the Ab mixture. This suggested Erk1/2 MAPK pathway activation 
conferred by APC in EA.hy926 cells is dependent on the activation of PAR1. 
 
Newly-confluent EA.hy926 cells in transwell inserts were identically incubated with 
the Ab mixture before APC treatment (50 nM, 3 hours). As shown in figure 6.11B, In 
cells not treated with the PAR1 Ab mixture, 50 nM APC decreased the permeability 
of the newly-confluent cells by ~ 50%; In comparison, in cells preincubated with 
PAR1 Abs, the reduction of permeability by APC is greatly attenuated. These 
results indicated an important role of PAR1 in the APC-mediated EA.hy926 cell 
barrier stabilisation.  
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Figure 6.11 The effect of ATAP2 & WEDE15 on APC-mediated Erk1/2 
phosphorylation and EC permeability reduction in EA.hy926 cells.  
A), confluent cells in normal 24-well plate were preincubated with ATAP2 (10 µg/ml) 
and WEDE15 (25 µg/ml) Ab mixture for 30 minutes before treated with 40 nM APC 
for 10 minutes and followed by Erk1/2 phosphorylation analysis. The left panel 
shows a representative Western blot and the right one shows the quantification of 
p-Erk level normalised by total Erk1/2. B), 4×104 EA.hy926 cells were seeded in 24-
well transwell inserts and left grown for 40 hours. Cells were incubated with Ab 
mixture in the same way as that in A followed by the treatment with 50 nM APC for 
3 hours. Permeability was analysed and the untreated group was set to 100%. 
Values are expressed as mean ± S.E.M for three independent experiments (A) or 
three experiments in triplicates (B). p-Erk1/2, phosphorylated Erk1/2; *, P<0.05; **, 
P<0.01; N.S., not significant.  
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6.4 Discussion 
 
The aim of the studies in this chapter was to establish in vitro EC models that were 
responsive to APC and/or thrombin and to use these to examine their dose- or time-
dependent effects of these proteases in these cellular assays. Thereafter, I sought 
to verify the receptors upon which the EC signalling effects mediated by APC and 
thrombin are dependent. 
 
In the current study, EA.hy926 cells were used as an EC model in which the APC 
and thrombin cellular responses were assessed. This ‘immortal’ cell line, first 
established by Edgell et al, was derived by hybridization of primary HUVECs with 
the human lung carcinoma cell line A549. These cells have sustained expression of 
VWF, a specific function of vascular EC, which maintains for more than 100 
population doubling [346]. EA.hy926 cells also preserve many other characteristics 
of HUVECs [347-357].  
 
There are many advantages of using this cell line - it is easily maintained cell line 
with stable vascular endothelial characteristics. Moreover, many studies have used 
this cell line as a model of vascular ECs to study APC and thrombin signalling 
[50,111,128,129,167,216,220,223,224,306,340,358]. Although primary ECs, such 
as HUVECs, have additional advantages, such as they are not immortalised and 
closer to physiological EC which are not as proliferative or synthetic as immortalised 
cells. HUVECs require time to prepare and limited number of passages that can be 
used. However, a big disadvantage of using these primary cells is the variability 
between batches from different donors, a major obstacle for obtaining reproducible 
results. It was observed in the early stages of optimising the Erk1/2 phosphorylation 
by APC in HUVECs that phosphorylated Erk1/2 was readily detected in some 
HUVEC preps but was rather modest in the others. Studies have reported the 
differences in various transfection efficiencies [359], mRNA levels [360] between 
HUVECs from different donors and others have demonstrated that cellular 
characteristics differ between HUVECs from single and multiple-pooled donors 
[361]. Therefore, studies often use pooled HUVECs from ~4 donors [362,363], 
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however this was impractical and time-consuming for the present study, and 
particularly as the EA.hy926 cells were available.   
 
EC signalling responses including Erk1/2 activation and EC permeability regulation 
mediated by APC and thrombin were studied in this thesis. I hypothesised that 
different PKC isozyme involvement contributes to the divergent signalling pathways 
between APC and thrombin. The Erk1/2-MAPK cascade involves Raf, MEK1/2 and 
Erk1/2, which are ubiquitously expressed in mammalian cells and regulate diverse 
cellular responses such as cell proliferation, differentiation, survival and motility 
[364]. Both APC and thrombin induce Erk1/2-MAPK cascade activation, which is 
implicated in the EC proliferation [198,365]. In agreement with the literature 
[129,164,198-200,214], Erk1/2 pathway activation was detected in both APC and 
thrombin stimulated EA.hy926 cells (Figure 6.2), and the activation was specifically 
due to their protease activities (Figure 6.2A & Figure 6.6). Erk1/2 is also involved in 
the APC-mediated cytoprotective signalling which suppresses both mRNA level and 
secretion of apoptosis factor-TRAIL. At high concentrations (180 nM), APC is 
capable of attenuating the TNF-α induced ICAM-1 expression on EC surface, in 
which Erk1/2 also plays an important role [200]. 
 
My results also showed that Erk1/2-MAPK cascade activation by APC required 
EPCR binding. This was initially demonstrated by using APC-L8V, an APC variant 
which has been reported to have impaired EPCR-binding function [93,124]. In the 
current study, APC-L8V treated cells have indistinguishable level of p-Erk1/2 
compared to unstimulated cells. Additionally, by taking advantage of EPCR blocking 
Ab (RCR252), the requirement of EPCR in APC-driven activation of Erk1/2 was 
further confirmed. This was consistent with previous studies demonstrating that 
APC induces Erk1/2 activation in an EPCR-dependent manner [164,172,198,225].  
EPCR not only serves to recruit protein C to the EC surface, it also augments the 
generation of APC on EC cell surfaces [117,366], and enables PAR1 activation by 
APC [338], and is therefore a critical component for its cytoprotective signalling 
[50,216].  
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To investigate if the signalling response to APC was dependent on PAR1 activation 
in EA.hy926 cells, I employed APC-E330A/E333A. This variant, first generated by 
Yang et al, was reported to have normal anticoagulant activity but fail to cleave 
PAR1 thereby incapable of protecting ECs from apoptosis and barrier disruption 
[110]. Based on these results, it was proposed by the authors that Glu330 and 
Glu333 form an exosite important for PAR1 interaction/proteolysis [110]. The 
normal anticoagulant activity of this variant was confirmed in chapter 4 using the 
CAT assay. Surprisingly, in cultured EA.hy926 cells, APC-E330A/E333A induced 
Erk1/2 phosphorylation similar to WT APC. Importantly, a dramatic attenuation in 
APC-induced activation of Erk1/2 was observed if PAR1 blocking Ab mixture 
(ATAP2 & WEDE15) was used, which indicated the important role of PAR1 in this 
cellular response to APC, in agreement with previous studies [129,165,167,307-
310] .  
 
This raises the question of why APC-E330A/E333A induced the signalling response 
while PAR1 was found to be responsible for this signal transduction? One 
explanation is that Erk1/2 phosphorylation might be a sensitive readout of PAR1 
signalling and thus low rate activation of PAR1, which might be afforded by APC-
E330A/E333A, may support the activation of Erk1/2 signalling pathway. In 
comparison, other downstream pathways such as anti-apoptosis or EC barrier 
protection, which were assessed by Yang et al, require a more extensive PAR1 
activation. Although the APC variant failed to cleave transfected PAR1, it is 
important to keep in mind that the capability of the APC variant in PAR1 cleavage is 
assayed in PAR1 overexpression system. As discussed in chapter 5, due to the 
lack of colocalisation of EPCR with transfected PAR1, cleavage of these exogenous 
PAR1 requires a much higher concentration of APC (APC is ~20 fold more efficient 
in cleaving endogenous PAR1 than transfected PAR1 [110,220]). Therefore, it is 
possible APC-E330A/E333A might still be capable of cleaving endogenous PAR1 
and thereby signalling intracellularly. Consequently, this variant is a poor tool to 
determine the PAR1 dependence of APC signalling. 
 
Regulation of EA.hy926 cell permeability by APC and thrombin was also evaluated. 
It was found that thrombin can increase the permeability of EA.hy926 cell 
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monolayer (Figure 6.4 A), whereas APC protected cells from this thrombin-induced 
barrier disruption (Figure 6.4B). It is believed that the robust PAR1 activation 
induced by thrombin leads to the coupling of Gq/G12/13 protein, which in turn 
activates RhoA, NF-κB and phosphorylates MLCK, triggers actomyocin contraction, 
resulting in the cell rounding and interendothelial gap formation [216,367]. APC 
exhibited a dose-dependent inhibition of thrombin-driven hyperpermeability, with a 
half-maximum endothelial barrier protection was achieved at ~ 5 nM (Figure 6.4 B). 
This is consistent with published ~ 1.2 nM [129] and 9.85 nM [111]. It might be 
easily speculated that cleavage of PAR1 by APC prevents further actions of 
thrombin since the latter also requires PAR1 activation to signal into the cells. 
However, several studies have suggested this is not the case. Using a PAR1 
cleavage sensitive Ab, Schuepbach et al have shown that more PAR1 get cleaved 
on ECs surface by thrombin even after APC preincubation [220]. In addition, 
thrombin is able to induce the signalling activity in ECs pretreated with APC [129]. 
 
Moreover, APC also stimulated newly-confluent EC stabilisation, probably through 
the establishment of tighter cell-cell contacts (Figure 6.5B). Although the exact 
mechanism of APC-triggered EC barrier protection is not fully understood, it is 
generally accepted that it involves PAR1 activation-induced Gi protein coupling and 
subsequent Rac-1 activation, which further lead to cytoprotective signalling 
responses [216]. APC also exhibits EC barrier enhancing effect without the 
presence of hyperpermeability-inducing agonist, such as thrombin. This also 
indicates that cytoprotective effect of APC is not caused by the desensitisation of 
PAR1 level on cell surface. This notion is reinforced by the previously published 
study showed that preincubation with APC does not affect the PAR1-dependent 
activation of Erk1/2 by thrombin [129]. In addition, these might also indirectly 
support the recently accepted notion that APC and thrombin activate PAR1 
localised at different compartment of EC membrane. 
 
ECs have been reported to express all four PARs [50-52] with expression of PAR1 
and PAR2 being highest [368]. It is evident that HUVEC activation and up-
regulation of gene expression (i.e. TR3) in response to thrombin are ablated by 
PAR1 blocking Abs (ATAP2 & WEDE15), whereas these responses are only partly 
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inhibited when a PAR1 antagonist (BMS200261) is used [51,307]. This PAR1 
antagonist blocks receptor activation by binding to the tethered ligand binding site in 
extracellular loop 2. It was proposed that thrombin activates HUVECs and 
modulates gene expression through the activation of both PAR1 and PAR2, in 
which PAR2 is trans-activated by the tethered ligand of PAR1 [51]. In view of this, 
although my results suggests a requirement of PAR1 cleavage using the same 
PAR1 blocking Abs, the possible involvement of PAR2 cannot be excluded. The 
hypothesis that PAR2 might also be responsible for the cytoprotective effects 
promoted by APC in our system is supported by the observations by Riewald et al 
that APC can induce PAR2 activation [164,307] and by Kaneider et al showing that 
the protective effect of PAR1 requires transactivation of the PAR2 signalling 
pathway in mouse model of sepsis [369]. It has been reported that PAR1 and PAR2 
reside in close proximity to each other on cell membrane [369], and a more recent 
study has shown the heterodimer formation between PAR1 and PAR2 on vascular 
smooth muscle cells [370]. If this is the case in ECs remains to be determined, and 
even if heterodimerisation of PAR1 and PAR2 occurs on ECs, their localisation in 
caveolae has to be assured before APC can signalling through this way.  
Consequently, further studies are recommended to address this issue first. 
Thereafter, it would be interesting to investigate if APC-induced cytoprotective 
effect is through the cleavage of PAR1 and activation both PAR1 and PAR2, which 
can be assessed using PAR1 and PAR2 antagonists.  
 
In conclusion, the results in this chapter show that 1) both APC and thrombin are 
able to activate Erk1/2 pathway which require their protease activities, 2) thrombin 
induces the increase of permeability of EA.hy926 cell monolayers, 3) APC is not 
only able to reduce the EA.hy926 cell permeability in newly-confluent EA.hy926 
cells, it also protects confluent cell monolayers from disruption upon exposure to 
thrombin, 4) APC-mediated signalling requires its binding to EPCR, 5) PAR1 is the 
predominant receptor for both APC and thrombin-induced activation of Erk1/2 
phosphorylation and regulation of EC permeability, 6) it also suggests the lack of 
anticoagulant property of APC does not prevent APC from signalling through PAR1. 
Finally, the cultured-EC model established in this chapter enabled me to investigate 
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the PKC involvement in APC and thrombin-induced cell signalling, which is 
described next in chapter 7. 
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Chapter 7 Involvement of PKC in APC and thrombin 
mediated EC responses 
 
PKC has been implicated in many cell signalling pathways, including the Erk1/2-
MAPK cascade activation and regulation of EC barrier function. Different cellular 
effects were observed in EA.hy926 cells in response to APC and thrombin in 
chapter 6. In this chapter, I further explored the underlying mechanisms with 
particular reference to the involvement of PKC isozymes. This chapter includes 
analysing the roles of PKC (isozymes) in thrombin and APC induced Erk1/2 
phosphorylation (Section 7.1) and in regulation of EC barrier function (Section 7.2). 
In addition, the PKC isozyme activation mediated by thrombin and APC was 
assessed by their intracellular translocation and phosphorylation (Section 7.3). 
 
7.1 PKC involvement in the phosphorylation of Erk1/2 induced by PMA, 
APC and thrombin 
 
7.1.1 The effect of direct PKC activation on phosphorylation of Erk1/2  
 
Before investigating the involvement of PKC in EC signalling responses to APC and 
thrombin, I first endeavoured to assess if PKC activation per se could lead to the 
signal transduction to activate Erk1/2 in cultured EA.hy926 cells. PMA is a potent 
PKC activator that functions similarly to DAG and is generally considered to 
provoke the activation of classical and novel PKC isozymes [371-374]. Incubation of 
EA.hy926 cells with 100 nM PMA induced a dramatic increase of the intracellular 
level of phosphorylated Erk1/2 within 5 minutes (Figure 7.1A). The phosphorylation 
level was further elevated over incubation time, which plateaued at 60 minutes and 
persisted for another 2 hours (Figure 7.1A). These results clearly suggested a PKC-
dependent activation of Erk1/2 in EA.hy926 cells, consistent with what has been 
previously observed in many other cell types [375-378]. To explore the specific PKC 
isozymes responsible for this cellular response to PMA, pharmacological PKC 
inhibitors were employed. Serum-starved EA.hy926 cells were preincubated with 
GF109203X (1 μM) or Gö6976 (0.3 μM) for 30 minutes prior to the treatment of 
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PMA (100 nM, 1 hour). Whole cell lysates were then prepared and p-ERk1/2 and 
Erk1/2 were detected by immunoblotting described in section 2.7.4. As shown in 
figure 7.1B, a remarkable increase in p-Erk1/2 was seen in the cells treated with 
100 nM PMA for 1 hour compared to vehicle-treated cells. This increase was 
attenuated by GF109203X preincubation, whereas the effect of Gö6976 
pretreatment was negligible (Figure 7.1B and C). This suggested that PKC isoforms 
inhibited by GF109203X but not those by Gö6976 were responsible for the Erk1/2-
MAPK activation. GF109203X is well known to potently inhibit classical PKC 
isozymes (α and β1) and novel PKC isozymes (ε and δ) [379-381], whilst Gö6976 is 
specific for classical PKC isozymes (PKC α and β1) [382]. Based on this, novel 
PKCε or δ are implicated in the PMA-induced activation of the Erk1/2 cascade. This 
is compatible with the previous studies which showed that PMA-induced Erk1/2 
activation is PKCδ-dependent in intestinal epithelial cells [379], and overexpression 
of PKCδ enhances and sustains Erk1/2 activation in murine mammary cells 
exposed to PMA [383]. Collectively, these results implied that PKC activation could 
lead to Erk1/2-MAPK pathway activation and that not all the PMA-activated PKC 
isozymes (classical and novel) are equally responsible for this signalling pathway, 
demonstrated using PKC selective inhibitors (GF109203X and Gö6976). Based on 
these results, I investigated the involvement of PKC in APC- and thrombin-
mediated cellular effects using these PKC inhibitors. 
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Figure 7.1 PMA activation of Erk1/2 and effects of pharmacological PKC 
inhibitors (GF109203X, Gö6976) on this PMA effects.  
Serum starved EA.hy926 cells were incubated with 100 nM PMA for various times 
(A) or preincubated with PKC inhibitors GF109203X (1 µM) or Gö6976 (0.3 µM) for 
30 minutes followed by 60 minute PMA (100 nM) exposure (B). Cells were lysed for 
Erk1/2 phosphorylation analysis (section 2.7.3). C), Quantitative result of B from two 
independent experiments is shown, where the band intensity (p-Erk1/2 / Erk1/2) of 
untreated group is set to 1 and values are expressed as mean±S.E.M (n=2). 
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7.1.2 The involvement of PKC isozymes in thrombin-induced phosphorylation 
of Erk1/2 
 
To define the involvement of PKCs in Erk1/2 activation by thrombin in EA.hy926 
cells, selective PKC inhibitors Gö6976 and GF109203X were employed. Serum-
starved confluent EA.hy926 cells were treated with 0-10 μM GF109203X for 30 
minutes prior to stimulation with 5 nM thrombin or control (TBS) for 10 minutes. 
Representative Western blots are shown in Figure 7.2A. To quantitatively illustrate 
the influence of GF109203X to Erk1/2 phosphorylation, densitometric analyses of 
immunoblots from three independent experiments were performed and data were 
expressed as the fold changes of p-Erk1/2 (normalised to total Erk1/2) to untreated 
cells. It is evident from Figure 7.2B (left panel) that higher concentrates of 
GF109203X (≥ 5 μM) inhibited the basal levels of Erk1/2 phosphorylation. These 
results also showed that thrombin-induced Erk1/2 phosphorylation was reduced at 
concentrations ≥ 5 μM of GF109203X (Figure 7.2B right).  
 
Although GF109203X is a selective inhibitor of PKCs, it does not inhibit various 
PKC subtypes equipotently [382,384]. A report characterising the inhibition of 
different PKCs by GF109203X showed that it exhibits potent inhibition of classical 
(PKC α and β1) and novel (PKC δ and ε) PKCs with IC50 values ≤ 0.132 μM, whilst 
its inhibition of PKCζ is much less efficient (IC50  5.8 μM) [385]. Therefore, use of ≥ 
5 μM GF109203X is often employed to inhibit atypical PKCζ in cells [386-389]. In 
respect to this, the results shown in Figure 7.2 might suggest that whereas 
classical/novel PKCs are less likely to play an important role in thrombin-mediated 
Erk1/2 activation, PKCζ participation was still conceivable.  
 
The involvement of classical PKC isozyme in Erk1/2 phosphorylation upon thrombin 
treatment was studied using Gö6976 which potently inhibits classical PKC α and β1 
(IC50 < 7 nM) [382]. Pretreatment of the cells with 1 μM Gö6976 for 30 minutes 
failed to attenuate the phosphorylation of Erk1/2 triggered by thrombin (Figure 7.3), 
which excluded the role of classical PKCs in response to thrombin. This was 
consistent with the results obtained using GF109203X, which suggested that this 
signalling response is not dependent on either PKCα or PKCβ. 
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Figure 7.2 The effect of GF109203X on thrombin-induced phosphorylation of 
Erk1/2.  
A), Serum-starved confluent EA.hy926 cells were preincubated with 0-10 μM 
GF109203X for 30 minute before the addition of vehicle control (top panel) or 5 nM 
thrombin (bottom panel) and incubated for a further 10 minutes. One representative 
Western blot analysing the intracellular level of p-Erk1/2 and total Erk1/2 was given 
for each. B), the band intensities (p-Erk1/2/Erk1/2) of each treatment were 
quantified and values were expressed as mean ± S.E.M for three independent 
experiments. *, p<0.01; **, p<0.001, compared to vehicle control or otherwise 
indicated on the figure.  
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Figure 7.3 The effect of Gö6976 on thrombin-induced phosphorylation of 
Erk1/2.  
Serum-starved confluent EA.hy926 cells were preincubated with 1 μM Gö6976 for 
30 minute before treatment with 5 nM thrombin for 10 minutes. Representative 
Western blots analysing the intracellular level of p-Erk1/2 and total Erk1/2 are 
shown (n=3).  
 
 
That activation of Erk1/2 in EA.hy926 cells by thrombin cannot be inhibited either by 
Gö6976 or lower concentrations (< 5 μM) GF109203X, suggests that atypical PKCζ 
might be involved in this signalling. Therefore, to test this hypothesis, a cell 
permeable PKCζ inhibiting peptide was employed. All PKC isozymes contain 
specific pesudosubstrate domains that keep the protein inactive through binding to 
its kinase domain. Pesudosubstrate inhibitory peptides (PSIs) mimic the 
pesudosubstrate domain and prevent activation of PKCs [390]. Cell permeable 
modifications, such as myristorylation (Myr-PSI) and antennapedia domain vector 
peptide attachment to the N-terminus of the peptide (Antp-PSI), ensures their 
efficient delivery into the cells. 
 
Confluent EA.hy926 cells were preincubated with Myr-PSIζ (10 µM) for 30 minutes, 
followed by thrombin challenge (5 nM, 10 minutes) and subsequent p-Erk1/2 
analysis. As shown in figure 7.4, Myr-PSIζ treatment for 30 minutes reduced 
thrombin-mediated Erk1/2 activation by 59% compared to the absence of Myr-PSIζ. 
This indicated the PKCζ is likely the important upstream modulator of the Erk1/2-
MAPK pathway activated by thrombin. 
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Figure 7.4 The effect of Myr-PSIζ on thrombin-induced Erk1/2 phosphorylation.  
Confluent EA.hy926 cells were serum starved for 5 hours prior to incubation with 10 
μM of Myr-PSIζ for 30 minutes followed by thrombin stimulation (5 nM, 10 minutes). 
The p-Erk1/2 and total Erk1/2 levels were analysed as before. Quantitative result of 
three repeated experiments using 10 µM Myr-PSIζ is shown in the lower panel, 
where the band intensity (p-Erk1/2 / Erk1/2) of untreated group was set to 1 and 
values are expressed as mean ± S.E.M (n=3). *, p<0.01; **, p<0.001, compared to 
compared to vehicle control or otherwise indicated on the figure.  
  
7.1.3 The involvement of PKC in APC-induced phosphorylation of Erk1/2 
 
Having identified PKCζ as an important isozyme in Erk1/2 activation following 
thrombin stimulation, I examined the involvement of different PKC isozymes in 
APC-induced phosphorylation of Erk1/2, initially using PKC inhibitors GF109203X 
and Gö6976. In contrast to the effect of GF109203X on thrombin-mediated Erk1/2 
activation, this inhibitor (0-10 µM) dose-dependently inhibited the phosphorylation of 
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Erk1/2 in confluent EA.hy926 cells in response to APC treatment (10 minutes, 40 
nM) (Figure 7.5). This suggested a potential role of GF109203X-sensitive PKC 
isozymes (PKCα, β1, δ, ε and ζ) in APC-dependent Erk1/2 phosphorylation. Further 
studies using Gö6976 ruled out the possibility of classical PKC (PKCα and β) 
involvement, since this inhibitor did not influence the activation of Erk1/2 in these 
experiments (Figure 7.6).  
 
 
 
Figure 7.5 The effect of GF109203X on APC-induced phosphorylation of 
Erk1/2.  
A), Serum-starved confluent EA.hy926 cells were preincubated with 0-10 μM 
GF109203X for 30 minute before the addition of vehicle control (top panel) or 40 
nM APC (bottom panel) and incubated for a further 10 minutes. One representative 
Western blot analysing the intracellular level of p-Erk1/2 and total Erk1/2 was given 
for each. B), the band intensities (p-Erk1/2/Erk1/2) of each treatment were 
quantified and values were expressed as mean ± S.E.M for three independent 
experiments. *, p<0.01; **, p<0.001, compared to vehicle control or otherwise 
indicated on the figure.  
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Figure 7.6 The effect of Gö6976 on APC-induced phosphorylation of Erk1/2.  
Serum-starved confluent EA.hy926 cells were preincubated with 1 μM Gö6976 for 
30 minute before treatment with 40 nM APC for 10 minutes. Representative 
Western blots analysing the intracellular level of p-Erk1/2 and total Erk1/2 are 
shown (n=3).  
 
The results using PKC inhibitors suggested the possible involvement of PKC δ, ζ 
and/or ε in Erk1/2 phosphorylation in response to APC. To further explore this, I first 
assessed the involvement of PKCδ in APC-mediated Erk1/2 activation. Permeable 
PSIs are widely used to investigate the activity of specific PKC isozyme, due to their 
unique way of inhibition, efficient delivery to the target protein and their quick action 
once inside the cells. However, a PSI for PKCδ is not available. Gene knockdown 
approaches such as siRNA transfection is a general method for suppression of 
gene expression and the subsequent expression of protein counterpart. This 
method is also often used for identification of PKC isozymes in signalling pathways. 
Therefore, siRNA specific for PKCδ was employed to examine the importance of 
PKCδ in APC-induced Erk1/2 phosphorylation.  
 
A representative Western blot, in which PKCδ was specifically detected, 
demonstrated optimal knockdown of PKCδ expression in EA.hy926 cells was 
achieved when cells were transfected with 10 nM PKCδ siRNA using 1 μl 
Lipofectamine (Figure 7.7A).  This resulted in the reduction of PKCδ expression by 
~ 90% after 72 hours (Figure 7.7A). Cells transfected by PKCδ siRNA were allowed 
to grow for 3 days prior to be incubation with 40 nM APC for 10 minutes. Thereafter, 
Erk1/2 phosphorylation was assessed. These results revealed that PKCδ gene 
suppression had no effect on Erk1/2 activation in response to APC (Figure 7.7B). 
This suggested that PKCδ was unlikely involved in this APC signalling pathway.  
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Figure 7.7 PKCδ siRNA transfection and its effect in APC-induced Erk1/2 
phosphorylation.  
A), 50% confluent EA.hy926 cells seeded in 24-well plate were transfected with the 
combination of various concentration of PKCδ siRNA and volumes of lipofectamine 
2000 (LF) as described in methodology. Cells were left to grow for 72 hours before 
the expression level of PKCδ was analysed by immunoblotting. ‘Expression’ 
represents the relative expression level of PKCδ against total Erk1/2, which is 
compared to scrambled siRNA transfected cells. B), 10 nM PKCδ siRNA or 
scrambled siRNA control was used to transfect one well (24 wp) of 50% confluent 
EA.hy926 cells using 1 μl lipofectamine 2000. Cells were allowed to grow for 72 
hours before 5 hours serum deprivation followed by 10 minute incubation with 40 
nM APC. Total cell lysate were subjected to Western blotting for the assessment of 
Erk1/2 phosphorylation. One representative Western blot is shown (n=2).  
 
Although PKCδ was involved in Erk1/2 activation by APC, the results obtained 
using selective PKC inhibitors GF109203X (Figure 7.5) and Gö6976 (Figure 7.6) 
still suggested the potential role of PKCζ and/or PKCε. Therefore, to assess this 
possiblity, cell permeable Myr-PSIζ was employed. Confluent EA.hy926 cells were 
preincubated with 10 μM Myr-PSIζ for 30 minutes before APC treatment (40 nM, 10 
minutes). As shown in figure 7.8, 10 μM Myr-PSIζ almost completely ablated the 
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increase in p-Erk1/2 responsive to APC administration, which compared to the 
absence of peptide inhibitor. As EA.hy926 cells do not express PKCθ [391], Myr-
PSIθ was used as a negative control for the PKCζ inhibitor. Surprisingly, 10 μM 
Myr-PSIθ pretreatment for 30 minutes also appreciably attenuated this signalling 
cellular response to APC (Figure 7.8B). The inhibitory effect of the control peptide 
caused me to question the specificity of these results. 
 
 
 
Figure 7.8 The effect of Myr-PSIζ on the Erk1/2 phosphorylation by APC. 
EA.hy926 cells were serum-starved for 5 hours followed by the Myr-PSIζ (10 μM) 
(A) or Myr-PSIθ (10 μM) (B) incubation for 30 minutes. Thereafter, cells were 
incubated with APC (40 nM) for 10 minutes prior to the Erk1/2 phosphorylation 
analysis of the cell lysate as described in section 2.7.3. 
 
 
One possibility to explain these findings was that the Myr-PSI might have a direct 
inhibitory effect upon the proteolytic activity of APC, which was in turn inhibiting the 
signalling by the protease. To test if PSIs influence the activity of APC, 10 μM cell 
permeable PSIs (Myr-PSIζ, Myr-PSIθ, and Antp-PSIζ) were incubated with 40 nM 
APC for 10 minutes, after which hydrolysis of the chromogenic peptide (S2366) was 
assessed over time. Interestingly, all the assessed PSIs affected the enzymatic 
function of APC to some extent: Myr-PSIζ reduced the catalytic activity of APC by 
~90%, and Myr-PSIθ and Antp-PSIζ reduced the hydrolytic activity by ~ 43% and ~ 
57%, respectively (Figure 7.9A). In contrast, this effect was not observed when the 
PSIs were incubated with thrombin (Figure 7.9B). The reason why these cell-
permeable PSIs inhibited the enzymatic activity of APC was not clear, and there 
have been no prior reports suggesting this. To ascertain whether, in the cellular 
assay, inhibition of APC signalling by these PSIs was due to their attenuation of 
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proteolytic activity of APC or the blockage of intracellular PKC isozymes, EA.hy926 
cells were incubated with 10 μM Myr-PSIζ, Myr-PSIθ, Antp-PSIζ or vehicle control 
(ddH2O) for 30 minutes before incubation with 40 nM APC for 10 minutes. The 
medium was collected and APC activity was analysed using the S2366 assay. The 
results showed that after incubation on cells, PSIs also caused ~20-30% inhibition 
of catalytic activity of APC (Figure 7.9C). However, the extent of inhibition, when 
compared to PSI not preincubated with cells (Figure 7.9A), was greatly reduced, 
suggesting appreciable but incomplete cell uptake of the peptide. To circumvent 
this direct APC inhibition, a modified approach was adopted in which cells were 
washed after preincubation with PSIs (i.e. aiming to remove any extracellular PSI). 
To assess the feasibility of this approach, confluent EA.hy926 cells were incubated 
with 10 μM Myr-PSI for 30 minutes, thereafter cells were washed or left intact 
before treatment of 40 nM APC for 10 minutes followed by the collection of medium 
in which the APC activity was assessed in the S2366 assay. As shown in figure 
7.9D, the washing procedure eliminated the inhibitory effects afforded by the 
undelivered peptide inhibitor.  
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Figure 7.9 The effect of cell permeable PSI on the enzymatic property of APC 
and thrombin.  
APC (40 nM, A) and thrombin (5 nM, B) were incubated with 10 μM Myr-PSIζ, Myr-
PSIθ, or Antp-PSIζ for 10 minutes followed by the assessment of their ability to 
cleave S2366 substrate. C), Serum-starved EA.hy926 cells were preincubated with 
indicated permeable PSI before the addition of 40 nM APC. Medium was collected 
after 10 minutes followed by the S2366 analysis. D), Myr-PSIζ was used to incubate 
serum-starved EA.hy926 cells for 30 minutes, and APC (40 nM) was supplemented 
directly into the medium or added after previous medium was washed. The medium 
of each treatment were collected and subjected to S2366 analysis.  
 
The effect of Myr-PSIζ on APC-induced Erk1/2 phosphorylation was assessed 
again, including the extra washing step before 10 minute incubation with 40 nM 
APC. In contrast to previous result where Myr-PSIζ exerted a full inhibition on APC-
induced Erk1/2 signalling (Figure 7.8A), Myr-PSIζ preincubation followed by the 
wash had no effect on such cell signalling in response to APC (Figure 7.10A), 
suggesting PKCζ is unlikely important in transducing this signal. Notably, this lack of 
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inhibition was unlikely due to the peptide leakage since Myr-PSIs were proven to be 
irreversibly internalised [392]. In addition, the additional washing step did not alter 
the effect of Myr-PSIζ since inhibition of thrombin-triggered Erk1/2-MAPK activation 
by this peptide was not changed after washing (Figure 7.10B) 
 
 
 
Figure 7.10 The effect of Myr-PSIζ on the Erk1/2 phosphorylation by APC or 
thrombin using modified approach. 
EA.hy926 cells were serum-starved for 5 hours followed by the Myr-PSIζ (10 μM) 
incubation for 30 minutes. Thereafter, cells were washed with HBSS and fresh 
warm serum-free medium was replaced before 40 nM APC was added and cells 
were incubated for 10 minutes (A). Alternatively, cells were left unwashed (U) or 
washed (W) with HBSS before the addition of 5 nM thrombin for 10 minutes (B). 
Erk1/2 phosphorylation analysis was performed as described in section 2.7.3. One 
representative Western blot is shown (n=3 for A). 
 
Having excluded the role of PKCδ and ζ as essential signalling effectors in APC 
signalling, I wanted to assess the contribution of PKCε. However, due to the lack of 
appropriate PKCε inhibitors, PKCε activation was analysed by the assessment of 
translocation/phosphorylation of PKCε and are described in section 7.3.  
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7.2 PKC involvement in thrombin or APC-induced EC barrier regulation 
 
7.2.1 PKC involvement in thrombin-induced EC barrier dysfunction 
 
Changes in EC barrier permeability is a terminal effect led by numbers upstream 
signalling pathways, in which Erk1/2 activation might also be involved. I had 
demonstrated that the involvement of PKC isoforms in the Erk1/2 phosphorylation 
induced by thrombin and APC were different in section 7.1. Despite of this, the PKC 
isozymes responsible for the regulation of EC barrier integrity by the two proteases 
can be distinct to those important in Erk1/2 activation. To assess the role of PKC in 
thrombin-mediated endothelial barrier disruption, the permeability of thrombin-
treated EA.hy926 cells was measured in the presence and absence of PKC 
inhibitors, including both pharmacological inhibitors and cell-permeable PSIs. To 
begin with, a confluent EA.hy926 monolayer was preincubated with 1 μM or 3 μM 
GF109203X for 30 minutes followed by thrombin treatment (5 nM, 10 minutes) prior 
to analysis of cell barrier permeability. Figure 7.11A shows that the thrombin-driven 
increase in EC permeability was reduced by ~50% by 1 and 3 μM GF109203X, 
implicating PKCs in the signalling pathways leading to EC barrier dysfunction. In 
addition, Gö6976 (targeting PKCα and β1) incubation for 30 minutes also promoted 
a dose-dependent inhibition on thrombin-induced EC hyperpermeability (Figure 
7.11B), with 1 μM Gö6976 almost completely inhibiting the permeability increase. 
This suggested that the classical PKCα and/or PKCβ1 could play an important role 
in this thrombin-triggered signalling. 
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Figure 7.11 The effect of GF109203X and Gö6976 on thrombin triggered EC 
hyperpermeability.  
EA.hy926 cells were seeded in transwell inserts and allowed to grow confluent. 
Cells were serum starved for 3 hours prior to the preincubation by GF109203X (A) 
or Gö6976 (B) for 30 minutes followed by thrombin treatment (5 nM, 10 minutes). 
Permeability was assessed as described in section 2.7.4. 
 
To confirm that the classical PKCs were critical in thrombin-induced EC barrier 
dysfunction, Myr-PSIα/β was used. As shown in Figure 7.12, 50 μM Myr-PSIα/β 
treatment of cells for 30 minutes decreased the thrombin-driven hyperpermeability 
by ~78%. This is consistent with the results using Gö6976, and strongly supported 
the finding that classical PKCs are important for the hyperpermeability effect of 
thrombin in EA.hy926 cells. In agreement with my results, previous reports have 
demonstrated an essential role of PKCα in EC barrier disruption in response to 
thrombin [268,393,394]. However, a recent study suggested the involvement of 
PKCζ in thrombin-triggered EC barrier inter gap formation in human microvessel 
endothelial cells (HMECs) [291]. With regard to this, it was interesting to test 
whether PKCζ is important in thrombin-mediated EC barrier dysfunction in 
EA.hy926 cells which are derived from large vascular ECs (HUVECs). To do this, 
cells were incubated with permeable PSIζ, including Antp-PSIζ (10-30 μM) and Myr-
PSIζ (20-30 μM), for 30 minutes before thrombin stimulation (5 nM, 10 minutes). At 
all the tested concentrations, both PSIs markedly inhibited the hyperpermeability 
effect on the cell monolayer in response to thrombin stimulation (Figure 7.12). 
Quantitative analysis of three independent experiments demonstrated the maximum 
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inhibition was observed at 20 μM for both PSIζ, which reduced permeability by 47-
55% (Figure 7.12). Collectively, these results clearly demonstrated the involvement 
of classical PKC (α and/or β1) and PKCζ in thrombin-mediated EA.hy926 cell 
barrier disruption. 
 
 
 
Figure 7.12 The involvement of PKCα/β and PKCζ in thrombin-induced 
hyperpermeability.  
Serum-starved confluent EA.hy926 cells seeded in transwell inserts were treated 
with Antp-PSIζ (10- 30 µM), Myr-PSIα/β (10 or 20 µM), or Myr-PSIα/β (50 µM) for 
30 minutes prior to thrombin treatment (5 nM, 10 minutes). Permeability was 
expressed as percentage of the fluorescence of cells not treated with inhibitor, 
following subtraction of the fluorescence detected in the respective thrombin 
untreated cells (see equation in 2.7.4). The values represent for mean ± S.E.M (n=3) 
for three independent experiments each performed in duplicate. *, p<0.01; **, 
p<0.001. Concentrations of each PSI were chosen according to the IC50 provided 
by respective manufacturer. 
 
 
7.2.2 PKC involvement in APC-mediated endothelial barrier stablisation 
 
After identifying PKC isozymes involved in thrombin-mediated EA.hy926 cell 
monolayer disruption, I next sought to investigate whether PKCs were also involved 
in APC-mediated EC barrier integrity protection, and if so, whether the PKC 
isozyme(s) were different to those participating in thrombin signalling. As shown in 
previous section and also in figure 7.13, 50 nM APC treatment for 3 hours 
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enhanced the EC barrier integrity, as observed by its capability to progressively 
reduce the permeability of newly-confluent EA.hy926 cells. However, preincubation 
of the cells with GF109203X (5 μM, 30 minutes) failed to appreciably attenuate this 
APC effect (Figure 7.13). It is therefore unlikely that a PKC-dependent mechanism 
is responsible for the barrier-stabilising effect of APC.  
 
 
 
Figure 7.13 The effect of GF109203X in APC-mediated EC barrier integrity 
enhancement.  
Serum-straved newly-confluent cells were preincubated with 5 μM GF109203X in 
serum-free DMEM medium for 30 minutes prior to the treatment with APC (50 nM, 3 
hours), and the permeability was measured as stated in section 2.7.4. Values were 
expressed as mean ± S.E.M (n=3) for three independent experiments, and the 
permeability (%) was plotted as a percentage of permeability of the untreated cells 
which is set to 100%. *, p<0.01, N.S., not significant, compared to untreated control 
cells or otherwise indicated on figure. 
 
 
7.3 PKC activation by thrombin or APC 
7.3.1 PKC isozymes translocation 
 
The activation of PKCs is associated with a series of events, among which the 
translocation of PKCs from cell cytosol to membrane and subsequent 
phosphorylation are the most commonly used criteria to assess a direct activation of 
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PKC. Since I have already demonstrated that classical PKCα and/or β1 and atypical 
PKCζ were involved in thrombin-induced signalling in EA.hy926 cells, I next aimed 
to confirm these findings by assessing their activation upon thrombin treatment. To 
do this, confluent EA.hy926 cells were treated with 5 nM thrombin for 0-120 minutes 
before the cells were subcellularly fractionated (section 2.7.6). PKCα, β1 and ζ 
present in both membrane and cytosolic fractions were detected using specific Abs 
(section 2.7.7). Figure 7.14 showed that upon stimulation with 5 nM thrombin 
translocation of PKCβ1 and ζ from cytosol to the membrane in EA.hy926 cells was 
observed after 5 minutes. Thereafter, the membrane association of both PKC 
isozymes was reduced slightly at 30 minutes, before such association was restored 
at 60 minutes which was then gradually lost again (Figure 7.14). In contrast, PKCα 
translocation by thrombin treatment was not detected in repeated experiments, as 
depicted in figure 7.14 in which the PKCα detected in membrane fraction was not 
appreciably altered compared to untreated cells. To serve as a positive control for 
PKC translocation, PMA incubation (100 nM, 10 minutes) induced a massive 
translocation of PKCα and β1 as expected, whereas it caused no or little 
translocation of PKCζ (Figure 7.14), in agreement with the literature [371].  
 
In section 7.1.3, the experiments using GF109203X and Gö6976 suggested that 
PKC ε, δ or ζ might be involved in APC-mediated Erk1/2 pathway activation. Further 
studies using Myr-PSIζ and PKCδ siRNA excluded the involvement of PKCζ and δ. 
Subsequently, to assess if PKCε translocation was altered by APC, confluent 
EA.hy926 cells were treated with 50 nM APC for 0-180 minutes, and PKCε present 
in both membrane and cytosol fraction in cells was detected as described in 2.7.7. 
However, no translocation of PKCε was induced by APC at any incubation time 
(Figure 7.15), suggesting APC did not induce activation of PKCε. Fractionated cell 
lysates were also analysed by using anti-PKCδ and anti-PKCζ Abs. As expected, 
no translocation was observed for either PKC isozyme (Figure 7.15), indicating that 
APC did not activate PKCδ or PKCζ. Collectively, as implied by using PKC 
inhibitors or assessing the direct PKC activation, APC-promoted signalling 
transduction appears to be independent of PKC activation. 
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Figure 7.14 Thrombin induces the translocation of PKCβ1 and ζ but not PKCα. 
Serum-starved cells were incubated with 5 nM thrombin for various times (0-120 
minutes) before membrane (M) and cytosolic (C) fractions were extracted (Section 
2.7.6) and analysed by Western blotting (n=2) (Section 2.7.7). A representative 
immunoblot is shown for each PKC isozyme translocation. In right panels, cells 
were incubated with 100 nM PMA for 10 minutes before cell fractionation and 
Western blot analysis in the same way. 
 
 
173 
 
 
 
Figure 7.15 APC does not induce the translocation of PKCε, δ or ζ in 
EA.hy926 cells.  
Serum-starved cells were incubated with 50 nM APC for various times (0-180 
minutes) before membrane (M) and cytosolic (C) fractions were extracted and 
analysed by Western blotting (n=2). A representative immunoblot is shown for each 
PKC isozyme translocation. 
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7.3.2 Assessment of PKC phosphorylation 
 
In addition to the subcellular translocation, another hallmark of PKC activation is 
phosphorylation [244,245,248]. Therefore, I also assessed if APC can induce the 
phosphorylation of PKCε and ζ. Basel level of phosphorylation was detected for 
both PKCε and PKCζ in resting EA.hy926 cells, however this level was not 
enhanced by 50 nM APC treatment at any time point tested (Figure 7.16), again 
indicating APC was not able to activate PKCε and PKCζ.  
 
 
 
Figure 7.16 Effects of APC on PKCε and PKCζ phosphorylation.  
Serum-starved EA.hy926 cells were treated with 50 nM APC for 0-120 minutes 
before the cell lysate was assessed for PKCε-Ser729 and PKCζ-Thr410 
phosphorylation by Western blotting described in section 2.7.7. One representative 
Western blot is shown for p-PKCε-Ser729 (n=2) and p-PKCζ-Thr410 (n=4), 
respectively. p-PKC: phosphorylated PKC. 
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7.4 Thrombin-induced EC barrier disruption is dependent on Erk1/2 
activation 
 
Erk1/2 has been implicated in VEGF triggered EC hyperpermeability and 
microvascular leakage [395,396]. In addition to growth factors, inflammatory 
mediators such as oxidants (H2O2) also induce increases in barrier permeability 
through the activation of Erk1/2 [397-399]. Since thrombin is capable of inducing 
Erk1/2 phosphorylation, and PKCζ was found to be important for both cellular 
effects in response to thrombin (Erk1/2 activation and EC hyperpermeability), I then 
investigated whether Erk1/2 acts as an upstream modulator leading to the 
permeability elevation in thrombin-treated EA.hy926 cells. Erk1/2 involvement in 
APC-mediated EC barrier stablisation was assessed in parallel. 
  
U0126 inhibits Erk1/2 activation through selective inhibition of MEK1/2 which 
directly phosphorylates residues T183 and Y185 on Erk1 and 2, respectively, 
resulting in their activation [400,401]. Ten µM U0126 abrogated the effect of Erk1/2 
phosphorylation promoted by both APC and thrombin (Figure 7.17). This result 
agrees well with previous studies, demonstrating that 10 µM is sufficient for 
complete inhibition of Erk1/2 activation [402]. U0126 (10 µM) also attenuated the 
increase of permeability in the cells treated with thrombin by ~57% (Figure 7.18A). 
Conversely, this inhibitor had no effect on APC-mediated cell barrier enhancement 
(Figure 7.18B). These results suggested that Erk1/2 acts as an upstream effector in 
thrombin-induced EC hyperpermeability, whereas APC-mediated EC barrier 
protection is Erk1/2-independent. The inhibition of thrombin-induced barrier 
disruption by 10 µM U0126 was only partial, suggesting the existence of another 
signaling branch that contributed to this permeability regulation in response to 
thrombin.  
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Figure 7.17 The effect of U0126 on thrombin or APC induced Erk1/2 
phosphorylation.  
Serum-starved EA.hy926 cells were incubated with 10 μM U0126 for 30 minutes 
prior to a 10 minute stimulation with thrombin (5 nM) or APC (40 nM) before the 
Erk1/2 phosphorylation was analysed by Western blotting.  
 
 
 
 
Figure 7.18 The effect of U0126 on thrombin or APC mediated EC barrier 
alteration.  
A), confluent EA.hy926 cells seeded in transwell inserts were incubated with 10 μM 
U0126 for 30 minutes before stimulation with thrombin (5 nM, 10 minutes). Cell 
permeability was analysed and values (fluorescence) were expressed as mean ± 
S.E.M (n=4). B), Newly-confluent EA.hy926 cells in transwell inserts were incubated 
with 100 μM U0126 for 30 minutes followed by 50 nM APC incubation for 3 hours. 
Cell permeability was analysed and values (mean±S.E.M, n=3) were presented as 
the percentage to the untreated cells. *, P< 0.05; **, P<0.01; ***, P< 0.001; N.S., not 
significant, compared to carrier control or otherwise indicated on the figure.  
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7.5 Discussion  
 
The MAPK cascade, involving Raf, MEK and Erk1/2, is ubiquitously present in 
mammalian cells and implicated in various physiological functions [403]. It has been 
reported in various cell types that the Erk1/2 pathway can be activated either PKC-
dependently or PKC-independently in response to different stimuli [404,405]. For 
PKC-dependent Erk1/2 activation, different PKC isotypes are involved depending 
on the stimuli, treatment duration, and cell type [406-410]. In the current study, the 
role of PKC in activation of Erk1/2 in EA.hy926 cells was first studied using PMA, a 
classical and novel PKC isozyme activator. When Erk1/2 phosphorylation was 
assessed, PMA was found to induce a substantial activation of this protein, shown 
in Figure 7.1A. Experiments using pharmacological inhibitors, GF109203X and 
Gö6976, revealed the involvement of novel PKCs in the signalling response to PMA 
(Figure 7.1B&C), which agreed with previous studies suggesting an important role 
of PKC δ and/or ε in Erk1/2 phosphorylation in variety of different cell types 
[379,383,411]. My experiments using PMA as a PKC activator provided a primary, 
yet important validation of the intracellular mechanism of Erk1/2 activation in 
EA.hy926 cells. The data also indicated the important PKC isozymes modulating 
PMA-induced Erk1/2 activation are most likely the novel PKC ε, δ, as determined 
using PKC selective inhibitors. 
 
Next, the involvement of PKC in thrombin-induced Erk1/2 phosphorylation was 
investigated using PKC inhibitors, GF109203X and Gö6976. It was found that 
Gö6976 failed to block thrombin-mediated Erk1/2 activation (Figure 7.3), suggesting 
classical PKCs are probably not important in this signalling pathway. GF109203X 
inhibits PKC ε and δ at nM concentration, whereas its inhibition towards PKCζ 
requires its administration at μM range. Thrombin-promoted Erk1/2 activation was 
only inhibited by high concentrations (≥ 5 μM) of GF109203X (Figure 7.2), 
suggesting the involvement of PKC ε, δ is unlikely, whereas PKCζ is perhaps more 
likely to play an important role. Myr-PSIζ, a cell permeable PKCζ-specific inhibitor, 
markedly attenuated the Erk1/2 phosphorylation induced by thrombin (Figure 7.4). 
Furthermore, evidence of PKCζ translocation from cell cytosol and membrane, a 
characteristic of PKC activation, was also observed in thrombin-treated EA.hy926 
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cells (Figure 7.14), suggesting thrombin can activate PKCζ in these cells supporting 
the importance of PKCζ in thrombin-mediated signalling. The finding that PKCζ acts 
as a critical upstream effector of Erk1/2 activation in ECs is novel and is similar to 
other’s study using retinal pigment epithelial cells, and might suggest a common 
pathway in these cell types [409].  
 
The exact PKCζ-dependent mechanism of thrombin-driven Erk1/2 activation is not 
well understood. The canonical activation of the Raf-MEK-Erk module by 
extracellular stimuli (i.e. growth factors and cytokines) relies on the activation of Ras 
GTPase. Although thrombin has been reported to activate the classic Ras-
dependent Erk1/2 cascade in smooth muscle cells [412,413]; Palma-Nicolas et al 
have shown the PKCζ-dependent activation of Erk1/2 pathway by thrombin does 
not involve the activity of Ras in retinal pigment epithelial cells using an inhibitor 
that prevents Ras anchoring to the membrane [409]. Other studies have also 
suggested a direct phosphorylation of Raf-1 by PKC which bypasses Ras activation 
[414,415]. Therefore, my observations in EA.hy926 cells might suggest that PAR1 
activation by thrombin could induce PKCζ-dependent Erk1/2 pathway activation in a 
Ras-independent manner. However, further studies are needed to test this 
hypothesis. 
 
In contrast to a lack of inhibition of thrombin-mediated Erk1/2 phosphorylation, low 
concentrations GF109203X elicited a more pronounced inhibition against APC-
induced Erk1/2 phosphorylation (Figure 7.5), suggesting a possible involvement of 
PKCα, β1, ε, δ, and ζ. However, the lack of inhibition using classical PKC inhibitor 
Gö6976 excluded the important role of PKCα, β1 (Figure 7.6). Using methods 
including PKCδ siRNA to knockdown PKCδ expression (Figure 7.7B) and Myr-PSIζ 
to inhibit PKCζ activation (Figure 7.10A), no inhibitory effect of Erk1/2 
phosphorylation in response to APC was shown. Furthermore, APC did not induce 
any detectable cytosol to membrane translocation of either PKCε, δ, or ζ (Figure 
7.15), neither did it enhanced the phosphorylation of PKCε or ζ (Figure 7.16), 
suggesting these PKC isozymes are not activated by APC. Taken together, it 
therefore appears that PKC is not involved in APC-mediated Erk1/2 activation. 
However, EA.hy926 cells express PKCα, β1, δ, ε, η, ζ, λ, and μ [391], among which 
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PKC η, λ, and μ are not inhibited by GF109203X, and consequently their 
involvement cannot be excluded and may be assessed in further studies. 
 
Although GF109203X inhibition was observed for APC-mediated Erk1/2 activation, 
inhibitors specific for individual GF109203X-sensitive PKC isozymes failed to 
establish an important role of any of these PKC isozymes. This discrepancy might 
therefore come from the non-PKC specific inhibitory nature of GF109203X. 
GF109203X inhibits PKC by its competitively binding to the ATP-binding site within 
the PKC catalytic domain [385]. Due to the highly homology among the AGC family 
of protein kinases and closely related structure, the ability of GF109203X to inhibit 
other AGC kinases cannot be excluded. Indeed, GF109203X has been shown to 
promote PKC-independent specificities including direct inhibition of MLCK (IC50≈ 
0.6 µM) [384], protein kinase G (PKG, IC50≈4.6 µM) [384], RSK and p70/S6 kinase 
(potency in nM range) [416-418]. Consequently, it is reasonable to assume that the 
inhibitory effect of GF10920X on APC-induced Erk1/2 phosphorylation might be 
ascribed to its inhibition of other kinases (i.e. MLCK, PKG, and p70/S6 kinase).  
 
A study by Finigan et al showed that APC is able to induce phosphorylation of MLC 
in a peripheral distribution which is important for the EC barrier-stablising response 
[169]. As mentioned earlier in the introduction, MLC is the direct substrate of MLCK, 
it is therefore highly possible that MLCK activity is also stimulated by APC. However, 
whether APC induced MLC phosphorylation by MLCK could lead to the activation of 
Erk1/2 is not known, since a number of previous studies have suggested 
MLCK/MLC signalling occurs downstream of Erk1/2-MAPK cascade [419,420]. 
Further studies using MLCK specific inhibitor is highly recommended to address this 
issue. 
 
Furthermore, besides PKC and Src, PKG are known stimulators of Erk1/2 cascade 
in ECs. For example, VEGF-induced EC proliferation involve the PKG-dependent 
activation of Erk1/2 [421] In addition, NO either as an stimulator [422] or 
intermediary (in response to VEGF stimulation) [421] leads to the activation of 
Erk1/2 and subsequent EC proliferation, which requires the upstream activation of 
PKG. Notably, APC can activate eNOS [163,198] and also PI3K [183,198] (an 
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upstream effector for eNOS) both have been found important in the activation of 
Erk1/2 MAPK cascade and subsequent EC proliferation [198]. These findings 
propose the possibility that PKG might be activated by APC and modulate the 
downstream Erk1/2 pathway activation.  
 
Lastly, activation of Erk1/2 through p70/S6 kinase is also evident by other studies. 
For example, insulin-induced retinal neuron survival engages activation of PI3K-
mTOR pathway that leads to p70/S6 kinase phosphorylation [423], which is also 
involved in insulin-induced Erk1/2 activation [424]. Collectively, the above evidence 
suggests that APC might act as a growth factor or a survival factor and the 
involvement of MLCK, PKG or p70/S6 kinase in APC-mediated cell signalling is 
possible. Further studies are necessary to address this issue using specific 
inhibitors.  
 
PKCα [263,266-270], cPKCβ [263,271-275] and PKCδ [276-279] are generally 
considered to be involved in barrier disruption, whereas PKCε is usually associated 
with endothelial barrier protective responses [270,280-283]. In contrast, PKCζ plays 
a role in both endothelial barrier protection [284-286] and disruption [287-289]. In 
the present study, using pharmaceutical and inhibitory peptide approaches, I have 
delineated the role of classical PKCs (Figure 7.11 & Figure 7.12) and PKCζ (Figure 
7.12) in the hyperpermeability response to thrombin-treated in EA.hy926 cells. 
Further investigation demonstrated that thrombin was able to induce PKCζ and 
PKCβ1 translocation from cell cytosol to membrane (Figure 7.14), PKCζ and β1 
were activated upon thrombin treatment in EA.hy926 cells. It is a novel finding that 
PKCβ1 is involved in thrombin-induced hyperpermeability in ECs, since the role of 
PKCα in thrombin-triggered barrier dysfunction of ECs has been reported in various 
vascular beds [268,393,394].  
 
In contrast to thrombin, APC mediates barrier-protective signaling effects, observed 
in the current study (chapter 6) as well as by other groups [110,129,171,190,214]. 
This APC-induced EC barrier-enhancing response has been ascribed to the cross-
activation of S1P/S1P1 signalling [129,169], whereas thrombin is found to 
transactivate S1P3 which lead to an EC barrier disruptive effect [75,76]. Using 
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siRNA approaches, Feistritzer et al demonstrated the important role of both SK1 
and S1P1 in the barrier-enhancing effect of APC [129]. However, the mechanism of 
how S1P1 signalling is coordinated into APC signalling is unknown. It has been 
suggested that growth factor receptor and S1P1 transactivation depend on the 
increased SK activity and subsequent secretion of newly generated S1P, allowing 
S1P1 occupation to occur [425]. Therefore one possibility is that APC stimulates 
S1P secretion thereby signalling through S1P1.  A previous study has shown that 
PKCε is required in the S1P-dependent cardioprotective signalling in response to 
the SK stimulator, ganglioside GM-1 [79]. However, the involvement of PKCε was 
not found in EA.hy926 cells stimulated with APC in the present study, even though 
APC has been previously reported to stimulate S1P generation and results in the 
subsequent cytoprotective effects [129,169,215]. APC failed to activate PKCε, 
demonstrated using immunoblotting showing that neither PKCε translocation nor 
phosphorylation was stimulated by APC treatment. Previous studies suggest that 
differences in cell types likely explain the distinct results observed in the relevance 
to PKC involvement.  Evidences for this include: 1) In myocardial ventricular tissue, 
exogenous S1P fails to induce PKCε translocation [79], whereas PKCε is important 
in HPAECs migration by exogenous S1P [78]; 2) Abundant S1P accumulates in the 
conditioned medium of HUVECs [426], whereas S1P was not detected in the 
medium of HPAECs [427], suggesting difference in S1P secretion by different cell 
types. 
 
I have also found that all the tested cell permeable PSIs inhibit the catalytic activity 
of APC to varying degrees. This approach has been used extensively to identify the 
intracellular activity of PKC isozymes, but the issue raised from the current study 
has not been reported before. The mechanism of these peptides inhibiting APC 
activity is not known but it is possible that they bind to APC, which leads to its 
conformational changes and affects the enzymatic property of APC. Another 
possibility is that the peptide binds closely to the active site of APC and somewhat 
hampers it cleaving the substrate. In light of this finding, permeable peptides should 
be used with caution and results from studies using these peptides should also be 
interpreted carefully. 
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My experiments suggest that APC failed to signal through any of the PKC isozymes 
largely expressed by ECs, such as PKCα, β1, ε, δ or ζ. Importantly, APC functions 
in cholesterol-enriched caveolar microdomains of the EC membrane, its 
cytoprotective activity requires its activating the caveolae compartmentised PAR1 
that is also associated with EPCR and caveolin-1 [50,216]. The essential role of 
EPCR and PAR1 in APC-mediated EC barrier protection using EA.hy926 cell as EC 
model has been demonstrated in the current study. Rezaie et al showed that the 
association between EPCR and caveolin-1 in lipid rafts can be disturbed by APC 
occupation of EPCR. As a consequence, dissociated caveolin-1 might then be able 
to interact with other proteins. Indeed, caveolin-1, through its scaffolding domain, is 
able to interact with and inhibit activity of many signalling proteins including eNOS, 
PI3K, Src, and PKC [428,429]. With respect to PKCs, the inhibition is limited to 
PKCα and PKCζ [430], which might due to the blockage of agonist-induced PKC 
translocation to the plasma membrane [430] as well as their autophosphorylation 
[431]. Caveolin-1 has been suggested to be an essential component allowing the 
successful signalling transduction induced by APC [50,216]. In the present study, I 
have shown thrombin induces EC barrier disruption is dependent on the activation 
of PKCζ. As APC leads to the dissociation of caveolin-1 with the EPCR [50], it is 
possible that APC inhibits the hyperpermeability (i.e. induced by thrombin) by 
blocking PKCζ through the activity of caveolin-1. Another piece of evidence that 
agrees with this hypothesis is that Ang1, of which the expression is enhanced by 
APC [217], counteracts thrombin-mediated hyperpermeabilitiy through inhibition of 
PKCζ activation in HUVECs [386]. Ang1 is a secreted protein that interacts with the 
endothelial specific receptor, Tie2. The Ang1/Tie2 axis is critical to the maintenance 
of EC barrier integrity as well as prevention of the blood vessel leakage during 
inflammation and allergic reactions [386]. Although an inhibition of PKCζ is found to 
be critical in the EC integrity protection by Ang1, the exact mechanism is not 
resolved [386]. It is interesting to test, in our system, if Ang-1 and subsequent 
blockage of PKCζ activity play roles in APC-mediated EC barrier protection. 
Nevertheless, my results suggested the cellular responses to thrombin and APC 
involve different intracellular modulators, such that thrombin activates PKCζ and β1 
leading to cell barrier disruption, whereas APC promoted-EC barrier enhancing 
effect does not require PKC activation.  
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Finally, using U0126, an Erk1/2 phosphorylation inhibitor, I found EC 
hyperpermeablity in response to thrombin was attenuated by ~57% (Figure 7.16A), 
suggesting thrombin-driven permeability increase was partly dependent on Erk1/2 
activation. This is consistent with a previous study, demonstrating that PKC 
activation by PMA is observed to induce barrier dysfunction in ECs via the 
activation of Erk1/2 signalling pathway [432]. In contrast, APC was found to protect 
EC barrier integrity in a Erk1/2-independent manner, determined by the lack of 
inhibition of the APC activity using 10 fold higher concentration of U0126 (100 µM) 
(Figure 7.16B). This is in agreement with the finding that S1P-mediated cortactin 
translocation does not involve Erk1/2 activation [74]. 
 
Notably, the concentration of U0126 (10 μM) that completely inhibited Erk1/2 
activation only partly blocked the permeability increase driven by thrombin, 
suggesting that Erk1/2 phosphorylation is necessary but not sufficient for this 
response. Therefore branched signalling pathways are proposed to contribute to 
the hyperpermeability response in EA.hy926 cells. The Erk1/2-independent 
pathway remains unknown but Zhang et al have suggested that the CaMKIIδ6-
dependent activation of RhoA and ROCK might contribute to thrombin-induced 
increase of permeability that bypasses Erk1/2 MAPK cascade [402]. Although both 
PKCζ and β1 are critical for the hyperpermeability effect in response to thrombin, 
the involvement of PKCβ1 was not important in the Erk1/2 activation using Gö6976. 
This suggests PKCβ1 acts downstream of Erk1/2 activation. 
 
Together, the results described in this chapter provide a novel understanding on the 
disruption of EC barrier in response to thrombin in EA.hy926 cells. Through 
activation of PAR1, thrombin causes the PKCζ-dependent activation of Erk1/2 
which ultimately induces the permeability increase of EC monolayer. In addition, 
PAR1 activation by thrombin also evokes a PKCβ1-dependent EC barrier disruption 
downstream of Erk1/2-MAPK activation, although a direct activation of PKCβ1 by 
Erk1/2 pathway remains to be established. Schematic illustration of the proposed 
PKC-dependent signalling pathways of thrombin-induced EC barrier disruption is 
given in figure 7.17. In addition, my study also demonstrated that APC/PAR1-driven 
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cytoprotective cellular responses (at least Erk1/2 activation and EC barrier 
protection) are independent of PKC activation. The involvement of EPCR in APC-
mediated PAR1 activation might switch the downstream signaling from barrier 
disruption to barrier protection.  
 
 
 
Thrombin
PKCζ
?
Erk1/2
PKCβ1
EC barrier disruption
PAR1
ATAP2+WEDE15
GF109203X
Myr-PSIζ
U0126
GF109203X
Gö6976
Myr-PSIα/β
EC membrane
P
?
 
 
 
Figure 7.19 Schematic illustrations of the PKC-dependent signalling pathways 
responsible for thrombin-mediated hyperpermeability in EA.hy926 cells. 
Thrombin sequentially activates PKCζ and PKCβ1 which contribute to the 
hyperpermeability response. This cellular effect also dependent on the Erk1/2 
activation upstream of PKCβ1 activity, and a Erk1/2-independent parallel pathway 
remains to be determined. The inhibitors used to determine the role of each effector 
are also given in red text. 
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Chapter 8 Concluding remarks 
 
8.1 Discussion 
 
Coagulation and inflammation are two main self-defensive systems that help to 
maintain blood fluid, limit the tissue lesion, and eliminate invading pathogens. Both 
pathways involve diverse coordinated events and are triggered by different stimuli. 
Despite this, the two pathways are also intricately linked and considerably affect 
each other. Extensive evidence suggests that inflammatory responses can trigger 
coagulation, and that coagulation in turn also enhances the inflammatory responses. 
Considering the complexity of the coagulation and inflammatory pathways it is vital 
that both systems are tightly regulated, and it is also inevitable that disturbances in 
either mechanism may significantly contribute to many human diseases.  
 
APC and thrombin, which are the focus of this thesis, are two crucial serine 
proteases that contribute to the interplay of coagulation and inflammation. APC is 
conventionally identified as an anticoagulant, but recent studies have also 
delineated its multiple roles in anti-inflammation. Deficiency in protein C results in 
severe thrombotic conditions, and homozygous protein C deficiency even leads to 
fatal systemic disseminated intravascular thrombosis in newborns [433]. In addition, 
enhanced inflammation is observed in mice expressing low level of protein C 
compared to WT mice, which can be treated with protein C administration [433]. 
The impairment of protein C synthesis and activation in various inflammatory 
diseases further reinforced the notion that APC plays an important role in 
maintaining normal haemostasis and controlled inflammation [237,434-437]. In 
contrast to APC, the properties of thrombin are often regarded as procoagulant, 
owing to its potent activation of fibrin and platelets; and proinflammatory, evident by 
its induction of many inflammatory mediators and stimulation of inflammation 
progression. Unregulated thrombin generation and function have been associated 
with thrombotic diseases. Thrombin also plays an important role in the 
pathogenesis of inflammatory and cardiovascular diseases [438-440]. Despite that 
the functions of APC and thrombin have been extensively studies in the process of 
coagulation, their mechanism in regulating inflammation through intracellular 
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signalling remains poorly understood. Interestingly, both proteases signal, at least 
in ECs, through the activation of cell membrane receptor, PAR1. It is evident that on 
EC membranes, PAR1 that colocalises with EPCR in caveolae is the substrate of 
APC [215], whereas, thrombin appears to activate PAR1 that is not in caveolae, but 
rather in other membrane location [216]. The distinctive signalling pathways 
triggered by APC and thrombin are potentially due to activation of distinct PAR1 
subpopulations [50]. EPCR, an essential component in APC signaling, does not 
seem to only augment the catalytic activity of APC in PAR1 activation, but is also a 
key element in determining the signalling directions [50]. However, understanding of 
the distinct signalling pathways initiated by APC and thrombin activation of PAR1 is 
still lacking. By performing in vitro studies, this project is aiming to explore the 
intracellular signal transduction mechanisms underlying the distinct EC responses 
to APC and thrombin, with particular focus on the involvement of different PKC 
isozymes. 
 
8.1.1 Characterisation of protein C and its variants 
 
To assess the molecular specificity of APC-mediated EC signalling, I first aimed to 
generate APC variants with each has an impaired function. This includes APC-L8V 
(impaired EPCR binding), APC-E330A/E333A (impaired PAR1 binding), APC-
D36A/L38D/A39V (impaired protein S cofactor activity) and APC-S360A (impaired 
protease activity).  
     
Activation of protein C by thrombin in free solution was assessed in the current 
study. The results show that Ca2+ has an inhibitory effect on protein C activation by 
free thrombin, in agreement with the literature [101]. In contrast, the presence of 
Ca2+ is necessary for protein C activation by thrombin/TM complex [101]. Previous 
reports have shown that the Ca2+ binding in the 70-loop of protein C influences the 
conformation of the activation peptide. Therefore, the P3 (Glu167) and P3’ (Glu172) 
residues might be repulsed by the acidic residues (Glu192 and Glu39) of thrombin, 
preventing the enzyme docking with the substrate [420,441]. However, a 
conformational change of thrombin is induced upon binding to TM, leading to 
allosteric torsion of Glu39 and Glu192, which induces more favourable interactions 
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with the substrate [318,442]. It is worth noting that activation of protein C by free 
thrombin is unlikely to occur physiologically, due to the presence Ca2+ and a high 
affinity between thrombin and TM (Kd  2 nM). 
 
By using a plasma-based CAT assay, I observed that APC-L8V and APC-
E330A/E333A exhibited comparable anticoagulant activity to WT APC. This 
suggests the residues responsible for EPCR binding or PAR1 interaction are not 
required for APC to fulfil its anticoagulant functions. The normal anticoagulant 
activity of APC-L8V is also consistent with the generally accepted notion that 
inactivation of coagulation cofactors (FVa and FVIIIa) by APC depends on its direct 
binding to the negatively charged phospholipid membrane but not EPCR. CAT 
assays also revealed the severely impaired anticoagulant property of APC-
D36A/L38D/A39V, confirming an essential role of protein S in the anticoagulant 
activity of protein C. Although APC-S360A has mutated active site, residual 
anticoagulant activity is observed in the current study. This may be mainly due to 
the binding of the APC variant to FVa, which competes with FX binding to FVa [328]. 
 
The cell-signalling efficiencies of these APC variants were examined using an EC 
model of Erk1/2 phosphorylation. APC-L8V and APC-S360A were incapable of 
inducing Erk1/2 activation, in consistent with the previous findings that both EPCR 
binding as well as proteolytic activity are required for APC signalling in ECs 
[164,172,198,225]. It was unexpected that APC-E330A/E333A was able to induce 
Erk1/2 activation since the variant has been shown incapable of cleavage of 
exogenous PAR1 [110]. I extrapolated that Erk1/2 phosphorylation may be sensitive 
to low rates of PAR1 activation. Therefore APC-E330A/E333A, which might has 
residual PAR1-cleavage activity, is able to activate Erk1/2 pathway. Since it is 
impossible to determine the PAR1 involvement using this variant, PAR1 blocking 
Abs were employed. It shows that APC-mediated EC signalling is PAR1-dependent. 
Among 4 APC variants generated in this project, APC-D36A/L38D/A39V is the only 
mutant that induces Erk1/2 phosphorylation at a comparable level to WT APC. This 
suggests that although mutations in this APC variant lead to the impaired 
anticoagulant activity due to the lack of protein S cofactor activity, APC-
D36A/L38D/A39V can still signal indistinguishably to WT APC in ECs.  
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The above findings suggest the possibility of dissociation of anticoagulant activity 
and cytoprotective signalling activity of APC through mutagenesis, which agrees 
with previous publications [94,124,223,224]. These APC variants can serve as 
exceptional tools for examination of the molecular specificities of APC signalling. 
Moreover, APC variants lacking anticoagulant activity, such as APC-
D36A/L38D/A39V, might be of particular interest due to its therapeutic potential. 
 
8.1.2 The mechanism of cytoprotective cell signalling of APC and its 
therapeutic potential 
 
APC-mediated signalling in ECs is dependent on PAR1 and EPCR, which is shown 
in this study as well as by other groups [129,164,165,167,172,198,225,307-310]. 
Essentially, when bound with EPCR, APC is able to cleave and signal through the 
EPCR-colocalised PAR1 in caveolae, which causes Gi protein coupling to the 
receptor, activation of Rac-1, and subsequent inhibition of NF-κB that leads to the 
anti-inflammatory and anti-apoptotic effects in ECs [216]. Particularly, APC-induced 
EC barrier protection also depends on the cross-activation of other cytoprotective 
pathways, such as S1P/S1P1 and Ang-1/Tie2 axes (refer to section 1.3.4). Although 
the involvement of PKC has been extensively reported in the anti-
inflammatory/apoptotic pathways in response to numerous stimuli, my results 
suggest that the cytoprotective activities exerted by APC on ECs appear to be 
independent of PKC activation. Interestingly, some evidence might support the 
speculation that APC may protect the cells, at least partly, through the inhibition of 
PKC activity. This is because, firstly, the intracellular signalling activities of APC are 
dependent on the presence of caveolae-associated protein, caveolin-1, which is 
able to inhibit PKC, particularly PKCα and PKCζ [50,216,430,431]. Secondly, APC 
protects the EC barrier integrity through stimulation of Ang-1 expression [217], and 
Ang-1 has been reported to potently inhibit thrombin-induced hyperpermeability 
through down-regulation of PKCζ activation [386]. It is reasonable to extrapolate 
that APC might act to protect EC barrier disruption by thrombin through inhibiting 
rather than activating PKCζ. Indeed, activation of PKC was not found in cells 
stimulated with APC in the current study.   
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The potential therapeutic applications of APC are implied by its beneficial effects in 
various animal injury model systems including ischemic stroke [173,174,443], 
sepsis [444], lung injury and inflammation [179,445], and neuroinflammatory 
disease [179]. While being beneficial, the administration of APC in either preclinical 
or clinical studies has been evident to be associated with increased risk of 
concomitant bleeding. For example, during the recent clinical trial (PROWESS), 
APC reduced the mortality rate by 6.1% in patients with severe sepsis, however this 
is also associated with a low but significant elevated risk of serious bleeding [444]. 
The human APC-3K3A variant retains normal cytoprotective activities in cells as 
compared to human WT APC, whilst its anticoagulant effects are severely impaired 
[223]. The murine counterpart of this variant was reported to exert WT-comparable 
efficiency both in preventing death in mouse models of endotoxemia and promotes 
neuroprotection in ischemic stroke models [304]. The above studies using APC-
3K3A imply that the beneficial actions of APC in those injury models rely on its anti-
inflammatory properties whilst the anticoagulant activity of APC is dispensable. This 
notion is reinforced by the observation in this thesis using APC-D36A/L38D/A39V 
lacking protein S cofactor activity. This variant was shown to have normal signalling 
activity (chapter 6) but it anticoagulant activity is severely ablated (chapter 4). In the 
work carried out by my colleague Anna Andreou, it was also observed that APC-
D36A/L38D/A39V has an advantage over WT APC in reducing the intracerabral 
bleeding associated with tPA administration in murine stroke model (unpublished 
data). Consequently, the APC variants (such as 3K3A and D36A/L38D/A39V), 
which provide sufficient cytoprotective properties while with reduced risks of 
haemorrhage, may hold remarkable promise to offer a safer treatment to severe 
inflammatory diseases such as sepsis and stroke. 
 
8.1.3 The therapeutic prospects for targeting PKC 
 
Microvascular hyperpermeability often occurs under the pathophysiological 
conditions of vascular inflammation which may contribute to the development of 
various diseases or pathological processes. These include sepsis, ischemia stroke, 
trauma, atherosclerosis, thrombosis, diabetes, and tumor development and 
metastasis [205]. The studies in the thesis have revealed that PAR-1 dependent 
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endothelial barrier disruption induced by thrombin involves the sequential activation 
of PKCζ, Erk1/2 and PKCβ1 (chapter 7). These findings provide further 
understanding of the molecular mechanism of thrombin-induced increase of EC 
permeability. Dysfunction of the microvascular barrier represents a crucial problem 
confronted in the clinical treatments for a variety of diseases. Thrombin and many 
other inflammatory mediators such as VEGF and H2O2 mediate EC 
hyperpermeability through the common pathway, involving activation of PKCβ 
[263,275]. With regard to this, classical PKC as a common modulator might be 
targeted with site specificity and may represent an effective adjunct therapy for the 
treatment of vascular inflammatory injury/diseases.  Notably, the administration of 
PKCβ inhibitor in diabetic patient and animals has been evident to ameliorate the 
vascular dysfunction [263,273,274]. 
 
8.2 Conclusion 
 
The studies in the thesis demonstrate that both APC and thrombin mediated EC 
signalling rely on PAR1 activation, and APC-induced signalling additionally requires 
EPCR binding. This differential molecular specificity of APC and thrombin activities 
is considered to primarily contribute to the divergent cellular responses. In addition, 
a novel finding from the thesis suggests these distinct cellular effects are also 
associated with the different involvement of PKC. While the hyperpermeability 
afforded by thrombin administration is dependent on the activation of PKCζ, Erk1/2-
MAPK, PKCβ1, APC-induced EC barrier protection does not involve the activation 
of PKC. Moreover, although the Erk1/2-MAPK pathway activation is also triggered 
by APC, it does not appear to be an upstream effector in the EC barrier enhancing 
response to APC.  
 
8.3 Further studies  
 
There are several questions arising from this study which are worthy of further 
investigation: 
 
 Does APC inhibit thrombin-induced hyperpermeability through the inhibition 
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of PKCζ? This can be explored by comparing the activation of PKCζ in ECs 
treated by thrombin with and without APC preincubation. 
 
 Does APC-induced EC protective activity also involve PAR2, the activation of 
which can be triggered by the tethered ligand of cleaved PAR1? This may be 
initially investigated using the PAR2 antagonist specifically against its 
tethered ligand binding site. 
 
 Does APC-mediated EC signalling (e.g Erk1/2-MAPK pathway activation) 
involve the activation of other AGC kinase such as PKG and MLCK? This 
question might be addressed using PKG or MLCK specific inhibitors. 
 
 Does the blockade of PKCβ1 improve the condition of EC barrier 
hyperpermeability related vascular inflammation? Suitable animal models are 
required to establish to address this issue.  
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APPENDIX 
 
Oligonucleotide primers for protein C variant generation 
Primer ID 5’-Oligonucleotide sequences-3’ 
D36A/L38D/A39V 
Sense CCA AAA TGT GGA AGC CAC AGA CGT CTT CTG 
GAT CAA GTA CTT TG 
Anti-sense CA AAG TAC TTG ATC CAG AAG ACG TCT GTC 
CCT TCC ACA TTT TGG 
L8V 
Sense AAC TCC TTC CTG GAG GAG GTC CGT CAC AGC 
Anti-sense GCT GTG ACG GAC CTC CTC CAG GAA GGA GTT 
S360A 
Sense GCC TGC GAG GGG GAC GCC GGG GGG CCC ATG 
Anti-sense CAT GGG CCC CCC GGC GTC GCC CTC GCA GGC 
E330A/E333A 
Sense GCT CAT GAC CGC GCT GCA CGC ATT GTG C 
Anti-sense GCA CAA TGC GTG CAG CGC GGT CAT GAG C 
 
Lysis buffer (1 ml) 
RIPA buffer (Thermo Scientific) 757 µl 
Protease inhibitor cocktail (Complete, mini, EDTA-free, Roche), 100 µl from 1 table 
dissolved in 1 ml PBS 
Phosphatase inhibitor cocktail (PhosSTOP, Roche), 143 µl from 1 table dissolved in 
1 ml PBS 
Prepared freshly each time in the scale of individual needs. 
  
193 
 
10% SDS gel formulation 
 
 10% Running gel 
(10 ml) 
3.7% Stacking gel 
(10 ml) 
ProtoGel (National diagnostics) 3.3 ml 1.2 ml 
2 M Tris (pH 8.8) 2 ml N/A 
0.5 M Tris (pH 6.4) N/A 1.4 ml 
TEMED (Sigma) 5 µl 10 µl 
20% SDS 25 µl 25 ul 
60 % Sucrose 2 ml 2 ml 
ddH2O 2.67 ml 5.37 ml 
Ammonium Persulfate (Sigma) 50 µl 50 µl 
 
 
PSI sequences for PKC isozymes 
 
Name aa sequence 
Myr-PSIζ Myr-SIYRRGARRWRKL-OH 
Myr-PSIθ Myr-LHQRRGAIKQAKVHHVKC-NH2 
Myr-PSIα/β Myr-RFARKGALRQKNV-OH 
Antp-PSIζ H-CSRQIKIWFQNRRMKWKKCSIYRRGARRWRKLYRAN-OH  
  
194 
 
REFERENCES 
[1] Adams, R.L. and Bird, R.J. (2009). Review article: Coagulation cascade and 
therapeutics update: relevance to nephrology. Part 1: Overview of 
coagulation, thrombophilias and history of anticoagulants. Nephrology 
(Carlton) 14, 462-70. 
[2] Reininger, A.J. (2008). Function of von Willebrand factor in haemostasis and 
thrombosis. Haemophilia 14 Suppl 5, 11-26. 
[3] Clemetson, K.J. (2012). Platelets and primary haemostasis. Thromb Res 129, 
220-4. 
[4] Lundblad, R.L. and White, G.C., 2nd. (2005). The interaction of thrombin with 
blood platelets. Platelets 16, 373-85. 
[5] Davie, E.W., Fujikawa, K. and Kisiel, W. (1991). The coagulation cascade: 
initiation, maintenance, and regulation. Biochemistry 30, 10363-70. 
[6] Zhang, Y. and Wang, H. Integrin signalling and function in immune cells. 
Immunology 135, 268-75. 
[7] Lentz, B.R. (2003). Exposure of platelet membrane phosphatidylserine 
regulates blood coagulation. Prog Lipid Res 42, 423-38. 
[8] Davie, E.W. and Ratnoff, O.D. (1964). Waterfall Sequence for Intrinsic Blood 
Clotting. Science 145, 1310-2. 
[9] Camerer, E., Kolsto, A.B. and Prydz, H. (1996). Cell biology of tissue factor, 
the principal initiator of blood coagulation. Thromb Res 81, 1-41. 
[10] Morrissey, J.H., Macik, B.G., Neuenschwander, P.F. and Comp, P.C. (1993). 
Quantitation of activated factor VII levels in plasma using a tissue factor 
mutant selectively deficient in promoting factor VII activation. Blood 81, 734-
44. 
[11] Dahlback, B. (2000). Blood coagulation. Lancet 355, 1627-32. 
[12] Crawley, J.T. and Lane, D.A. (2008). The haemostatic role of tissue factor 
pathway inhibitor. Arterioscler Thromb Vasc Biol 28, 233-42. 
[13] Mann, K.G., Nesheim, M.E., Church, W.R., Haley, P. and Krishnaswamy, S. 
(1990). Surface-dependent reactions of the vitamin K-dependent enzyme 
complexes. Blood 76, 1-16. 
[14] Furie, B. and Furie, B.C. (1988). The molecular basis of blood coagulation. 
Cell 53, 505-18. 
[15] Girard, T.J., Warren, L.A., Novotny, W.F., Likert, K.M., Brown, S.G., Miletich, 
J.P. and Broze, G.J., Jr. (1989). Functional significance of the Kunitz-type 
inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 
518-20. 
[16] Mann, K.G., Butenas, S. and Brummel, K. (2003). The dynamics of thrombin 
formation. Arterioscler Thromb Vasc Biol 23, 17-25. 
[17] Quinsey, N.S., Greedy, A.L., Bottomley, S.P., Whisstock, J.C. and Pike, R.N. 
(2004). Antithrombin: in control of coagulation. Int J Biochem Cell Biol 36, 
386-9. 
[18] Novotny, W.F., Brown, S.G., Miletich, J.P., Rader, D.J. and Broze, G.J., Jr. 
(1991). Plasma antigen levels of the lipoprotein-associated coagulation 
inhibitor in patient samples. Blood 78, 387-93. 
[19] Olson, S.T., Bjork, I. and Shore, J.D. (1993). Kinetic characterization of 
heparin-catalyzed and uncatalyzed inhibition of blood coagulation 
proteinases by antithrombin. Methods Enzymol 222, 525-59. 
195 
 
[20] Lindahl, U. and Kjellen, L. (1991). Heparin or heparan sulfate--what is the 
difference? Thromb Haemost 66, 44-8. 
[21] Dahlback, B. and Villoutreix, B.O. (2005). The anticoagulant protein C 
pathway. FEBS Lett 579, 3310-6. 
[22] Pratt, C.W. and Church, F.C. (1993). General features of the heparin-binding 
serpins antithrombin, heparin cofactor II and protein C inhibitor. Blood 
Coagul Fibrinolysis 4, 479-90. 
[23] Heeb, M.J., Gruber, A. and Griffin, J.H. (1991). Identification of divalent metal 
ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and 
alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, 
thrombin, and plasmin. J Biol Chem 266, 17606-12. 
[24] Rijken, D.C. and Lijnen, H.R. (2009). New insights into the molecular 
mechanisms of the fibrinolytic system. J Thromb Haemost 7, 4-13. 
[25] Bajzar, L., Morser, J. and Nesheim, M. (1996). TAFI, or plasma 
procarboxypeptidase B, couples the coagulation and fibrinolytic cascades 
through the thrombin-thrombomodulin complex. J Biol Chem 271, 16603-8. 
[26] Ma, L. and Dorling, A. (2012). The roles of thrombin and protease-activated 
receptors in inflammation. Semin Immunopathol 34, 63-72. 
[27] Siller-Matula, J.M., Schwameis, M., Blann, A., Mannhalter, C. and Jilma, B. 
(2011). Thrombin as a multi-functional enzyme Focus on in vitro and in vivo 
effects. Thromb Haemost 106, 1020-1033. 
[28] Coughlin, S.R. (2000). Thrombin signalling and protease-activated receptors. 
Nature 407, 258-64. 
[29] Coughlin, S.R. (2001). Protease-activated receptors in vascular biology. 
Thromb Haemost 86, 298-307. 
[30] Di Cera, E. (2007). Thrombin as procoagulant and anticoagulant. Journal of 
Thrombosis and Haemostasis 5, 196-202. 
[31] Chang, J.Y. (1985). Thrombin specificity. Requirement for apolar amino 
acids adjacent to the thrombin cleavage site of polypeptide substrate. Eur J 
Biochem 151, 217-24. 
[32] Bode, W. (2006). The structure of thrombin: a janus-headed proteinase. 
Semin Thromb Hemost 32 Suppl 1, 16-31. 
[33] Coughlin, S.R. (2005). Protease-activated receptors in hemostasis, 
thrombosis and vascular biology. J Thromb Haemost 3, 1800-14. 
[34] Walker, R.K. and Krishnaswamy, S. (1994). The activation of prothrombin by 
the prothrombinase complex. The contribution of the substrate-membrane 
interaction to catalysis. J Biol Chem 269, 27441-50. 
[35] Krishnaswamy, S., Church, W.R., Nesheim, M.E. and Mann, K.G. (1987). 
Activation of human prothrombin by human prothrombinase. Influence of 
factor Va on the reaction mechanism. J Biol Chem 262, 3291-9. 
[36] Bode, W. (2006). Structure and interaction modes of thrombin. Blood Cells 
Mol Dis 36, 122-30. 
[37] Crawley, J.T., Zanardelli, S., Chion, C.K. and Lane, D.A. (2007). The central 
role of thrombin in hemostasis. J Thromb Haemost 5 Suppl 1, 95-101. 
[38] Bode, W., Mayr, I., Baumann, U., Huber, R., Stone, S.R. and Hofsteenge, J. 
(1989). The refined 1.9 A crystal structure of human alpha-thrombin: 
interaction with D-Phe-Pro-Arg chloromethylketone and significance of the 
Tyr-Pro-Pro-Trp insertion segment. EMBO J 8, 3467-75. 
[39] Ratnoff, O.D. (1954). An accelerating property of plasma for the coagulation 
of fibrinogen by thrombin. J Clin Invest 33, 1175-82. 
196 
 
[40] Wolberg, A.S. and Aleman, M.M. (2010). Influence of cellular and plasma 
procoagulant activity on the fibrin network. Thromb Res 125 Suppl 1, S35-7. 
[41] Ponce, R.A. et al. (2005). Preclinical safety and pharmacokinetics of 
recombinant human factor XIII. Toxicol Pathol 33, 495-506. 
[42] Suzuki, H., Shima, M., Nogami, K., Sakurai, Y., Nishiya, K., Saenko, E.L., 
Tanaka, I. and Yoshioka, A. (2006). Factor V C2 domain contains a major 
thrombin-binding site responsible for thrombin-catalyzed factor V activation. J 
Thromb Haemost 4, 1354-60. 
[43] Fritsch, P. et al. (2006). Thrombin generation in factor VIII-depleted neonatal 
plasma: nearly normal because of physiologically low antithrombin and tissue 
factor pathway inhibitor. J Thromb Haemost 4, 1071-7. 
[44] von dem Borne, P.A., Cox, L.M. and Bouma, B.N. (2006). Factor XI 
enhances fibrin generation and inhibits fibrinolysis in a coagulation model 
initiated by surface-coated tissue factor. Blood Coagul Fibrinolysis 17, 251-7. 
[45] Kahn, M.L., Nakanishi-Matsui, M., Shapiro, M.J., Ishihara, H. and Coughlin, 
S.R. (1999). Protease-activated receptors 1 and 4 mediate activation of 
human platelets by thrombin. J Clin Invest 103, 879-87. 
[46] Macfarlane, S.R., Seatter, M.J., Kanke, T., Hunter, G.D. and Plevin, R. 
(2001). Proteinase-activated receptors. Pharmacol Rev 53, 245-82. 
[47] Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moormann, C., 
Vergnolle, N., Luger, T.A. and Hollenberg, M.D. (2005). Proteinase-activated 
receptors: transducers of proteinase-mediated signaling in inflammation and 
immune response. Endocr Rev 26, 1-43. 
[48] Verrall, S., Ishii, M., Chen, M., Wang, L., Tram, T. and Coughlin, S.R. (1997). 
The thrombin receptor second cytoplasmic loop confers coupling to Gq-like 
G proteins in chimeric receptors. Additional evidence for a common 
transmembrane signaling and G protein coupling mechanism in G protein-
coupled receptors. J Biol Chem 272, 6898-902. 
[49] Chen, J., Ishii, M., Wang, L., Ishii, K. and Coughlin, S.R. (1994). Thrombin 
receptor activation. Confirmation of the intramolecular tethered liganding 
hypothesis and discovery of an alternative intermolecular liganding mode. J 
Biol Chem 269, 16041-5. 
[50] Bae, J.S., Yang, L., Manithody, C. and Rezaie, A.R. (2007). The ligand 
occupancy of endothelial protein C receptor switches the protease-activated 
receptor 1-dependent signaling specificity of thrombin from a permeability-
enhancing to a barrier-protective response in endothelial cells. Blood 110, 
3909-16. 
[51] O'Brien, P.J., Prevost, N., Molino, M., Hollinger, M.K., Woolkalis, M.J., 
Woulfe, D.S. and Brass, L.F. (2000). Thrombin responses in human 
endothelial cells. Contributions from receptors other than PAR1 include the 
transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 275, 
13502-9. 
[52] McLaughlin, J.N., Shen, L., Holinstat, M., Brooks, J.D., Dibenedetto, E. and 
Hamm, H.E. (2005). Functional selectivity of G protein signaling by agonist 
peptides and thrombin for the protease-activated receptor-1. J Biol Chem 
280, 25048-59. 
[53] Shi, X., Gangadharan, B., Brass, L.F., Ruf, W. and Mueller, B.M. (2004). 
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell 
motility and metastasis. Mol Cancer Res 2, 395-402. 
197 
 
[54] Jennings, L.K. (2009). Mechanisms of platelet activation: need for new 
strategies to protect against platelet-mediated atherothrombosis. Thromb 
Haemost 102, 248-57. 
[55] Vu, T.K., Hung, D.T., Wheaton, V.I. and Coughlin, S.R. (1991). Molecular 
cloning of a functional thrombin receptor reveals a novel proteolytic 
mechanism of receptor activation. Cell 64, 1057-68. 
[56] Ishii, K., Gerszten, R., Zheng, Y.W., Welsh, J.B., Turck, C.W. and Coughlin, 
S.R. (1995). Determinants of thrombin receptor cleavage. Receptor domains 
involved, specificity, and role of the P3 aspartate. J Biol Chem 270, 16435-
40. 
[57] Vu, T.K., Wheaton, V.I., Hung, D.T., Charo, I. and Coughlin, S.R. (1991). 
Domains specifying thrombin-receptor interaction. Nature 353, 674-7. 
[58] Liu, L.W., Vu, T.K., Esmon, C.T. and Coughlin, S.R. (1991). The region of 
the thrombin receptor resembling hirudin binds to thrombin and alters 
enzyme specificity. J Biol Chem 266, 16977-80. 
[59] Lova, P., Canobbio, I., Guidetti, G.F., Balduini, C. and Torti, M. (2010). 
Thrombin induces platelet activation in the absence of functional protease 
activated receptors 1 and 4 and glycoprotein Ib-IX-V. Cell Signal 22, 1681-7. 
[60] Ruggeri, Z.M., Zarpellon, A., Roberts, J.R., Mc Clintock, R.A., Jing, H. and 
Mendolicchio, G.L. (2010). Unravelling the mechanism and significance of 
thrombin binding to platelet glycoprotein Ib. Thromb Haemost 104, 894-902. 
[61] Johnson, K., Choi, Y., DeGroot, E., Samuels, I., Creasey, A. and Aarden, L. 
(1998). Potential mechanisms for a proinflammatory vascular cytokine 
response to coagulation activation. J Immunol 160, 5130-5. 
[62] Colotta, F., Sciacca, F.L., Sironi, M., Luini, W., Rabiet, M.J. and Mantovani, A. 
(1994). Expression of monocyte chemotactic protein-1 by monocytes and 
endothelial cells exposed to thrombin. Am J Pathol 144, 975-85. 
[63] Kranzhofer, R., Clinton, S.K., Ishii, K., Coughlin, S.R., Fenton, J.W., 2nd and 
Libby, P. (1996). Thrombin potently stimulates cytokine production in human 
vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res 
79, 286-94. 
[64] Kaplanski, G., Fabrigoule, M., Boulay, V., Dinarello, C.A., Bongrand, P., 
Kaplanski, S. and Farnarier, C. (1997). Thrombin induces endothelial type II 
activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-
selectin expression. J Immunol 158, 5435-41. 
[65] Sugama, Y., Tiruppathi, C., offakidevi, K., Andersen, T.T., Fenton, J.W., 2nd 
and Malik, A.B. (1992). Thrombin-induced expression of endothelial P-
selectin and intercellular adhesion molecule-1: a mechanism for stabilizing 
neutrophil adhesion. J Cell Biol 119, 935-44. 
[66] Springer, T.A. (1994). Traffic signals for lymphocyte recirculation and 
leukocyte emigration: the multistep paradigm. Cell 76, 301-14. 
[67] Kaplanski, G., Marin, V., Fabrigoule, M., Boulay, V., Benoliel, A.M., 
Bongrand, P., Kaplanski, S. and Farnarier, C. (1998). Thrombin-activated 
human endothelial cells support monocyte adhesion in vitro following 
expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and 
vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 92, 1259-67. 
[68] Van Obberghen-Schilling, E., Vouret-Craviari, V., Chen, Y.H., Grall, D., 
Chambard, J.C. and Pouyssegur, J. (1995). Thrombin and its receptor in 
growth control. Ann N Y Acad Sci 766, 431-41. 
198 
 
[69] Olivot, J.M., Estebanell, E., Lafay, M., Brohard, B., Aiach, M. and Rendu, F. 
(2001). Thrombomodulin prolongs thrombin-induced extracellular signal-
regulated kinase phosphorylation and nuclear retention in endothelial cells. 
Circ Res 88, 681-7. 
[70] Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., 
Berman, K. and Cobb, M.H. (2001). Mitogen-activated protein (MAP) kinase 
pathways: regulation and physiological functions. Endocr Rev 22, 153-83. 
[71] Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S. and Pouyssegur, J. 
(1999). Nuclear translocation of p42/p44 mitogen-activated protein kinase is 
required for growth factor-induced gene expression and cell cycle entry. 
EMBO J 18, 664-74. 
[72] Petaja, J. (2011). Inflammation and coagulation. An overview. Thromb Res 
127 Suppl 2, S34-7. 
[73] Komarova, Y.A., Mehta, D. and Malik, A.B. (2007). Dual regulation of 
endothelial junctional permeability. Sci STKE 2007, re8. 
[74] McVerry, B.J. and Garcia, J.G. (2004). Endothelial cell barrier regulation by 
sphingosine 1-phosphate. J Cell Biochem 92, 1075-85. 
[75] Singleton, P.A., Moreno-Vinasco, L., Sammani, S., Wanderling, S.L., Moss, J. 
and Garcia, J.G. (2007). Attenuation of vascular permeability by 
methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell 
Mol Biol 37, 222-31. 
[76] van der Poll, T. and Levi, M. (2012). Crosstalk between Inflammation and 
Coagulation: The Lessons of Sepsis. Curr Vasc Pharmacol  
[77] Rosen, H., Gonzalez-Cabrera, P.J., Sanna, M.G. and Brown, S. (2009). 
Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78, 743-68. 
[78] Gorshkova, I. et al. (2008). Protein kinase C-epsilon regulates sphingosine 
1-phosphate-mediated migration of human lung endothelial cells through 
activation of phospholipase D2, protein kinase C-zeta, and Rac1. J Biol 
Chem 283, 11794-806. 
[79] Jin, Z.Q. et al. (2002). Cardioprotection mediated by sphingosine-1-
phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout 
mouse hearts. Am J Physiol Heart Circ Physiol 282, H1970-7. 
[80] Singleton, P.A., Dudek, S.M., Chiang, E.T. and Garcia, J.G. (2005). 
Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal 
rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, 
Tiam1/Rac1, and alpha-actinin. FASEB J 19, 1646-56. 
[81] Stenflo, J. (1976). A new vitamin K-dependent protein. Purification from 
bovine plasma and preliminary characterization. J Biol Chem 251, 355-63. 
[82] Castellino, F.J. and Ploplis, V.A. (2009). The protein C pathway and 
pathologic processes. J Thromb Haemost 7 Suppl 1, 140-5. 
[83] Esmon, C.T. (2003). The protein C pathway. Chest 124, 26S-32S. 
[84] Yamamoto, K. and Loskutoff, D.J. (1998). Extrahepatic expression and 
regulation of protein C in the mouse. Am J Pathol 153, 547-55. 
[85] Zhang, L. and Castellino, F.J. (1990). A gamma-carboxyglutamic acid 
(gamma) variant (gamma 6D, gamma 7D) of human activated protein C 
displays greatly reduced activity as an anticoagulant. Biochemistry 29, 
10828-34. 
[86] Foster, D. and Davie, E.W. (1984). Characterization of a cDNA coding for 
human protein C. Proc Natl Acad Sci U S A 81, 4766-70. 
199 
 
[87] Miletich, J.P. and Broze, G.J., Jr. (1990). Beta protein C is not glycosylated 
at asparagine 329. The rate of translation may influence the frequency of 
usage at asparagine-X-cysteine sites. J Biol Chem 265, 11397-404. 
[88] Perera, L., Foley, C., Darden, T.A., Stafford, D., Mather, T., Esmon, C.T. and 
Pedersen, L.G. (2000). Modeling zymogen protein C. Biophys J 79, 2925-43. 
[89] Stenflo, J., Fernlund, P., Egan, W. and Roepstorff, P. (1974). Vitamin K 
dependent modifications of glutamic acid residues in prothrombin. Proc Natl 
Acad Sci U S A 71, 2730-3. 
[90] Beckmann, R.J., Schmidt, R.J., Santerre, R.F., Plutzky, J., Crabtree, G.R. 
and Long, G.L. (1985). The structure and evolution of a 461 amino acid 
human protein C precursor and its messenger RNA, based upon the DNA 
sequence of cloned human liver cDNAs. Nucleic Acids Res 13, 5233-47. 
[91] Sunnerhagen, M., Drakenberg, T., Forsen, S. and Stenflo, J. (1996). Effect of 
Ca2+ on the structure of vitamin K-dependent coagulation factors. 
Haemostasis 26 Suppl 1, 45-53. 
[92] Castellino, F.J. (1995). Human protein C and activated protein C 
Components of the human anticoagulation system. Trends Cardiovasc Med 
5, 55-62. 
[93] Preston, R.J., Villegas-Mendez, A., Sun, Y.H., Hermida, J., Simioni, P., 
Philippou, H., Dahlback, B. and Lane, D.A. (2005). Selective modulation of 
protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS 
J 272, 97-108. 
[94] Harmon, S., Preston, R.J., Ni Ainle, F., Johnson, J.A., Cunningham, M.S., 
Smith, O.P., White, B. and O'Donnell, J.S. (2008). Dissociation of activated 
protein C functions by elimination of protein S cofactor enhancement. J Biol 
Chem 283, 30531-9. 
[95] Colpitts, T.L. and Castellino, F.J. (1994). Calcium and phospholipid binding 
properties of synthetic gamma-carboxyglutamic acid-containing peptides with 
sequence counterparts in human protein C. Biochemistry 33, 3501-8. 
[96] Christiansen, W.T., Geng, J.P. and Castellino, F.J. (1995). Structure-function 
assessment of the role of the helical stack domain in the properties of human 
recombinant protein C and activated protein C. Biochemistry 34, 8082-90. 
[97] Ohlin, A.K., Landes, G., Bourdon, P., Oppenheimer, C., Wydro, R. and 
Stenflo, J. (1988). Beta-hydroxyaspartic acid in the first epidermal growth 
factor-like domain of protein C. Its role in Ca2+ binding and biological activity. 
J Biol Chem 263, 19240-8. 
[98] Medved, L.V., Orthner, C.L., Lubon, H., Lee, T.K., Drohan, W.N. and Ingham, 
K.C. (1995). Thermal stability and domain-domain interactions in natural and 
recombinant protein C. J Biol Chem 270, 13652-9. 
[99] Hogg, P.J., Ohlin, A.K. and Stenflo, J. (1992). Identification of structural 
domains in protein C involved in its interaction with thrombin-thrombomodulin 
on the surface of endothelial cells. J Biol Chem 267, 703-6. 
[100] Grinnell, B.W., Walls, J.D. and Gerlitz, B. (1991). Glycosylation of human 
protein C affects its secretion, processing, functional activities, and activation 
by thrombin. J Biol Chem 266, 9778-85. 
[101] Rezaie, A.R. and Esmon, C.T. (1992). The function of calcium in protein C 
activation by thrombin and the thrombin-thrombomodulin complex can be 
distinguished by mutational analysis of protein C derivatives. J Biol Chem 
267, 26104-9. 
200 
 
[102] Gale, A.J., Tsavaler, A. and Griffin, J.H. (2002). Molecular characterization of 
an extended binding site for coagulation factor Va in the positive exosite of 
activated protein C. J Biol Chem 277, 28836-40. 
[103] He, X. and Rezaie, A.R. (1999). Identification and characterization of the 
sodium-binding site of activated protein C. J Biol Chem 274, 4970-6. 
[104] Gale, A.J., Heeb, M.J. and Griffin, J.H. (2000). The autolysis loop of 
activated protein C interacts with factor Va and differentiates between the 
Arg506 and Arg306 cleavage sites. Blood 96, 585-593. 
[105] Friedrich, U., Nicolaes, G.A., Villoutreix, B.O. and Dahlback, B. (2001). 
Secondary substrate-binding exosite in the serine protease domain of 
activated protein C important for cleavage at Arg-506 but not at Arg-306 in 
factor Va. J Biol Chem 276, 23105-8. 
[106] Rezaie, A.R. (2003). Exosite-dependent regulation of the protein C 
anticoagulant pathway. Trends Cardiovasc Med 13, 8-15. 
[107] Cramer, T.J. and Gale, A.J. (2011). Function of the activated protein C (APC) 
autolysis loop in activated FVIII inactivation. Br J Haematol 153, 644-54. 
[108] Knobe, K.E., Berntsdotter, A., Shen, L., Morser, J., Dahlback, B. and 
Villoutreix, B.O. (1999). Probing the activation of protein C by the thrombin-
thrombomodulin complex using structural analysis, site-directed mutagenesis, 
and computer modeling. Proteins 35, 218-34. 
[109] Gale, A.J. and Griffin, J.H. (2004). Characterization of a thrombomodulin 
binding site on protein C and its comparison to an activated protein C binding 
site for factor Va. Proteins 54, 433-41. 
[110] Yang, L., Bae, J.S., Manithody, C. and Rezaie, A.R. (2007). Identification of 
a specific exosite on activated protein C for interaction with protease-
activated receptor 1. J Biol Chem 282, 25493-500. 
[111] Ni Ainle, F., O'Donnell, J.S., Johnson, J.A., Brown, L., Gleeson, E.M., Smith, 
O.P. and Preston, R.J. (2011). Activated protein C N-linked glycans 
modulate cytoprotective signaling function on endothelial cells. J Biol Chem 
286, 1323-30. 
[112] Esmon, C.T. (1989). The roles of protein C and thrombomodulin in the 
regulation of blood coagulation. J Biol Chem 264, 4743-6. 
[113] Weiler, H. (2011). Multiple receptor-mediated functions of activated protein C. 
Hamostaseologie 31, 185-95. 
[114] Esmon, C.T. and Owen, W.G. (1981). Identification of an endothelial cell 
cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U 
S A 78, 2249-52. 
[115] Owen, W.G. and Esmon, C.T. (1981). Functional properties of an endothelial 
cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256, 
5532-5. 
[116] Esmon, N.L., Owen, W.G. and Esmon, C.T. (1982). Isolation of a membrane-
bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 
257, 859-64. 
[117] Esmon, C.T. (1995). Thrombomodulin as a model of molecular mechanisms 
that modulate protease specificity and function at the vessel surface. FASEB 
J 9, 946-55. 
[118] Rezaie, A.R., Cooper, S.T., Church, F.C. and Esmon, C.T. (1995). Protein C 
inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol 
Chem 270, 25336-9. 
201 
 
[119] Weisel, J.W., Nagaswami, C., Young, T.A. and Light, D.R. (1996). The shape 
of thrombomodulin and interactions with thrombin as determined by electron 
microscopy. Journal of Biological Chemistry 271, 31485-31490. 
[120] Taylor, F.B., Jr., Peer, G.T., Lockhart, M.S., Ferrell, G. and Esmon, C.T. 
(2001). Endothelial cell protein C receptor plays an important role in protein 
C activation in vivo. Blood 97, 1685-8. 
[121] Esmon, N.L., DeBault, L.E. and Esmon, C.T. (1983). Proteolytic formation 
and properties of gamma-carboxyglutamic acid-domainless protein C. J Biol 
Chem 258, 5548-53. 
[122] Fukudome, K. and Esmon, C.T. (1994). Identification, cloning, and regulation 
of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 
269, 26486-91. 
[123] Laszik, Z., Mitro, A., Taylor, F.B., Jr., Ferrell, G. and Esmon, C.T. (1997). 
Human protein C receptor is present primarily on endothelium of large blood 
vessels: implications for the control of the protein C pathway. Circulation 96, 
3633-40. 
[124] Preston, R.J., Ajzner, E., Razzari, C., Karageorgi, S., Dua, S., Dahlback, B. 
and Lane, D.A. (2006). Multifunctional specificity of the protein C/activated 
protein C Gla domain. J Biol Chem 281, 28850-7. 
[125] Fukudome, K., Kurosawa, S., Stearns-Kurosawa, D.J., He, X., Rezaie, A.R. 
and Esmon, C.T. (1996). The endothelial cell protein C receptor. Cell surface 
expression and direct ligand binding by the soluble receptor. J Biol Chem 
271, 17491-8. 
[126] Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J.S., Ferrell, G.L. and 
Esmon, C.T. (1996). The endothelial cell protein C receptor augments 
protein C activation by the thrombin-thrombomodulin complex. Proc Natl 
Acad Sci U S A 93, 10212-6. 
[127] Fukudome, K., Ye, X., Tsuneyoshi, N., Tokunaga, O., Sugawara, K., 
Mizokami, H. and Kimoto, M. (1998). Activation mechanism of anticoagulant 
protein C in large blood vessels involving the endothelial cell protein C 
receptor. J Exp Med 187, 1029-35. 
[128] Bae, J.S., Yang, L. and Rezaie, A.R. (2007). Receptors of the protein C 
activation and activated protein C signaling pathways are colocalized in lipid 
rafts of endothelial cells. Proc Natl Acad Sci U S A 104, 2867-72. 
[129] Feistritzer, C. and Riewald, M. (2005). Endothelial barrier protection by 
activated protein C through PAR1-dependent sphingosine 1-phosphate 
receptor-1 crossactivation. Blood 105, 3178-84. 
[130] Bangalore, N., Drohan, W.N. and Orthner, C.L. (1994). High affinity binding 
sites for activated protein C and protein C on cultured human umbilical vein 
endothelial cells. Independent of protein S and distinct from known ligands. 
Thromb Haemost 72, 465-74. 
[131] Zheng, X., Li, W., Song, Y., Hu, Y., Ferrell, G.L., Esmon, N.L. and Esmon, 
C.T. (2007). Non-hematopoietic EPCR regulates the coagulation and 
inflammatory responses during endotoxemia. J Thromb Haemost 5, 1394-
400. 
[132] Oganesyan, V., Oganesyan, N., Terzyan, S., Qu, D., Dauter, Z., Esmon, N.L. 
and Esmon, C.T. (2002). The crystal structure of the endothelial protein C 
receptor and a bound phospholipid. J Biol Chem 277, 24851-4. 
[133] Gruber, A. and Griffin, J.H. (1992). Direct detection of activated protein C in 
blood from human subjects. Blood 79, 2340-8. 
202 
 
[134] Espana, F., Gruber, A., Heeb, M.J., Hanson, S.R., Harker, L.A. and Griffin, 
J.H. (1991). In vivo and in vitro complexes of activated protein C with two 
inhibitors in baboons. Blood 77, 1754-60. 
[135] Heeb, M.J. and Griffin, J.H. (1988). Physiologic inhibition of human activated 
protein C by alpha 1-antitrypsin. J Biol Chem 263, 11613-6. 
[136] Sakata, Y., Loskutoff, D.J., Gladson, C.L., Hekman, C.M. and Griffin, J.H. 
(1986). Mechanism of protein C-dependent clot lysis: role of plasminogen 
activator inhibitor. Blood 68, 1218-23. 
[137] Camire, R.M. and Bos, M.H. (2009). The molecular basis of factor V and VIII 
procofactor activation. J Thromb Haemost 7, 1951-61. 
[138] Norstrom, E.A., Tran, S., Steen, M. and Dahlback, B. (2006). Effects of factor 
Xa and protein S on the individual activated protein C-mediated cleavages of 
coagulation factor Va. J Biol Chem 281, 31486-94. 
[139] Steen, M. and Dahlback, B. (2002). Thrombin-mediated proteolysis of factor 
V resulting in gradual B-domain release and exposure of the factor Xa-
binding site. J Biol Chem 277, 38424-30. 
[140] Nicolaes, G.A. and Dahlback, B. (2002). Factor V and thrombotic disease: 
description of a janus-faced protein. Arterioscler Thromb Vasc Biol 22, 530-8. 
[141] Tran, S., Norstrom, E. and Dahlback, B. (2008). Effects of prothrombin on 
the individual activated protein C-mediated cleavages of coagulation factor 
Va. J Biol Chem 283, 6648-55. 
[142] Chan, W.P., Lee, C.K., Kwong, Y.L., Lam, C.K. and Liang, R. (1998). A novel 
mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91, 1135-
9. 
[143] Mann, K.G., Hockin, M.F., Begin, K.J. and Kalafatis, M. (1997). Activated 
protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol 
Chem 272, 20678-83. 
[144] Gale, A.J., Cramer, T.J., Rozenshteyn, D. and Cruz, J.R. (2008). Detailed 
mechanisms of the inactivation of factor VIIIa by activated protein C in the 
presence of its cofactors, protein S and factor V. J Biol Chem 283, 16355-62. 
[145] yuan, J.X.-J., Garcia, J.G.N., Hales, C.A., Rich, S., Archer, S.L. and West, 
J.B. (2010) Textbook of Pulmonary Vascular Disease 
[146] DiScipio, R.G. and Davie, E.W. (1979). Characterization of protein S, a 
gamma-carboxyglutamic acid containing protein from bovine and human 
plasma. Biochemistry 18, 899-904. 
[147] Andersson, H.M., Arantes, M.J., Crawley, J.T., Luken, B.M., Tran, S., 
Dahlback, B., Lane, D.A. and Rezende, S.M. (2010). Activated protein C 
cofactor function of protein S: a critical role for Asp95 in the EGF1-like 
domain. Blood 115, 4878-85. 
[148] Ahnstrom, J. et al. (2011). Activated protein C cofactor function of protein S: 
a novel role for a gamma-carboxyglutamic acid residue. Blood 117, 6685-93. 
[149] Rezende, S.M., Simmonds, R.E. and Lane, D.A. (2004). Coagulation, 
inflammation, and apoptosis: different roles for protein S and the protein S-
C4b binding protein complex. Blood 103, 1192-201. 
[150] Maurissen, L.F., Thomassen, M.C., Nicolaes, G.A., Dahlback, B., Tans, G., 
Rosing, J. and Hackeng, T.M. (2008). Re-evaluation of the role of the protein 
S-C4b binding protein complex in activated protein C-catalyzed factor Va-
inactivation. Blood 111, 3034-41. 
203 
 
[151] Norstrom, E.A., Steen, M., Tran, S. and Dahlback, B. (2003). Importance of 
protein S and phospholipid for activated protein C-mediated cleavages in 
factor Va. J Biol Chem 278, 24904-11. 
[152] Yegneswaran, S., Wood, G.M., Esmon, C.T. and Johnson, A.E. (1997). 
Protein S alters the active site location of activated protein C above the 
membrane surface. A fluorescence resonance energy transfer study of 
topography. J Biol Chem 272, 25013-21. 
[153] Walker, F.J. (1981). Regulation of activated protein C by protein S. The role 
of phospholipid in factor Va inactivation. J Biol Chem 256, 11128-31. 
[154] Saller, F., Kaabache, T., Aiach, M., Gandrille, S. and Borgel, D. (2006). The 
protein S thrombin-sensitive region modulates phospholipid binding and the 
gamma-carboxyglutamic acid-rich (Gla) domain conformation in a non-
specific manner. J Thromb Haemost 4, 704-6. 
[155] Sun, Y.H., Shen, L. and Dahlback, B. (2003). Gla domain-mutated human 
protein C exhibiting enhanced anticoagulant activity and increased 
phospholipid binding. Blood 101, 2277-84. 
[156] Heeb, M.J., Kojima, Y., Hackeng, T.M. and Griffin, J.H. (1996). Binding sites 
for blood coagulation factor Xa and protein S involving residues 493-506 in 
factor Va. Protein Sci 5, 1883-9. 
[157] Jalbert, L.R., Rosen, E.D., Moons, L., Chan, J.C., Carmeliet, P., Collen, D. 
and Castellino, F.J. (1998). Inactivation of the gene for anticoagulant protein 
C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 
102, 1481-8. 
[158] Isermann, B., Hendrickson, S.B., Zogg, M., Wing, M., Cummiskey, M., 
Kisanuki, Y.Y., Yanagisawa, M. and Weiler, H. (2001). Endothelium-specific 
loss of murine thrombomodulin disrupts the protein C anticoagulant pathway 
and causes juvenile-onset thrombosis. J Clin Invest 108, 537-46. 
[159] Comp, P.C. and Esmon, C.T. (1984). Recurrent venous thromboembolism in 
patients with a partial deficiency of protein S. N Engl J Med 311, 1525-8. 
[160] Liu, D., Cheng, T., Guo, H., Fernandez, J.A., Griffin, J.H., Song, X. and 
Zlokovic, B.V. (2004). Tissue plasminogen activator neurovascular toxicity is 
controlled by activated protein C. Nat Med 10, 1379-83. 
[161] Esmon, C.T. (2004). Interactions between the innate immune and blood 
coagulation systems. Trends Immunol 25, 536-42. 
[162] Riewald, M. and Ruf, W. (2003). Science review: role of coagulation protease 
cascades in sepsis. Crit Care 7, 123-9. 
[163] Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B. and Grinnell, B.W. (2001). 
Gene expression profile of antithrombotic protein c defines new mechanisms 
modulating inflammation and apoptosis. J Biol Chem 276, 11199-203. 
[164] Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. and Ruf, W. (2002). 
Activation of endothelial cell protease activated receptor 1 by the protein C 
pathway. Science 296, 1880-2. 
[165] Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., 
Fukudome, K. and Zlokovic, B.V. (2003). Activated protein C blocks p53-
mediated apoptosis in ischemic human brain endothelium and is 
neuroprotective. Nat Med 9, 338-42. 
[166] Domotor, E., Benzakour, O., Griffin, J.H., Yule, D., Fukudome, K. and 
Zlokovic, B.V. (2003). Activated protein C alters cytosolic calcium flux in 
human brain endothelium via binding to endothelial protein C receptor and 
activation of protease activated receptor-1. Blood 101, 4797-801. 
204 
 
[167] Mosnier, L.O. and Griffin, J.H. (2003). Inhibition of staurosporine-induced 
apoptosis of endothelial cells by activated protein C requires protease-
activated receptor-1 and endothelial cell protein C receptor. Biochem J 373, 
65-70. 
[168] Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., 
Griffin, J.H. and Zlokovic, B.V. (2004). Activated protein C prevents neuronal 
apoptosis via protease activated receptors 1 and 3. Neuron 41, 563-72. 
[169] Finigan, J.H., Dudek, S.M., Singleton, P.A., Chiang, E.T., Jacobson, J.R., 
Camp, S.M., Ye, S.Q. and Garcia, J.G. (2005). Activated protein C mediates 
novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate 
receptor transactivation. J Biol Chem 280, 17286-93. 
[170] Madhusudhan, T. et al. (2012). Cytoprotective signaling by activated protein 
C requires protease-activated receptor-3 in podocytes. Blood 119, 874-83. 
[171] Schuepbach, R.A., Feistritzer, C., Fernandez, J.A., Griffin, J.H. and Riewald, 
M. (2009). Protection of vascular barrier integrity by activated protein C in 
murine models depends on protease-activated receptor-1. Thromb Haemost 
101, 724-33. 
[172] Xue, M., Campbell, D., Sambrook, P.N., Fukudome, K. and Jackson, C.J. 
(2005). Endothelial protein C receptor and protease-activated receptor-1 
mediate induction of a wound-healing phenotype in human keratinocytes by 
activated protein C. J Invest Dermatol 125, 1279-85. 
[173] Fernandez, J.A., Xu, X., Liu, D., Zlokovic, B.V. and Griffin, J.H. (2003). 
Recombinant murine-activated protein C is neuroprotective in a murine 
ischemic stroke model. Blood Cells Mol Dis 30, 271-6. 
[174] Shibata, M., Kumar, S.R., Amar, A., Fernandez, J.A., Hofman, F., Griffin, J.H. 
and Zlokovic, B.V. (2001). Anti-inflammatory, antithrombotic, and 
neuroprotective effects of activated protein C in a murine model of focal 
ischemic stroke. Circulation 103, 1799-805. 
[175] Riewald, M. and Schuepbach, R.A. (2008). Protective signaling pathways of 
activated protein C in endothelial cells. Arterioscler Thromb Vasc Biol 28, 1-3. 
[176] Franscini, N., Bachli, E.B., Blau, N., Leikauf, M.S., Schaffner, A. and 
Schoedon, G. (2004). Gene expression profiling of inflamed human 
endothelial cells and influence of activated protein C. Circulation 110, 2903-9. 
[177] Yuksel, M., Okajima, K., Uchiba, M., Horiuchi, S. and Okabe, H. (2002). 
Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-
alpha production by inhibiting activation of both nuclear factor-kappa B and 
activator protein-1 in human monocytes. Thromb Haemost 88, 267-73. 
[178] White, B. et al. (2000). Activated protein C inhibits lipopolysaccharide-
induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and 
tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic 
cell line. Br J Haematol 110, 130-4. 
[179] Han, M.H. et al. (2008). Proteomic analysis of active multiple sclerosis 
lesions reveals therapeutic targets. Nature 451, 1076-81. 
[180] Nick, J.A. et al. (2004). Recombinant human activated protein C reduces 
human endotoxin-induced pulmonary inflammation via inhibition of neutrophil 
chemotaxis. Blood 104, 3878-85. 
[181] Shu, F., Kobayashi, H., Fukudome, K., Tsuneyoshi, N., Kimoto, M. and 
Terao, T. (2000). Activated protein C suppresses tissue factor expression on 
U937 cells in the endothelial protein C receptor-dependent manner. FEBS 
Lett 477, 208-212. 
205 
 
[182] Stephenson, D.A., Toltl, L.J., Beaudin, S. and Liaw, P.C. (2006). Modulation 
of monocyte function by activated protein C, a natural anticoagulant. J 
Immunol 177, 2115-22. 
[183] Yang, X.V. et al. (2009). Activated protein C ligation of ApoER2 (LRP8) 
causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A 
106, 274-9. 
[184] Cao, C., Gao, Y., Li, Y., Antalis, T.M., Castellino, F.J. and Zhang, L. (2010). 
The efficacy of activated protein C in murine endotoxemia is dependent on 
integrin CD11b. J Clin Invest 120, 1971-80. 
[185] Elphick, G.F. et al. (2009). Recombinant human activated protein C inhibits 
integrin-mediated neutrophil migration. Blood 113, 4078-85. 
[186] Kurosawa, S., Esmon, C.T. and Stearns-Kurosawa, D.J. (2000). The soluble 
endothelial protein C receptor binds to activated neutrophils: involvement of 
proteinase-3 and CD11b/CD18. J Immunol 165, 4697-703. 
[187] Joyce, D.E. and Grinnell, B.W. (2002). Recombinant human activated protein 
C attenuates the inflammatory response in endothelium and monocytes by 
modulating nuclear factor-kappaB. Crit Care Med 30, S288-93. 
[188] Brueckmann, M. et al. (2006). Recombinant human activated protein C 
upregulates the release of soluble fractalkine from human endothelial cells. 
Br J Haematol 133, 550-7. 
[189] Neyrinck, A.P., Liu, K.D., Howard, J.P. and Matthay, M.A. (2009). Protective 
mechanisms of activated protein C in severe inflammatory disorders. Br J 
Pharmacol 158, 1034-47. 
[190] Mosnier, L.O., Zlokovic, B.V. and Griffin, J.H. (2007). The cytoprotective 
protein C pathway. Blood 109, 3161-72. 
[191] Hoffmann, J.N., Vollmar, B., Laschke, M.W., Inthorn, D., Fertmann, J., 
Schildberg, F.W. and Menger, M.D. (2004). Microhemodynamic and cellular 
mechanisms of activated protein C action during endotoxemia. Crit Care Med 
32, 1011-7. 
[192] Grinnell, B.W., Hermann, R.B. and Yan, S.B. (1994). Human protein C 
inhibits selectin-mediated cell adhesion: role of unique fucosylated 
oligosaccharide. Glycobiology 4, 221-5. 
[193] Iba, T., Kidokoro, A., Fukunaga, M., Nagakari, K., Shirahama, A. and Ida, Y. 
(2005). Activated protein C improves the visceral microcirculation by 
attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide 
model. Crit Care Med 33, 368-72. 
[194] Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol 
Pathol 35, 495-516. 
[195] Boatright, K.M. and Salvesen, G.S. (2003). Mechanisms of caspase 
activation. Curr Opin Cell Biol 15, 725-31. 
[196] Reed, J.C. (2006). Proapoptotic multidomain Bcl-2/Bax-family proteins: 
mechanisms, physiological roles, and therapeutic opportunities. Cell Death 
Differ 13, 1378-86. 
[197] Perez-Casal, M., Downey, C., Cutillas-Moreno, B., Zuzel, M., Fukudome, K. 
and Toh, C.H. (2009). Microparticle-associated endothelial protein C receptor 
and the induction of cytoprotective and anti-inflammatory effects. 
Haematologica 94, 387-94. 
[198] Uchiba, M., Okajima, K., Oike, Y., Ito, Y., Fukudome, K., Isobe, H. and Suda, 
T. (2004). Activated protein C induces endothelial cell proliferation by 
206 
 
mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. 
Circ Res 95, 34-41. 
[199] O'Brien, L.A., Richardson, M.A., Mehrbod, S.F., Berg, D.T., Gerlitz, B., Gupta, 
A. and Grinnell, B.W. (2007). Activated protein C decreases tumor necrosis 
factor related apoptosis-inducing ligand by an EPCR- independent 
mechanism involving Egr-1/Erk-1/2 activation. Arterioscler Thromb Vasc Biol 
27, 2634-41. 
[200] Guitton, C., Cottereau, A., Gerard, N., Quillard, T., Chauveau, A., Devalliere, 
J., Tonnerre, P. and Charreau, B. (2011). Protective cross talk between 
activated protein C and TNF signaling in vascular endothelial cells: 
implication of EPCR, noncanonical NF-kappaB, and ERK1/2 MAP kinases. 
Am J Physiol Cell Physiol 300, C833-42. 
[201] Sarangi, P.P., Lee, H.W. and Kim, M. (2009). Activated protein C action in 
inflammation. Br J Haematol  
[202] Baldwin, A.L. and Thurston, G. (2001). Mechanics of endothelial cell 
architecture and vascular permeability. Crit Rev Biomed Eng 29, 247-78. 
[203] van Hinsbergh, V.W. and van Nieuw Amerongen, G.P. (2002). Intracellular 
signalling involved in modulating human endothelial barrier function. J Anat 
200, 549-60. 
[204] Beckers, C.M., van Hinsbergh, V.W. and van Nieuw Amerongen, G.P. (2010). 
Driving Rho GTPase activity in endothelial cells regulates barrier integrity. 
Thromb Haemost 103, 40-55. 
[205] Kumar, P., Shen, Q., Pivetti, C.D., Lee, E.S., Wu, M.H. and Yuan, S.Y. 
(2009). Molecular mechanisms of endothelial hyperpermeability: implications 
in inflammation. Expert Rev Mol Med 11, e19. 
[206] Yuan, S.Y. and Rigor, R.R. (2010). In Regulation of Endothelial Barrier 
Function ed.^eds), San Rafael (CA). 
[207] Monaghan-Benson, E. and Burridge, K. (2009). The regulation of vascular 
endothelial growth factor-induced microvascular permeability requires Rac 
and reactive oxygen species. J Biol Chem 284, 25602-11. 
[208] Lampugnani, M.G. et al. (2002). VE-cadherin regulates endothelial actin 
activating Rac and increasing membrane association of Tiam. Mol Biol Cell 
13, 1175-89. 
[209] Wildenberg, G.A., Dohn, M.R., Carnahan, R.H., Davis, M.A., Lobdell, N.A., 
Settleman, J. and Reynolds, A.B. (2006). p120-catenin and p190RhoGAP 
regulate cell-cell adhesion by coordinating antagonism between Rac and 
Rho. Cell 127, 1027-39. 
[210] Adamson, R.H., Liu, B., Fry, G.N., Rubin, L.L. and Curry, F.E. (1998). 
Microvascular permeability and number of tight junctions are modulated by 
cAMP. Am J Physiol 274, H1885-94. 
[211] Adamson, R.H., Ly, J.C., Sarai, R.K., Lenz, J.F., Altangerel, A., Drenckhahn, 
D. and Curry, F.E. (2008). Epac/Rap1 pathway regulates microvascular 
hyperpermeability induced by PAF in rat mesentery. Am J Physiol Heart Circ 
Physiol 294, H1188-96. 
[212] Kuebler, W.M. The Janus-faced regulation of endothelial permeability by 
cyclic GMP. Am J Physiol Lung Cell Mol Physiol 301, L157-60. 
[213] Kouklis, P., Konstantoulaki, M., Vogel, S., Broman, M. and Malik, A.B. (2004). 
Cdc42 regulates the restoration of endothelial barrier function. Circ Res 94, 
159-66. 
207 
 
[214] Russo, A., Soh, U.J., Paing, M.M., Arora, P. and Trejo, J. (2009). Caveolae 
are required for protease-selective signaling by protease-activated receptor-
1. Proc Natl Acad Sci U S A 106, 6393-7. 
[215] Bae, J.S. and Rezaie, A.R. (2008). Protease activated receptor 1 (PAR-1) 
activation by thrombin is protective in human pulmonary artery endothelial 
cells if endothelial protein C receptor is occupied by its natural ligand. 
Thromb Haemost 100, 101-9. 
[216] Bae, J.S. and Rezaie, A.R. (2009). Thrombin inhibits nuclear factor kappaB 
and RhoA pathways in cytokine-stimulated vascular endothelial cells when 
EPCR is occupied by protein C. Thromb Haemost 101, 513-20. 
[217] Minhas, N., Xue, M., Fukudome, K. and Jackson, C.J. Activated protein C 
utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. 
FASEB J 24, 873-81. 
[218] Quest, A.F., Leyton, L. and Parraga, M. (2004). Caveolins, caveolae, and 
lipid rafts in cellular transport, signaling, and disease. Biochem Cell Biol 82, 
129-44. 
[219] Swift, S., Xu, J., Trivedi, V., Austin, K.M., Tressel, S.L., Zhang, L., Covic, L. 
and Kuliopulos, A. (2010). A novel protease-activated receptor-1 interactor, 
Bicaudal D1, regulates G protein signaling and internalization. J Biol Chem 
285, 11402-10. 
[220] Schuepbach, R.A., Feistritzer, C., Brass, L.F. and Riewald, M. (2008). 
Activated protein C-cleaved protease activated receptor-1 is retained on the 
endothelial cell surface even in the presence of thrombin. Blood 111, 2667-
73. 
[221] Rezaie, A.R. (2010). Regulation of the protein C anticoagulant and 
antiinflammatory pathways. Curr Med Chem 17, 2059-69. 
[222] McLaughlin, J.N., Patterson, M.M. and Malik, A.B. (2007). Protease-activated 
receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc 
Natl Acad Sci U S A 104, 5662-7. 
[223] Mosnier, L.O., Gale, A.J., Yegneswaran, S. and Griffin, J.H. (2004). 
Activated protein C variants with normal cytoprotective but reduced 
anticoagulant activity. Blood 104, 1740-4. 
[224] Bae, J.S., Yang, L., Manithody, C. and Rezaie, A.R. (2007). Engineering a 
disulfide bond to stabilize the calcium-binding loop of activated protein C 
eliminates its anticoagulant but not its protective signaling properties. J Biol 
Chem 282, 9251-9. 
[225] Kurata, T., Hayashi, T., Yoshikawa, T., Okamoto, T., Yoshida, K., Iino, T., 
Uchida, A. and Suzuki, K. (2010). Activated protein C stimulates osteoblast 
proliferation via endothelial protein C receptor. Thromb Res 125, 184-91. 
[226] Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 
454, 428-35. 
[227] Serhan, C.N. and Savill, J. (2005). Resolution of inflammation: the beginning 
programs the end. Nat Immunol 6, 1191-7. 
[228] Kang, J.Y. and Lee, J.O. (2011). Structural biology of the Toll-like receptor 
family. Annu Rev Biochem 80, 917-41. 
[229] Zhang, D.K., Zhang, G.L., Hayden, M.S., Greenblatt, M.B., Bussey, C., 
Flavell, R.A. and Ghosh, S. (2004). A toll-like receptor that prevents infection 
by uropathogenic bacteria. Science 303, 1522-1526. 
[230] Mantovani, A., Bussolino, F. and Dejana, E. (1992). Cytokine regulation of 
endothelial cell function. FASEB J 6, 2591-9. 
208 
 
[231] Pober, J.S. and Sessa, W.C. (2007). Evolving functions of endothelial cells in 
inflammation. Nat Rev Immunol 7, 803-15. 
[232] Lentsch, A.B. and Ward, P.A. (1999). Activation and regulation of NFkappaB 
during acute inflammation. Clin Chem Lab Med 37, 205-8. 
[233] van der Poll, T. et al. (1994). Elimination of interleukin 6 attenuates 
coagulation activation in experimental endotoxemia in chimpanzees. J Exp 
Med 179, 1253-9. 
[234] Shebuski, R.J. and Kilgore, K.S. (2002). Role of inflammatory mediators in 
thrombogenesis. J Pharmacol Exp Ther 300, 729-35. 
[235] Levi, M. and van der Poll, T. (2010). Inflammation and coagulation. Crit Care 
Med 38, S26-34. 
[236] Esmon, C.T. (2001). Role of coagulation inhibitors in inflammation. Thromb 
Haemost 86, 51-6. 
[237] Faust, S.N. et al. (2001). Dysfunction of endothelial protein C activation in 
severe meningococcal sepsis. N Engl J Med 345, 408-16. 
[238] Nawroth, P.P. and Stern, D.M. (1986). Modulation of endothelial cell 
hemostatic properties by tumor necrosis factor. J Exp Med 163, 740-5. 
[239] Garcia de Frutos, P., Alim, R.I., Hardig, Y., Zoller, B. and Dahlback, B. 
(1994). Differential regulation of alpha and beta chains of C4b-binding 
protein during acute-phase response resulting in stable plasma levels of free 
anticoagulant protein S. Blood 84, 815-22. 
[240] Taylor, F.B., Jr. et al. (2000). The endothelial cell protein C receptor aids in 
host defense against Escherichia coli sepsis. Blood 95, 1680-6. 
[241] van der Poll, T., Levi, M., Buller, H.R., van Deventer, S.J., de Boer, J.P., 
Hack, C.E. and ten Cate, J.W. (1991). Fibrinolytic response to tumor 
necrosis factor in healthy subjects. J Exp Med 174, 729-32. 
[242] van der Poll, T., de Jonge, E. and Levi, M. (2001). Regulatory role of 
cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 
27, 639-51. 
[243] Dempsey, E.C., Newton, A.C., Mochly-Rosen, D., Fields, A.P., Reyland, 
M.E., Insel, P.A. and Messing, R.O. (2000). Protein kinase C isozymes and 
the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 
279, L429-38. 
[244] Newton, A.C. (1995). Protein kinase C: structure, function, and regulation. J 
Biol Chem 270, 28495-8. 
[245] Newton, A.C. (2003). Regulation of the ABC kinases by phosphorylation: 
protein kinase C as a paradigm. Biochem J 370, 361-71. 
[246] House, C. and Kemp, B.E. (1987). Protein kinase C contains a 
pseudosubstrate prototope in its regulatory domain. Science 238, 1726-8. 
[247] Newton, A.C. (2010). Protein kinase C: poised to signal. Am J Physiol 
Endocrinol Metab 298, E395-402. 
[248] Steinberg, S.F. (2008). Structural basis of protein kinase C isoform function. 
Physiol Rev 88, 1341-78. 
[249] Walker, J.M. and Sando, J.J. (1988). Activation of protein kinase C by short 
chain phosphatidylcholines. J Biol Chem 263, 4537-40. 
[250] Orr, J.W. and Newton, A.C. (1994). Intrapeptide regulation of protein kinase 
C. J Biol Chem 269, 8383-7. 
[251] Takai, Y., Kishimoto, A., Iwasa, Y., Kawahara, Y., Mori, T. and Nishizuka, Y. 
(1979). Calcium-dependent activation of a multifunctional protein kinase by 
membrane phospholipids. J Biol Chem 254, 3692-5. 
209 
 
[252] Dutil, E.M., Toker, A. and Newton, A.C. (1998). Regulation of conventional 
protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). 
Curr Biol 8, 1366-75. 
[253] Le Good, J.A., Ziegler, W.H., Parekh, D.B., Alessi, D.R., Cohen, P. and 
Parker, P.J. (1998). Protein kinase C isotypes controlled by phosphoinositide 
3-kinase through the protein kinase PDK1. Science 281, 2042-5. 
[254] Cenni, V., Doppler, H., Sonnenburg, E.D., Maraldi, N., Newton, A.C. and 
Toker, A. (2002). Regulation of novel protein kinase C epsilon by 
phosphorylation. Biochem J 363, 537-45. 
[255] Chou, M.M. et al. (1998). Regulation of protein kinase C zeta by PI 3-kinase 
and PDK-1. Curr Biol 8, 1069-77. 
[256] Yang, J., Cron, P., Thompson, V., Good, V.M., Hess, D., Hemmings, B.A. 
and Barford, D. (2002). Molecular mechanism for the regulation of protein 
kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9, 1227-40. 
[257] Oliva, J.L., Griner, E.M. and Kazanietz, M.G. (2005). PKC isozymes and 
diacylglycerol-regulated proteins as effectors of growth factor receptors. 
Growth Factors 23, 245-52. 
[258] Asaoka, Y., Nakamura, S., Yoshida, K. and Nishizuka, Y. (1992). Protein 
kinase C, calcium and phospholipid degradation. Trends Biochem Sci 17, 
414-7. 
[259] Nishizuka, Y. (1992). Intracellular signaling by hydrolysis of phospholipids 
and activation of protein kinase C. Science 258, 607-14. 
[260] Nishizuka, Y. (1995). Protein kinase C and lipid signaling for sustained 
cellular responses. FASEB J 9, 484-96. 
[261] Dekker, L.V. and Parker, P.J. (1994). Protein kinase C--a question of 
specificity. Trends Biochem Sci 19, 73-7. 
[262] Steinberg, R. et al. (2007). A protein kinase Cepsilon-anti-apoptotic kinase 
signaling complex protects human vascular endothelial cells against 
apoptosis through induction of Bcl-2. J Biol Chem 282, 32288-97. 
[263] Aiello, L.P. et al. (1997). Vascular endothelial growth factor-induced retinal 
permeability is mediated by protein kinase C in vivo and suppressed by an 
orally effective beta-isoform-selective inhibitor. Diabetes 46, 1473-80. 
[264] Wang, A., Nomura, M., Patan, S. and Ware, J.A. (2002). Inhibition of protein 
kinase Calpha prevents endothelial cell migration and vascular tube 
formation in vitro and myocardial neovascularization in vivo. Circ Res 90, 
609-16. 
[265] Teicher, B.A., Alvarez, E., Menon, K., Esterman, M.A., Considine, E., Shih, C. 
and Faul, M.M. (2002). Antiangiogenic effects of a protein kinase Cbeta-
selective small molecule. Cancer Chemother Pharmacol 49, 69-77. 
[266] Mehta, D. (2001). Serine/threonine phosphatase 2B regulates protein kinase 
C-alpha activity and endothelial barrier function. Am J Physiol Lung Cell Mol 
Physiol 281, L544-5. 
[267] Hempel, A., Lindschau, C., Maasch, C., Mahn, M., Bychkov, R., Noll, T., Luft, 
F.C. and Haller, H. (1999). Calcium antagonists ameliorate ischemia-induced 
endothelial cell permeability by inhibiting protein kinase C. Circulation 99, 
2523-9. 
[268] Sandoval, R., Malik, A.B., Minshall, R.D., Kouklis, P., Ellis, C.A. and 
Tiruppathi, C. (2001). Ca(2+) signalling and PKCalpha activate increased 
endothelial permeability by disassembly of VE-cadherin junctions. J Physiol 
533, 433-45. 
210 
 
[269] Lucas, R. et al. Protein Kinase C-alpha and Arginase I Mediate 
Pneumolysin-Induced Pulmonary Endothelial Hyperpermeability. Am J 
Respir Cell Mol Biol  
[270] Andreeva, A.Y., Piontek, J., Blasig, I.E. and Utepbergenov, D.I. (2006). 
Assembly of tight junction is regulated by the antagonism of conventional 
and novel protein kinase C isoforms. Int J Biochem Cell Biol 38, 222-33. 
[271] Nagpala, P.G., Malik, A.B., Vuong, P.T. and Lum, H. (1996). Protein kinase 
C beta 1 overexpression augments phorbol ester-induced increase in 
endothelial permeability. J Cell Physiol 166, 249-55. 
[272] Lum, H. and Malik, A.B. (1996). Mechanisms of increased endothelial 
permeability. Can J Physiol Pharmacol 74, 787-800. 
[273] Ishii, H. et al. (1996). Amelioration of vascular dysfunctions in diabetic rats by 
an oral PKC beta inhibitor. Science 272, 728-31. 
[274] Koya, D. et al. (2000). Amelioration of accelerated diabetic mesangial 
expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a 
rodent model for type 2 diabetes. FASEB J 14, 439-47. 
[275] Siflinger-Birnboim, A., Goligorsky, M.S., Del Vecchio, P.J. and Malik, A.B. 
(1992). Activation of protein kinase C pathway contributes to hydrogen 
peroxide-induced increase in endothelial permeability. Lab Invest 67, 24-30. 
[276] Kim, J.H., Jun, H.O., Yu, Y.S. and Kim, K.W. (2010). Inhibition of protein 
kinase C delta attenuates blood-retinal barrier breakdown in diabetic 
retinopathy. Am J Pathol 176, 1517-24. 
[277] Banan, A., Farhadi, A., Fields, J.Z., Zhang, L.J., Shaikh, M. and 
Keshavarzian, A. (2003). The delta-isoform of protein kinase C causes 
inducible nitric-oxide synthase and nitric oxide up-regulation: key mechanism 
for oxidant-induced carbonylation, nitration, and disassembly of the 
microtubule cytoskeleton and hyperpermeability of barrier of intestinal 
epithelia. J Pharmacol Exp Ther 305, 482-94. 
[278] Mullin, J.M. et al. (1998). Overexpression of protein kinase C-delta increases 
tight junction permeability in LLC-PK1 epithelia. Am J Physiol 275, C544-54. 
[279] Tinsley, J.H., Teasdale, N.R. and Yuan, S.Y. (2004). Involvement of 
PKCdelta and PKD in pulmonary microvascular endothelial cell 
hyperpermeability. Am J Physiol Cell Physiol 286, C105-11. 
[280] Sonobe, Y. et al. (2009). Interleukin-25 expressed by brain capillary 
endothelial cells maintains blood-brain barrier function in a protein kinase 
Cepsilon-dependent manner. J Biol Chem 284, 31834-42. 
[281] Miura, T., Yano, T., Naitoh, K., Nishihara, M., Miki, T., Tanno, M. and 
Shimamoto, K. (2007). Delta-opioid receptor activation before ischemia 
reduces gap junction permeability in ischemic myocardium by PKC-epsilon-
mediated phosphorylation of connexin 43. Am J Physiol Heart Circ Physiol 
293, H1425-31. 
[282] Naitoh, K. et al. (2009). Roles of Cx43-associated protein kinases in 
suppression of gap junction-mediated chemical coupling by ischemic 
preconditioning. Am J Physiol Heart Circ Physiol 296, H396-403. 
[283] Suzuki, T., Seth, A. and Rao, R. (2008). Role of phospholipase Cgamma-
induced activation of protein kinase Cepsilon (PKCepsilon) and PKCbetaI in 
epidermal growth factor-mediated protection of tight junctions from 
acetaldehyde in Caco-2 cell monolayers. J Biol Chem 283, 3574-83. 
[284] Oubaha, M. and Gratton, J.P. (2009). Phosphorylation of endothelial nitric 
oxide synthase by atypical PKC zeta contributes to angiopoietin-1-dependent 
211 
 
inhibition of VEGF-induced endothelial permeability in vitro. Blood 114, 3343-
51. 
[285] Banan, A., Fields, J.Z., Zhang, L.J., Shaikh, M., Farhadi, A. and 
Keshavarzian, A. (2003). Zeta isoform of protein kinase C prevents oxidant-
induced nuclear factor-kappaB activation and I-kappaBalpha degradation: a 
fundamental mechanism for epidermal growth factor protection of the 
microtubule cytoskeleton and intestinal barrier integrity. J Pharmacol Exp 
Ther 307, 53-66. 
[286] Banan, A., Zhang, L., Fields, J.Z., Farhadi, A., Talmage, D.A. and 
Keshavarzian, A. (2002). PKC-zeta prevents oxidant-induced iNOS 
upregulation and protects the microtubules and gut barrier integrity. Am J 
Physiol Gastrointest Liver Physiol 283, G909-22. 
[287] Datta, K., Li, J., Bhattacharya, R., Gasparian, L., Wang, E. and 
Mukhopadhyay, D. (2004). Protein kinase C zeta transactivates hypoxia-
inducible factor alpha by promoting its association with p300 in renal cancer. 
Cancer Res 64, 456-62. 
[288] Caraballo, J.C., Yshii, C., Butti, M.L., Westphal, W., Borcherding, J.A., 
Allamargot, C. and Comellas, A.P. (2011). Hypoxia increases transepithelial 
electrical conductance and reduces occludin at the plasma membrane in 
alveolar epithelial cells via PKC-zeta and PP2A pathway. Am J Physiol Lung 
Cell Mol Physiol 300, L569-78. 
[289] Datta, K., Li, J., Karumanchi, S.A., Wang, E., Rondeau, E. and 
Mukhopadhyay, D. (2004). Regulation of vascular permeability 
factor/vascular endothelial growth factor (VPF/VEGF-A) expression in 
podocytes. Kidney Int 66, 1471-8. 
[290] Mehta, D., Tiruppathi, C., Sandoval, R., Minshall, R.D., Holinstat, M. and 
Malik, A.B. (2002). Modulatory role of focal adhesion kinase in regulating 
human pulmonary arterial endothelial barrier function. J Physiol 539, 779-89. 
[291] Minshall, R.D. et al. (2010). Role of protein kinase Czeta in thrombin-induced 
RhoA activation and inter-endothelial gap formation of human dermal 
microvessel endothelial cell monolayers. Microvasc Res 80, 240-9. 
[292] Garcia, J.G., Schaphorst, K.L., Verin, A.D., Vepa, S., Patterson, C.E. and 
Natarajan, V. (2000). Diperoxovanadate alters endothelial cell focal contacts 
and barrier function: role of tyrosine phosphorylation. J Appl Physiol 89, 
2333-43. 
[293] Stasek, J.E., Jr., Patterson, C.E. and Garcia, J.G. (1992). Protein kinase C 
phosphorylates caldesmon77 and vimentin and enhances albumin 
permeability across cultured bovine pulmonary artery endothelial cell 
monolayers. J Cell Physiol 153, 62-75. 
[294] Alexander, J.S., Jackson, S.A., Chaney, E., Kevil, C.G. and Haselton, F.R. 
(1998). The role of cadherin endocytosis in endothelial barrier regulation: 
involvement of protein kinase C and actin-cadherin interactions. Inflammation 
22, 419-33. 
[295] Ramirez, M.M., Kim, D.D. and Duran, W.N. (1996). Protein kinase C 
modulates microvascular permeability through nitric oxide synthase. Am J 
Physiol 271, H1702-5. 
[296] Duran, W.N., Seyama, A., Yoshimura, K., Gonzalez, D.R., Jara, P.I., 
Figueroa, X.F. and Boric, M.P. (2000). Stimulation of NO production and of 
eNOS phosphorylation in the microcirculation in vivo. Microvasc Res 60, 
104-11. 
212 
 
[297] Huang, Q. and Yuan, Y. (1997). Interaction of PKC and NOS in signal 
transduction of microvascular hyperpermeability. Am J Physiol 273, H2442-
51. 
[298] Li, S., Okamoto, T., Chun, M., Sargiacomo, M., Casanova, J.E., Hansen, 
S.H., Nishimoto, I. and Lisanti, M.P. (1995). Evidence for a regulated 
interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270, 
15693-701. 
[299] Lawson, J.H., Kalafatis, M., Stram, S. and Mann, K.G. (1994). A model for 
the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 269, 
23357-66. 
[300] Mason, J.C., Steinberg, R., Lidington, E.A., Kinderlerer, A.R., Ohba, M. and 
Haskard, D.O. (2004). Decay-accelerating factor induction on vascular 
endothelium by vascular endothelial growth factor (VEGF) is mediated via a 
VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon 
(PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is 
inhibited by cyclosporin A. J Biol Chem 279, 41611-8. 
[301] Patel, V., Brown, C. and Boarder, M.R. (1996). Protein kinase C isoforms in 
bovine aortic endothelial cells: role in regulation of P2Y- and P2U-
purinoceptor-stimulated prostacyclin release. Br J Pharmacol 118, 123-30. 
[302] Wildhagen, K.C., Lutgens, E., Loubele, S.T., ten Cate, H. and Nicolaes, G.A. 
The structure-function relationship of activated protein C. Lessons from 
natural and engineered mutations. Thromb Haemost 106, 1034-45. 
[303] Gale, A.J., Sun, X., Heeb, M.J. and Griffin, J.H. (1997). Nonenzymatic 
anticoagulant activity of the mutant serine protease Ser360Ala-activated 
protein C mediated by factor Va. Protein Sci 6, 132-40. 
[304] Kerschen, E.J. et al. (2007). Endotoxemia and sepsis mortality reduction by 
non-anticoagulant activated protein C. J Exp Med 204, 2439-48. 
[305] Mosnier, L.O., Yang, X.V. and Griffin, J.H. (2007). Activated protein C mutant 
with minimal anticoagulant activity, normal cytoprotective activity, and 
preservation of thrombin activable fibrinolysis inhibitor-dependent 
cytoprotective functions. J Biol Chem 282, 33022-33. 
[306] Mosnier, L.O. et al. (2009). Hyperantithrombotic, noncytoprotective 
Glu149Ala-activated protein C mutant. Blood 113, 5970-8. 
[307] Riewald, M. and Ruf, W. (2005). Protease-activated receptor-1 signaling by 
activated protein C in cytokine-perturbed endothelial cells is distinct from 
thrombin signaling. J Biol Chem 280, 19808-14. 
[308] Brueckmann, M. et al. (2005). Recombinant human activated protein C 
upregulates cyclooxygenase-2 expression in endothelial cells via binding to 
endothelial cell protein C receptor and activation of protease-activated 
receptor-1. Thromb Haemost 93, 743-50. 
[309] Perez-Casal, M., Downey, C., Fukudome, K., Marx, G. and Toh, C.H. (2005). 
Activated protein C induces the release of microparticle-associated 
endothelial protein C receptor. Blood 105, 1515-22. 
[310] Ruf, W. (2005). Is APC activation of endothelial cell PAR1 important in 
severe sepsis?: Yes. J Thromb Haemost 3, 1912-4. 
[311] Ohsawa, K. et al. (1992). Purification of sufficiently gamma-carboxylated 
recombinant protein C and its derivatives. Calcium-dependent affinity shift in 
immunoaffinity and ion-exchange chromatography. J Chromatogr 597, 285-
91. 
213 
 
[312] Yan, S.C., Razzano, P., Chao, Y.B., Walls, J.D., Berg, D.T., McClure, D.B. 
and Grinnell, B.W. (1990). Characterization and novel purification of 
recombinant human protein C from three mammalian cell lines. 
Biotechnology (N Y) 8, 655-61. 
[313] Sugiura, T., Kurosawaohsawa, K., Takahashi, M. and Maruyama, H.B. 
(1990). Relationship between Productivity and Gamma-Carboxylation 
Efficiency of Recombinant Protein-C. Biotechnology Letters 12, 799-804. 
[314] Yan, S.B. (1996). Review of conformation-specific affinity purification 
methods for plasma vitamin K-dependent proteins. J Mol Recognit 9, 211-8. 
[315] Foster, D.C., Sprecher, C.A., Holly, R.D., Gambee, J.E., Walker, K.M. and 
Kumar, A.A. (1990). Endoproteolytic processing of the dibasic cleavage site 
in the human protein C precursor in transfected mammalian cells: effects of 
sequence alterations on efficiency of cleavage. Biochemistry 29, 347-54. 
[316] Johnstone, I.B. and Martin, C.A. (2000). Comparative effects of the human 
protein C activator, Protac, on the activated partial thromboplastin clotting 
times of plasmas, with special reference to the dog. Can J Vet Res 64, 117-
22. 
[317] Stocker, K., Fischer, H., Meier, J., Brogli, M. and Svendsen, L. (1987). 
Characterization of the protein C activator Protac from the venom of the 
southern copperhead (Agkistrodon contortrix) snake. Toxicon 25, 239-52. 
[318] Yang, L., Manithody, C. and Rezaie, A.R. (2006). Activation of protein C by 
the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of 
thrombin and Arg-67 of protein C. Proc Natl Acad Sci U S A 103, 879-84. 
[319] Duchemin, J., Pan-Petesch, B., Arnaud, B., Blouch, M.T. and Abgrall, J.F. 
(2008). Influence of coagulation factors and tissue factor concentration on 
the thrombin generation test in plasma. Thromb Haemost 99, 767-73. 
[320] Chantarangkul, V., Clerici, M., Bressi, C., Giesen, P.L.A. and Tripodi, A. 
(2003). Thrombin generation assessed as endogenous thrombin potential in 
patients with hyper- or hypo-coagulability. Haematologica 88, 547-554. 
[321] Hemker, H.C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., 
Wagenvoord, R., Lecompte, T. and Beguin, S. (2003). Calibrated automated 
thrombin generation measurement in clotting plasma. Pathophysiol Haemost 
Thromb 33, 4-15. 
[322] Keularts, I.M., Zivelin, A., Seligsohn, U., Hemker, H.C. and Beguin, S. (2001). 
The role of factor XI in thrombin generation induced by low concentrations of 
tissue factor. Thromb Haemost 85, 1060-5. 
[323] Beltran-Miranda, C.P., Khan, A., Jaloma-Cruz, A.R. and Laffan, M.A. (2005). 
Thrombin generation and phenotypic correlation in haemophilia A. 
Haemophilia 11, 326-34. 
[324] Dargaud, Y., Beguin, S., Lienhart, A., Al Dieri, R., Trzeciak, C., Bordet, J.C., 
Hemker, H.C. and Negrier, C. (2005). Evaluation of thrombin generating 
capacity in plasma from patients with haemophilia A and B. Thromb Haemost 
93, 475-80. 
[325] Chantarangkul, V., Clerici, M., Bressi, C., Giesen, P.L. and Tripodi, A. (2003). 
Thrombin generation assessed as endogenous thrombin potential in patients 
with hyper- or hypo-coagulability. Haematologica 88, 547-54. 
[326] Gempeler-Messina, P.M., Volz, K., Buhler, B. and Muller, C. (2001). Protein 
C activators from snake venoms and their diagnostic use. Haemostasis 31, 
266-72. 
214 
 
[327] van 't Veer, C., Golden, N.J., Kalafatis, M. and Mann, K.G. (1997). Inhibitory 
mechanism of the protein C pathway on tissue factor-induced thrombin 
generation. Synergistic effect in combination with tissue factor pathway 
inhibitor. J Biol Chem 272, 7983-94. 
[328] Nicolaes, G.A., Bock, P.E., Segers, K., Wildhagen, K.C., Dahlback, B. and 
Rosing, J. (2010). Inhibition of thrombin formation by active site mutated 
(S360A) activated protein C. J Biol Chem 285, 22890-900. 
[329] Block, H., Maertens, B., Spriestersbach, A., Brinker, N., Kubicek, J., Fabis, 
R., Labahn, J. and Schafer, F. (2009). Immobilized-Metal Affinity 
Chromatography (Imac): A Review. Guide to Protein Purification, Second 
Edition 463, 439-473. 
[330] Porath, J. (1992). Immobilized Metal-Ion Affinity-Chromatography. Protein 
Expression and Purification 3, 263-281. 
[331] Hedstrom, L. (2002). Serine protease mechanism and specificity. Chem Rev 
102, 4501-24. 
[332] Serrano, S.M. and Maroun, R.C. (2005). Snake venom serine proteinases: 
sequence homology vs. substrate specificity, a paradox to be solved. 
Toxicon 45, 1115-32. 
[333] Kisiel, W., Kondo, S., Smith, K.J., McMullen, B.A. and Smith, L.F. (1987). 
Characterization of a protein C activator from Agkistrodon contortrix 
contortrix venom. J Biol Chem 262, 12607-13. 
[334] Compton, S.J., Renaux, B., Wijesuriya, S.J. and Hollenberg, M.D. (2001). 
Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) 
by human mast cell tryptase. Br J Pharmacol 134, 705-18. 
[335] Compton, S.J., Sandhu, S., Wijesuriya, S.J. and Hollenberg, M.D. (2002). 
Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell 
surface expression and signalling. Biochem J 368, 495-505. 
[336] Soto, A.G. and Trejo, J. (2010). N-linked glycosylation of protease-activated 
receptor-1 second extracellular loop: a critical determinant for ligand-induced 
receptor activation and internalization. J Biol Chem 285, 18781-93. 
[337] Xiao, Y.P., Morice, A.H., Compton, S.J. and Sadofsky, L. (2011). N-linked 
glycosylation regulates human proteinase-activated receptor-1 cell surface 
expression and disarming via neutrophil proteinases and thermolysin. J Biol 
Chem 286, 22991-3002. 
[338] Ludeman, M.J., Kataoka, H., Srinivasan, Y., Esmon, N.L., Esmon, C.T. and 
Coughlin, S.R. (2005). PAR1 cleavage and signaling in response to activated 
protein C and thrombin. J Biol Chem 280, 13122-8. 
[339] Scarborough, R.M. et al. (1992). Tethered ligand agonist peptides. Structural 
requirements for thrombin receptor activation reveal mechanism of 
proteolytic unmasking of agonist function. J Biol Chem 267, 13146-9. 
[340] Feistritzer, C., Schuepbach, R.A., Mosnier, L.O., Bush, L.A., Di Cera, E., 
Griffin, J.H. and Riewald, M. (2006). Protective signaling by activated protein 
C is mechanistically linked to protein C activation on endothelial cells. J Biol 
Chem 281, 20077-84. 
[341] Griffin, J.H., Fernandez, J.A., Mosnier, L.O., Liu, D., Cheng, T., Guo, H. and 
Zlokovic, B.V. (2006). The promise of protein C. Blood Cells Mol Dis 36, 211-
6. 
[342] Brass, L.F., Pizarro, S., Ahuja, M., Belmonte, E., Blanchard, N., Stadel, J.M. 
and Hoxie, J.A. (1994). Changes in the structure and function of the human 
215 
 
thrombin receptor during receptor activation, internalization, and recycling. J 
Biol Chem 269, 2943-52. 
[343] Riewald, M. and Ruf, W. (2001). Mechanistic coupling of protease signaling 
and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 98, 
7742-7. 
[344] Hoxie, J.A., Ahuja, M., Belmonte, E., Pizarro, S., Parton, R. and Brass, L.F. 
(1993). Internalization and recycling of activated thrombin receptors. J Biol 
Chem 268, 13756-63. 
[345] Nieman, M.T. and Schmaier, A.H. (2007). Interaction of thrombin with PAR1 
and PAR4 at the thrombin cleavage site. Biochemistry 46, 8603-10. 
[346] Edgell, C.J., McDonald, C.C. and Graham, J.B. (1983). Permanent cell line 
expressing human factor VIII-related antigen established by hybridization. 
Proc Natl Acad Sci U S A 80, 3734-7. 
[347] Emeis, J.J. and Edgell, C.J. (1988). Fibrinolytic properties of a human 
endothelial hybrid cell line (Ea.hy 926). Blood 71, 1669-75. 
[348] Saijonmaa, O., Nyman, T., Hohenthal, U. and Fyhrquist, F. (1991). 
Endothelin-1 is expressed and released by a human endothelial hybrid cell 
line (EA.hy 926). Biochem Biophys Res Commun 181, 529-36. 
[349] Suggs, J.E., Madden, M.C., Friedman, M. and Edgell, C.J. (1986). 
Prostacyclin expression by a continuous human cell line derived from 
vascular endothelium. Blood 68, 825-9. 
[350] Ahn, K., Pan, S., Beningo, K. and Hupe, D. (1995). A permanent human cell 
line (EA.hy926) preserves the characteristics of endothelin converting 
enzyme from primary human umbilical vein endothelial cells. Life Sci 56, 
2331-41. 
[351] Unger, R.E., Krump-Konvalinkova, V., Peters, K. and Kirkpatrick, C.J. (2002). 
In vitro expression of the endothelial phenotype: comparative study of 
primary isolated cells and cell lines, including the novel cell line HPMEC-
ST1.6R. Microvasc Res 64, 384-97. 
[352] Lidington, E.A., Moyes, D.L., McCormack, A.M. and Rose, M.L. (1999). A 
comparison of primary endothelial cells and endothelial cell lines for studies 
of immune interactions. Transpl Immunol 7, 239-46. 
[353] Bauer, J., Margolis, M., Schreiner, C., Edgell, C.J., Azizkhan, J., Lazarowski, 
E. and Juliano, R.L. (1992). In vitro model of angiogenesis using a human 
endothelium-derived permanent cell line: contributions of induced gene 
expression, G-proteins, and integrins. J Cell Physiol 153, 437-49. 
[354] Pellegatta, F., Radaelli, A., Ferrero, E., Toninelli, E., Vidal, M.J., Chierchia, 
S.L. and Zocchi, M.R. (1994). Inducible nitric oxide synthase modulates 
fibronectin production in the EA.hy926 cell line and cultured human umbilical 
vein endothelial cells. J Cardiovasc Pharmacol 24, 1014-9. 
[355] Swiatkowska, M., Cierniewska-Cieslak, A., Pawlowska, Z. and Cierniewski, 
C.S. (2000). Dual regulatory effects of nitric oxide on plasminogen activator 
inhibitor type 1 expression in endothelial cells. Eur J Biochem 267, 1001-7. 
[356] Thornhill, M.H., Li, J. and Haskard, D.O. (1993). Leucocyte endothelial cell 
adhesion: a study comparing human umbilical vein endothelial cells and the 
endothelial cell line EA-hy-926. Scand J Immunol 38, 279-86. 
[357] Baranska, P.J., H; Pawlowska, Z; Koziolkiewicz, W and Cierniewski, C. S. 
(2003). Expression of Integrins and Adhesive Properties of Human 
endothelial cell line EA.hy 926. Cancer Genomics & Proteomics 2, 265-270. 
216 
 
[358] Ammollo, C.T., Semeraro, F., Xu, J., Esmon, N.L. and Esmon, C.T. (2011). 
Extracellular histones increase plasma thrombin generation by impairing 
thrombomodulin-dependent protein C activation. J Thromb Haemost 9, 1795-
803. 
[359] Hunt, M.A., Currie, M.J., Robinson, B.A. and Dachs, G.U. (2010). Optimizing 
transfection of primary human umbilical vein endothelial cells using 
commercially available chemical transfection reagents. J Biomol Tech 21, 
66-72. 
[360] Dichek, D. and Quertermous, T. (1989). Variability in messenger RNA levels 
in human umbilical vein endothelial cells of different lineage and time in 
culture. In Vitro Cell Dev Biol 25, 289-92. 
[361] Glee, P.M., Cutler, J.E., Benson, E.E., Bargatze, R.F. and Hazen, K.C. 
(2001). Inhibition of hydrophobic protein-mediated Candida albicans 
attachment to endothelial cells during physiologic shear flow. Infect Immun 
69, 2815-20. 
[362] Bellou, S., Hink, M.A., Bagli, E., Panopoulou, E., Bastiaens, P.I., Murphy, C. 
and Fotsis, T. (2009). VEGF autoregulates its proliferative and migratory 
ERK1/2 and p38 cascades by enhancing the expression of DUSP1 and 
DUSP5 phosphatases in endothelial cells. Am J Physiol Cell Physiol 297, 
C1477-89. 
[363] Solomon, D. (2002). An in vitro examination of an extracellular matrix 
scaffold for use in wound healing. Int J Exp Pathol 83, 209-16. 
[364] Cargnello, M. and Roux, P.P. (2011). Activation and Function of the MAPKs 
and Their Substrates, the MAPK-Activated Protein Kinases. Microbiology 
and Molecular Biology Reviews 75, 50-83. 
[365] Xue, M.L., Campbell, D. and Jackson, C.J. (2007). Protein C is an autocrine 
growth factor for human skin keratinocytes. Journal of Biological Chemistry 
282, 13610-13616. 
[366] Esmon, C.T. et al. (1999). Endothelial protein C receptor. Thromb Haemost 
82, 251-8. 
[367] Bogatcheva, N.V., Garcia, J.G. and Verin, A.D. (2002). Molecular 
mechanisms of thrombin-induced endothelial cell permeability. Biochemistry 
(Mosc) 67, 75-84. 
[368] Kataoka, H., Hamilton, J.R., McKemy, D.D., Camerer, E., Zheng, Y.W., 
Cheng, A., Griffin, C. and Coughlin, S.R. (2003). Protease-activated 
receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 102, 
3224-3231. 
[369] Kaneider, N.C., Leger, A.J., Agarwal, A., Nguyen, N., Perides, G., Derian, C., 
Covic, L. and Kuliopulos, A. (2007). 'Role reversal' for the receptor PAR1 in 
sepsis-induced vascular damage. Nat Immunol 8, 1303-12. 
[370] Pawlinski, R. and Holinstat, M. (2011). We can do it together: PAR1/PAR2 
heterodimer signaling in VSMCs. Arterioscler Thromb Vasc Biol 31, 2775-6. 
[371] Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U. and Nishizuka, 
Y. (1982). Direct activation of calcium-activated, phospholipid-dependent 
protein kinase by tumor-promoting phorbol esters. J Biol Chem 257, 7847-51. 
[372] Blumberg, P.M. (1988). Protein kinase C as the receptor for the phorbol ester 
tumor promoters: sixth Rhoads memorial award lecture. Cancer Res 48, 1-8. 
[373] Niedel, J.E., Kuhn, L.J. and Vandenbark, G.R. (1983). Phorbol diester 
receptor copurifies with protein kinase C. Proc Natl Acad Sci U S A 80, 36-40. 
217 
 
[374] Johnson, K.R., Becker, K.P., Facchinetti, M.M., Hannun, Y.A. and Obeid, 
L.M. (2002). PKC-dependent activation of sphingosine kinase 1 and 
translocation to the plasma membrane. Extracellular release of sphingosine-
1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem 
277, 35257-62. 
[375] Huang, Z., Wang, C., Wei, L., Wang, J., Fan, Y., Wang, L., Wang, Y. and 
Chen, T. (2008). Resveratrol inhibits EMMPRIN expression via P38 and 
ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res 
Commun 374, 517-21. 
[376] Mudduluru, G., Leupold, J.H., Stroebel, P. and Allgayer, H. (2010). PMA up-
regulates the transcription of Axl by AP-1 transcription factor binding to TRE 
sequences via the MAPK cascade in leukaemia cells. Biol Cell 103, 21-33. 
[377] Stapleton, C.M., Joo, J.H., Kim, Y.S., Liao, G., Panettieri, R.A., Jr. and Jetten, 
A.M. (2010). Induction of ANGPTL4 expression in human airway smooth 
muscle cells by PMA through activation of PKC and MAPK pathways. Exp 
Cell Res 316, 507-16. 
[378] Rossomando, A.J., Payne, D.M., Weber, M.J. and Sturgill, T.W. (1989). 
Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-
activated serine/threonine protein kinase. Proc Natl Acad Sci U S A 86, 
6940-3. 
[379] Muthusamy, S., Shukla, S., Amin, M.R., Cheng, M., Orenuga, T., Dudeja, 
P.K. and Malakooti, J. (2012). PKCdelta-dependent activation of ERK1/2 
leads to upregulation of the human NHE2 transcriptional activity in intestinal 
epithelial cell line C2BBe1. Am J Physiol Gastrointest Liver Physiol 302, 
G317-25. 
[380] Jones, E., Adcock, I.M., Ahmed, B.Y. and Punchard, N.A. (2007). Modulation 
of LPS stimulated NF-kappaB mediated Nitric Oxide production by 
PKCepsilon and JAK2 in RAW macrophages. J Inflamm (Lond) 4, 23. 
[381] Carpenter, A.C. and Alexander, J.S. (2008). Endothelial PKC delta activation 
attenuates neutrophil transendothelial migration. Inflamm Res 57, 216-29. 
[382] Martiny-Baron, G., Kazanietz, M.G., Mischak, H., Blumberg, P.M., Kochs, G., 
Hug, H., Marme, D. and Schachtele, C. (1993). Selective inhibition of protein 
kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268, 9194-
7. 
[383] Grossoni, V.C., Falbo, K.B., Kazanietz, M.G., de Kier Joffe, E.D. and 
Urtreger, A.J. (2007). Protein kinase C delta enhances proliferation and 
survival of murine mammary cells. Mol Carcinog 46, 381-90. 
[384] Jacobson, P.B., Kuchera, S.L., Metz, A., Schachtele, C., Imre, K. and Schrier, 
D.J. (1995). Anti-inflammatory properties of Go 6850: a selective inhibitor of 
protein kinase C. J Pharmacol Exp Ther 275, 995-1002. 
[385] Toullec, D. et al. (1991). The bisindolylmaleimide GF 109203X is a potent 
and selective inhibitor of protein kinase C. J Biol Chem 266, 15771-81. 
[386] Li, X.C., Hahn, C.N., Parsons, M., Drew, J., Vadas, M.A. and Gamble, J.R. 
(2004). Role of protein kinase C zeta in thrombin-induced endothelial 
permeability changes: inhibition by angiopoietin-1. Blood 104, 1716-1724. 
[387] Obara, Y., Kobayashi, H., Ohta, T., Ohizumi, Y. and Nakahata, N. (2001). 
Scabronine G-methylester enhances secretion of neurotrophic factors 
mediated by an activation of protein kinase C-zeta. Mol Pharmacol 59, 1287-
97. 
218 
 
[388] Li, D., Sweeney, G., Wang, Q. and Klip, A. (1999). Participation of PI3K and 
atypical PKC in Na+-K+-pump stimulation by IGF-I in VSMC. Am J Physiol 
276, H2109-16. 
[389] Muscella, A., Storelli, C. and Marsigliante, S. (2005). Atypical PKC-zeta and 
PKC-iota mediate opposing effects on MCF-7 Na+/K+ATPase activity. J Cell 
Physiol 205, 278-85. 
[390] Eichholtz, T., de Bont, D.B., de Widt, J., Liskamp, R.M. and Ploegh, H.L. 
(1993). A myristoylated pseudosubstrate peptide, a novel protein kinase C 
inhibitor. J Biol Chem 268, 1982-6. 
[391] Li, H. et al. (1998). Activation of protein kinase C alpha and/or epsilon 
enhances transcription of the human endothelial nitric oxide synthase gene. 
Mol Pharmacol 53, 630-7. 
[392] Cardozo, A.K. et al. (2007). Cell-permeable peptides induce dose- and 
length-dependent cytotoxic effects. Biochim Biophys Acta 1768, 2222-34. 
[393] Siflinger-Birnboim, A. and Johnson, A. (2003). Protein kinase C modulates 
pulmonary endothelial permeability: a paradigm for acute lung injury. Am J 
Physiol Lung Cell Mol Physiol 284, L435-51. 
[394] Vandenbroucke, E.V., S; Gao, X.; Komarova, Y.; Malik, A.B. (2008). Deletion 
of PKC alpha in mice attenuates the thrombin-induced increase in lung 
vascular permeability. FASEB J 22 
[395] Lal, B.K., Varma, S., Pappas, P.J., Hobson, R.W., 2nd and Duran, W.N. 
(2001). VEGF increases permeability of the endothelial cell monolayer by 
activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase 
pathways. Microvasc Res 62, 252-62. 
[396] Kevil, C.G., Payne, D.K., Mire, E. and Alexander, J.S. (1998). Vascular 
permeability factor/vascular endothelial cell growth factor-mediated 
permeability occurs through disorganization of endothelial junctional proteins. 
J Biol Chem 273, 15099-103. 
[397] Forsyth, C.B. et al. (2007). Regulation of oxidant-induced intestinal 
permeability by metalloprotease-dependent epidermal growth factor receptor 
signaling. J Pharmacol Exp Ther 321, 84-97. 
[398] Fischer, S., Wiesnet, M., Renz, D. and Schaper, W. (2005). H2O2 induces 
paracellular permeability of porcine brain-derived microvascular endothelial 
cells by activation of the p44/42 MAP kinase pathway. Eur J Cell Biol 84, 
687-97. 
[399] Chen, Y., Lu, Q., Schneeberger, E.E. and Goodenough, D.A. (2000). 
Restoration of tight junction structure and barrier function by down-regulation 
of the mitogen-activated protein kinase pathway in ras-transformed Madin-
Darby canine kidney cells. Mol Biol Cell 11, 849-62. 
[400] Duncia, J.V. et al. (1998). MEK inhibitors: the chemistry and biological 
activity of U0126, its analogs, and cyclization products. Bioorg Med Chem 
Lett 8, 2839-44. 
[401] Favata, M.F. et al. (1998). Identification of a novel inhibitor of mitogen-
activated protein kinase kinase. J Biol Chem 273, 18623-32. 
[402] Wang, Z., Ginnan, R., Abdullaev, I.F., Trebak, M., Vincent, P.A. and Singer, 
H.A. (2010). Calcium/Calmodulin-dependent protein kinase II delta 6 
(CaMKIIdelta6) and RhoA involvement in thrombin-induced endothelial 
barrier dysfunction. J Biol Chem 285, 21303-12. 
219 
 
[403] Cargnello, M. and Roux, P.P. (2011). Activation and function of the MAPKs 
and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol 
Rev 75, 50-83. 
[404] Qiu, Z.H. and Leslie, C.C. (1994). Protein kinase C-dependent and -
independent pathways of mitogen-activated protein kinase activation in 
macrophages by stimuli that activate phospholipase A2. J Biol Chem 269, 
19480-7. 
[405] Lehoux, J.G. and Lefebvre, A. (2007). Angiotensin II activates p44/42 MAP 
kinase partly through PKCepsilon in H295R cells. Mol Cell Endocrinol 265-
266, 121-5. 
[406] Cheng, J.J., Wung, B.S., Chao, Y.J. and Wang, D.L. (2001). Sequential 
activation of protein kinase C (PKC)-alpha and PKC-epsilon contributes to 
sustained Raf/ERK1/2 activation in endothelial cells under mechanical strain. 
J Biol Chem 276, 31368-75. 
[407] Traub, O., Monia, B.P., Dean, N.M. and Berk, B.C. (1997). PKC-epsilon is 
required for mechano-sensitive activation of ERK1/2 in endothelial cells. J 
Biol Chem 272, 31251-7. 
[408] Cho, C.H. et al. (2004). Localization of VEGFR-2 and PLD2 in endothelial 
caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am 
J Physiol Heart Circ Physiol 286, H1881-8. 
[409] Palma-Nicolas, J.P., Lopez, E. and Lopez-Colome, A.M. (2008). PKC 
isoenzymes differentially modulate the effect of thrombin on MAPK-
dependent RPE proliferation. Biosci Rep 28, 307-17. 
[410] Lo, L.W., Cheng, J.J., Chiu, J.J., Wung, B.S., Liu, Y.C. and Wang, D.L. 
(2001). Endothelial exposure to hypoxia induces Egr-1 expression involving 
PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway. J Cell Physiol 188, 304-12. 
[411] Petiti, J.P., De Paul, A.L., Gutierrez, S., Palmeri, C.M., Mukdsi, J.H. and 
Torres, A.I. (2008). Activation of PKC epsilon induces lactotroph proliferation 
through ERK1/2 in response to phorbol ester. Molecular and Cellular 
Endocrinology 289, 77-84. 
[412] Lin, C.C., Shyr, M.H., Chien, C.S., Wang, C.C., Chiu, C.T., Hsiao, L.D. and 
Yang, C.M. (2001). Mechanisms of thrombin-induced MAPK activation 
associated with cell proliferation in human cultured tracheal smooth muscle 
cells. Cell Signal 13, 257-67. 
[413] Lin, C.C., Shyr, M.H., Chien, C.S., Wang, C.C., Chiu, C.T., Hsiao, L.D. and 
Yang, C.M. (2002). Thrombin-stimulated cell proliferation mediated through 
activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal 
smooth muscle cells. Cell Signal 14, 265-75. 
[414] Kolch, W. et al. (1993). Protein kinase C alpha activates RAF-1 by direct 
phosphorylation. Nature 364, 249-52. 
[415] Paruchuri, S., Hallberg, B., Juhas, M., Larsson, C. and Sjolander, A. (2002). 
Leukotriene D(4) activates MAPK through a Ras-independent but 
PKCepsilon-dependent pathway in intestinal epithelial cells. J Cell Sci 115, 
1883-93. 
[416] Alessi, D.R. (1997). The protein kinase C inhibitors Ro 318220 and GF 
109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and 
p70 S6 kinase. FEBS Lett 402, 121-3. 
[417] Roberts, N.A., Haworth, R.S. and Avkiran, M. (2005). Effects of 
bisindolylmaleimide PKC inhibitors on p90RSK activity in vitro and in adult 
ventricular myocytes. Br J Pharmacol 145, 477-89. 
220 
 
[418] Roberts, N.A., Marber, M.S. and Avkiran, M. (2004). Specificity of action of 
bisindolylmaleimide protein kinase C inhibitors: do they inhibit the 70kDa 
ribosomal S6 kinase in cardiac myocytes? Biochem Pharmacol 68, 1923-8. 
[419] Huntington, J.A. (2005). Molecular recognition mechanisms of thrombin. J 
Thromb Haemost 3, 1861-72. 
[420] Gamble, J.R. et al. (2000). Angiopoietin-1 is an antipermeability and anti-
inflammatory agent in vitro and targets cell junctions. Circ Res 87, 603-607. 
[421] Hood, J. and Granger, H.J. (1998). Protein kinase G mediates vascular 
endothelial growth factor-induced Raf-1 activation and proliferation in human 
endothelial cells. J Biol Chem 273, 23504-8. 
[422] Pyriochou, A., Vassilakopoulos, T., Zhou, Z. and Papapetropoulos, A. (2007). 
cGMP-dependent and -independent angiogenesis-related properties of nitric 
oxide. Life Sci 81, 1549-54. 
[423] Wu, X., Reiter, C.E., Antonetti, D.A., Kimball, S.R., Jefferson, L.S. and 
Gardner, T.W. (2004). Insulin promotes rat retinal neuronal cell survival in a 
p70S6K-dependent manner. J Biol Chem 279, 9167-75. 
[424] Pellegatta, F., Catapano, A.L., Luzi, L. and Terruzzi, I. (2006). In human 
endothelial cells amino acids inhibit insulin-induced Akt and ERK1/2 
phosphorylation by an mTOR-dependent mechanism. J Cardiovasc 
Pharmacol 47, 643-9. 
[425] Rosenfeldt, H.M., Hobson, J.P., Milstien, S. and Spiegel, S. (2001). The 
sphingosine-1-phosphate receptor EDG-1 is essential for platelet-derived 
growth factor-induced cell motility. Biochem Soc Trans 29, 836-9. 
[426] Ancellin, N. et al. (2002). Extracellular export of sphingosine kinase-1 
enzyme. Sphingosine 1-phosphate generation and the induction of 
angiogenic vascular maturation. J Biol Chem 277, 6667-75. 
[427] Berdyshev, E.V. et al. (2011). Intracellular S1P generation is essential for 
S1P-induced motility of human lung endothelial cells: role of sphingosine 
kinase 1 and S1P lyase. PLoS One 6, e16571. 
[428] Patel, H.H., Murray, F. and Insel, P.A. (2008). Caveolae as organizers of 
pharmacologically relevant signal transduction molecules. Annu Rev 
Pharmacol Toxicol 48, 359-91. 
[429] Sowa, G. (2012). Caveolae, caveolins, cavins, and endothelial cell function: 
new insights. Front Physiol 2, 120. 
[430] Taggart, M.J., Leavis, P., Feron, O. and Morgan, K.G. (2000). Inhibition of 
PKCalpha and rhoA translocation in differentiated smooth muscle by a 
caveolin scaffolding domain peptide. Exp Cell Res 258, 72-81. 
[431] Oka, N. et al. (1997). Caveolin interaction with protein kinase C. Isoenzyme-
dependent regulation of kinase activity by the caveolin scaffolding domain 
peptide. J Biol Chem 272, 33416-21. 
[432] Verin, A.D., Liu, F., Bogatcheva, N., Borbiev, T., Hershenson, M.B., Wang, P. 
and Garcia, J.G. (2000). Role of ras-dependent ERK activation in phorbol 
ester-induced endothelial cell barrier dysfunction. Am J Physiol Lung Cell 
Mol Physiol 279, L360-70. 
[433] Danese, S., Vetrano, S., Zhang, L., Poplis, V.A. and Castellino, F.J. (2010). 
The protein C pathway in tissue inflammation and injury: pathogenic role and 
therapeutic implications. Blood 115, 1121-30. 
[434] Ohdama, S., Yoshizawa, Y., Kubota, T. and Aoki, N. (1994). Plasma 
Thrombomodulin as an Indicator of Thromboembolic Disease in Systemic 
Lupus-Erythematosus. Int J Cardiol 47, S1-S6. 
221 
 
[435] Laszik, Z.G., Zhou, X.J., Ferrell, G.L., Silva, F.G. and Esmon, C.T. (2001). 
Down-regulation of endothelial expression of endothelial cell protein C 
receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 159, 
797-802. 
[436] Hataji, O., Taguchi, O., Gabazza, E.C., Yuda, H., Fujimoto, H., Suzuki, K. 
and Adachi, Y. (2002). Activation of protein C pathway in the airways. Lung 
180, 47-59. 
[437] Liaw, P.C.Y. et al. (2004). Patients with severe sepsis vary markedly in their 
ability to generate activated protein C. Blood 104, 3958-3964. 
[438] Patterson, C., Stouffer, G.A., Madamanchi, N. and Runge, M.S. (2001). New 
tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. 
Circ Res 88, 987-97. 
[439] Tracy, R.P. (2003). Thrombin, inflammation, and cardiovascular disease: an 
epidemiologic perspective. Chest 124, 49S-57S. 
[440] Flick, M.J. et al. (2011). The development of inflammatory joint disease is 
attenuated in mice expressing the anticoagulant prothrombin mutant 
W215A/E217A. Blood 117, 6326-6337. 
[441] Wu, M.H., Ustinova, E. and Granger, H.J. (2001). Integrin binding to 
fibronectin and vitronectin maintains the barrier function of isolated porcine 
coronary venules. J Physiol 532, 785-91. 
[442] Rezaie, A.R. and Yang, L. (2003). Thrombomodulin allosterically modulates 
the activity of the anticoagulant thrombin. Proc Natl Acad Sci U S A 100, 
12051-6. 
[443] Guo, H. et al. (2009). Neuroprotective activities of activated protein C mutant 
with reduced anticoagulant activity. Eur J Neurosci 29, 1119-30. 
[444] Bernard, G.R. et al. (2001). Efficacy and safety of recombinant human 
activated protein C for severe sepsis. N Engl J Med 344, 699-709. 
[445] Yuda, H. et al. (2004). Activated protein C inhibits bronchial 
hyperresponsiveness and Th2 cytokine expression in mice. Blood 103, 2196-
204. 
 
 
